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A B S T R A C T
Background
Genotype® MTBDRsl (MTBDRsl) is a rapid DNA-based test for detecting specific mutations associated with resistance to fluoro-
quinolones and second-line injectable drugs (SLIDs) in Mycobacterium tuberculosis complex. MTBDRsl version 2.0 (released in 2015)
identifies the mutations detected by version 1.0, as well as additional mutations. The test may be performed on a culture isolate or a
patient specimen, which eliminates delays associated with culture. Version 1.0 requires a smear-positive specimen, while version 2.0
may use a smear-positive or -negative specimen. We performed this updated review as part of a World Health Organization process to
develop updated guidelines for using MTBDRsl.
Objectives
To assess and compare the diagnostic accuracy of MTBDRsl for: 1. fluoroquinolone resistance, 2. SLID resistance, and 3. extensively
drug-resistant tuberculosis, indirectly on a M. tuberculosis isolate grown from culture or directly on a patient specimen. Participants
were people with rifampicin-resistant or multidrug-resistant tuberculosis. The role of MTBDRsl would be as the initial test, replacing
culture-based drug susceptibility testing (DST), for detecting second-line drug resistance.
Search methods
We searched the following databases without language restrictions up to 21 September 2015: the Cochrane Infectious Diseases Group
Specialized Register; MEDLINE; Embase OVID; Science Citation Index Expanded, Conference Proceedings Citation Index-Science,
and BIOSIS Previews (all three fromWeb of Science); LILACS; and SCOPUS; registers for ongoing trials; and ProQuest Dissertations
& Theses A&I. We reviewed references from included studies and contacted specialists in the field.
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Selection criteria
We included cross-sectional and case-control studies that determined MTBDRsl accuracy against a defined reference standard (culture-
based DST, genetic sequencing, or both).
Data collection and analysis
Two review authors independently extracted data and assessed quality using the Quality Assessment of Diagnostic Accuracy Studies
(QUADAS-2) tool. We synthesized data for versions 1.0 and 2.0 separately. We estimated MTBDRsl sensitivity and specificity for
fluoroquinolone resistance, SLID resistance, and extensively drug-resistant tuberculosis when the test was performed indirectly or
directly (smear-positive specimen for version 1.0, smear-positive or -negative specimen for version 2.0). We explored the influence on
accuracy estimates of individual drugs within a drug class and of different reference standards. We performed most analyses using a
bivariate random-effects model with culture-based DST as reference standard.
Main results
We included 27 studies. Twenty-six studies evaluated version 1.0, and one study version 2.0. Of 26 studies stating specimen country
origin, 15 studies (58%) evaluated patients from low- or middle-income countries. Overall, we considered the studies to be of high
methodological quality. However, only three studies (11%) had low risk of bias for the reference standard; these studies used World
Health Organization (WHO)-recommended critical concentrations for all drugs in the culture-based DST reference standard.
MTBDRsl version 1.0
Fluoroquinolone resistance: indirect testing, MTBDRsl pooled sensitivity and specificity (95% confidence interval (CI)) were 85.6%
(79.2% to 90.4%) and 98.5% (95.7% to 99.5%), (19 studies, 2223 participants); direct testing (smear-positive specimen), pooled
sensitivity and specificity were 86.2% (74.6% to 93.0%) and 98.6% (96.9% to 99.4%), (nine studies, 1771 participants, moderate
quality evidence).
SLID resistance: indirect testing, MTBDRsl pooled sensitivity and specificity were 76.5% (63.3% to 86.0%) and 99.1% (97.3% to
99.7%), (16 studies, 1921 participants); direct testing (smear-positive specimen), pooled sensitivity and specificity were 87.0% (38.1%
to 98.6%) and 99.5% (93.6% to 100.0%), (eight studies, 1639 participants, low quality evidence).
Extensively drug-resistant tuberculosis: indirect testing, MTBDRsl pooled sensitivity and specificity were 70.9% (42.9% to 88.8%) and
98.8% (96.1% to 99.6%), (eight studies, 880 participants); direct testing (smear-positive specimen), pooled sensitivity and specificity
were 69.4% (38.8% to 89.0%) and 99.4% (95.0% to 99.3%), (six studies, 1420 participants, low quality evidence).
Similar to the original Cochrane review, we found no evidence of a significant difference in MTBDRsl version 1.0 accuracy between
indirect and direct testing for fluoroquinolone resistance, SLID resistance, and extensively drug-resistant tuberculosis.
MTBDRsl version 2.0
Fluoroquinolone resistance: direct testing, MTBDRsl sensitivity and specificity were 97% (83% to 100%) and 98% (93% to 100%),
smear-positive specimen; 80% (28% to 99%) and 100% (40% to 100%), smear-negative specimen.
SLID resistance: direct testing, MTBDRsl sensitivity and specificity were 89% (72% to 98%) and 90% (84% to 95%), smear-positive
specimen; 80% (28% to 99%) and 100% (40% to 100%), smear-negative specimen.
Extensively drug-resistant tuberculosis: direct testing, MTBDRsl sensitivity and specificity were 79% (49% to 95%) and 97% (93% to
99%), smear-positive specimen; 50% (1% to 99%) and 100% (59% to 100%), smear-negative specimen.
We had insufficient data to estimate summary sensitivity and specificity of version 2.0 (smear-positive and -negative specimens) or to
compare accuracy of the two versions.
A limitation was that most included studies did not consistently use the World Health Organization (WHO)-recommended concen-
trations for drugs in the culture-based DST reference standard.
Authors’ conclusions
In people with rifampicin-resistant or multidrug-resistant tuberculosis, MTBDRsl performed on a culture isolate or smear-positive
specimen may be useful in detecting second-line drug resistance. MTBDRsl (smear-positive specimen) correctly classified around six
in seven people as having fluoroquinolone or SLID resistance, although the sensitivity estimates for SLID resistance varied. The test
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rarely gave a positive result for people without drug resistance. However, when second-line drug resistance is not detected (MTBDRsl
result is negative), conventional DST can still be used to evaluate patients for resistance to the fluoroquinolones or SLIDs.
We recommend that future work evaluate MTBDRsl version 2.0, in particular on smear-negative specimens and in different settings
to account for different resistance-causing mutations that may vary by strain. Researchers should also consider incorporating WHO-
recommended critical concentrations into their culture-based reference standards.
P L A I N L A N G U A G E S U M M A R Y
The rapid test GenoType® MTBDRsl for testing resistance to second-line TB drugs
Background
Different drugs are available to treat tuberculosis (TB), but resistance to these drugs is a growing problem. People with drug-resistant
TB require second-line TB drugs that, compared with first-line TB drugs, must be taken for longer and may be associated with more
harms. Detecting TB drug resistance quickly is important for improving health, reducing deaths, and decreasing the spread of drug-
resistant TB.
Definitions
Multidrug-resistant TB (MDR-TB) is caused by TB bacteria that are resistant to at least isoniazid and rifampicin, the two most potent
TB drugs.
Extensively drug-resistant TB (XDR-TB) is a type of MDR-TB that is resistant to nearly all TB drugs.
What test is evaluated by this review?
GenoType®MTBDRsl (MTBDRsl) is a rapid test for detecting resistance to second-line TBdrugs. In people withMDR-TB,MTBDRsl
is used to detect additional drug resistance. The test may be performed on TB bacteria grown in culture from a patient specimen
(indirect testing) or on a patient specimen (direct testing), which eliminates delays associated with culture. MTBDRsl version 1.0
requires a specimen to be smear-positive by microscopy, while version 2.0 (released in 2015) may use a smear-positive or -negative
specimen.
What are the aims of the review?
We wanted to find out how accurate MTBDRsl is for detecting drug resistance; to compare indirect and direct testing; and to compare
the two test versions.
How up-to-date is the review?
We searched for and used studies that had been published up to 21 September 2015.
What are the main results of the review?
We found 27 studies; 26 studies evaluated MTBDRsl version 1.0 and one study evaluated version 2.0.
Fluoroquinolone drugs
MTBDRsl version 1.0 (smear-positive specimen) detected 86% of people with fluoroquinolone resistance and rarely gave a positive
result for people without resistance (GRADE, moderate quality evidence).
Second-line injectable drugs
MTBDRsl version 1.0 (smear-positive specimen) detected 87% of people with second-line injectable drug resistance and rarely gave a
positive result for people without resistance (GRADE, low quality evidence).
XDR-TB
MTBDRsl version 1.0 (smear-positive specimen) detected 69% of people with XDR-TB and rarely gave a positive result for people
without resistance (GRADE, low quality evidence).
For MTBDRsl version 1.0, we found similar results for indirect and direct testing (smear-positive specimen).
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As we identified only one study evaluating MTBDRsl version 2.0, we could not be sure of the diagnostic accuracy of version 2.0. Also,
we could not compare accuracy of the two versions.
What is the methodological quality of the evidence?
We used the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool to assess study quality. Overall, we considered
the included studies to be of high quality; however, we had concerns about how the reference standard (the benchmark against which
MTBDRsl was measured) was applied.
What are the authors’ conclusions?
MTBDRsl (smear-positive specimen) identified most of the patients with second-line drug resistance. When the test reports a negative
result, conventional testing for drug resistance can still be used.
4GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Participants: pat ients with rif ampicin-resistant or MDR-TB
Prior testing: pat ients who received MTBDRsl test ing may have f irst received smear microscopy, Xpert® MTB/ RIF or other nucleic acid amplif icat ion test, and culture to
diagnose TB and Xpert® MTB/ RIF, MTBDRplus version 2.0 or an alternat ive line-probe assay to detect f irst-line drug resistance
Role: The role of MTBDRsl would be as the init ial test, replacing culture-based drug suscept ibility test ing, for detect ing second-line drug resistance
Settings: intermediate or central level laboratories
Index (new) test: MTBDRsl version 1.0.* The test was performed by direct test ing on smear-posit ive specimens
Reference standard: culture-based drug suscept ibility test ing
Studies: mainly cross-sect ional studies
Limitations: most included studies did not consistent ly use the World Health Organizat ion (WHO)-recommended concentrat ions for drugs in the culture-based reference
standard
Pooled sensitivity (95% CI): 86.2% (74.6% to 93.0%)
Pooled specificity (95% CI): 98.6% (96.9% to 99.4%)
Test result Number of results per 1000 patients tested (95% CI) Number of participants
(studies)
Quality of the evidence (GRADE)
Prevalence of 5% Prevalence of 10% Prevalence of 15%
True positives
(pat ients correct ly diag-
nosed with FQ resistance)
43 (37 to 47) 86 (75 to 93) 129 (112 to 140) 519
(9)
⊕⊕⊕©1,2,3,4
moderate
False negatives
(pat ients incorrect ly classi-
f ied as not having FQ resis-
tance)
7 (3 to 13) 14 (7 to 25) 21 (10 to 38)
True negatives
(pat ients correct ly classi-
f ied as not having FQ resis-
tance)
937 (921 to 944) 887 (872 to 895) 838 (824 to 845) 1252
(9)
⊕⊕⊕⊕1,2,3
high
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False positives
(pat ients incorrect ly clas-
sif ied as having FQ resis-
tance)
13 (6 to 29) 13 (5 to 28) 12 (5 to 26)
Abbreviat ions: CI: conf idence interval; DST: drug suscept ibility test ing; FQ: f luoroquinolone; GRADE: Grading of Recommenda-
t ions, Assessment, Development and Evaluat ion; SLID: second-line injectable drug; TB: tuberculosis; XDR-TB: extensively
drug-resistant TB.
By indirect test ing, MTBDRsl sensit ivity and specif icity (95%CI) were 85.6% (79.2% to 90.4%) and 98.5% (95.7% to 99.5%).
* This systematic review mainly evaluated MTBDRsl version 1.0, which has recent ly been replaced with version 2.0. We
considered the f indings in this review to be applicable to the current version of the test.
1Eight studies used a cross-sect ional study design and one study used a case-control study design.
2We used QUADAS-2 to assess risk of bias. All studies used consecut ive sampling. In seven studies, the reader of the index
test was blinded to results of the reference standard and in two studies information about blinding to the reference standard
was not reported. Several studies used crit ical concentrat ions for the culture-based DST reference standard that dif f ered
f rom the concentrat ions recommended by the WHO. This may have lowered specif icity, but this was not observed. We did not
downgrade.
3We considered indirectness (applicability) f rom the perspect ive of diagnost ic accuracy and had low concern. We did not
downgrade.
4For individual studies, sensit ivity est imates ranged f rom 33% to 100%. One small study with the lowest sensit ivity only
included three FQ-resistant pat ients. However, we could not explain the remaining heterogeneity by study quality or other
factors. We downgraded one level for inconsistency.
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B A C K G R O U N D
Tuberculosis (TB) is an infectious airborne disease caused byMy-
cobacterium tuberculosis bacteria. In 2014, an estimated 9.6 mil-
lion people developed TB and 1.5 million people died from TB;
1.1 million among human immunodeficiency virus (HIV)-nega-
tive people and 0.4 million among HIV-positive people (WHO
2015). Although the number of TB deaths has dropped by nearly
half since 1990, TB is now the most common cause of death from
an infectious disease in adults, surpassing HIV/acquired immune
deficiency syndrome (AIDS), which claimed 1.2 million lives. TB
is a preventable and treatable disease. TheWorldHealthOrganiza-
tion (WHO) estimated that, since 2000, 43million lives have been
saved through effective diagnosis and treatment (WHO 2015).
TB predominantly affects the lungs (pulmonary TB) but can af-
fect other parts of the body, such as the brain or the spine. Ac-
tive TB disease is confirmed by the presence of TB bacilli grown
in culture. The symptoms of pulmonary TB include a persistent
cough (for at least two weeks), fever, night sweats, weight loss,
chills, haemoptysis, and fatigue. TB that is drug sensitive (also re-
ferred to as drug-susceptible TB) is the most common type of TB
and may be effectively treated with a standardized regimen of first-
line anti-TB drugs (WHO 2015). However, TB bacilli may be-
come drug resistant, meaning that first-line anti-TB drugs can no
longer kill the bacilli. Drug resistance usually develops because of
inappropriate or incorrect use of first-line drugs, but new cases are
increasingly caused by person-to-person transmission (Streicher
2011; Zhao 2012).
The emergence of drug-resistant TB threatens to destabilize global
TB control. There are two standardized definitions of drug-resis-
tantTB:multidrug-resistantTB (MDR-TB) and extensively drug-
resistant TB (XDR-TB). MDR-TB is caused by M. tuberculosis
which, when tested microbiologically in the laboratory, is resistant
to rifampicin and isoniazid. These drugs are two of the most ef-
fective and widely-used anti-TB drugs that form part of the stan-
dardized first-line regimen for drug-susceptible TB. Patients with
MDR-TB are commonly treated with drugs belonging to the flu-
oroquinolone (FQ) and second-line injectable drug (SLID) anti-
TB drug classes. The FQ drugs include ofloxacin, levofloxacin,
moxifloxacin, and gatifloxacin and the SLIDs include amikacin
and kanamycin (two aminoglycoside drugs) and capreomycin (a
cyclic peptide drug). XDR-TB is caused by M. tuberculosis resis-
tant to isoniazid, rifampicin, plus any FQ and at least one of the
three SLIDs. Hence, patients with XDR-TB are resistant to both
first-line and second-line drugs.
Therapy for drug-resistant TB requires treatment formore than 12
months and is toxic and expensive. A systematic review estimated
only 62% (95% confidence interval (CI) 58% to 67%) of patients
initiated on treatment for MDR-TB were successfully treated (de-
fined as cured or completed treatment, Orenstein 2009). Around
10% of MDR-TB patients have XDR-TB, but this may be as high
as 30% in parts of Eastern Europe (WHO 2015). XDR-TB treat-
ment success rates are poor (26%), with high five-year mortality
(73%) inHIV-endemic settings (Pietersen 2014;WHO2015). In
South Africa in 2011, the treatment of approximately 8000 cases
of drug-resistant TB, which comprised only 2.2% of the total TB
burden, consumed 32% of the country’s annual national TB bud-
get of USD 218 million (Pooran 2013).
Improvements in the diagnosis of drug-resistantTBare also impor-
tant for reducing transmission. In South Africa, 80% ofMDR-TB
is thought to be spread from person-to-person (Streicher 2011),
and the same is likely true of MDR-TB and XDR-TB in China
(Zhao 2012). Modelling studies have shown that, through the im-
provement of capacity to rapidly diagnose drug-resistant TB, pa-
tient cure rates can be improved through the earlier initiation of
appropriate and effective TB treatment (Basu 2007; Basu 2009;
Dowdy 2008). Importantly, this can reduce infectiousness within
one to two weeks (Menzies 1997). However, the exact ’infectious-
ness period’ for drug-resistant TB remains unclear. There is thus
an urgent need for rapid tests that allow the early detection of drug
resistance and the selection of appropriate drugs.
The use of conventional phenotypic culture-based drug suscepti-
bility testing (DST) for detection of drug-resistant TB relies on the
growth of TBbacteria and is therefore associatedwith considerable
time delays (two to six months). These delays are exacerbated by
the technical and infrastructure requirements of testing, the lack
of standard methods for certain drugs and contamination (which
cause unclear results that require repeating) (Richter 2009), as well
as patient-associated difficulties, such as loss to follow-up. Once
a diagnosis of MDR-TB has been established, second-line DST
is typically used to diagnose second-line drug resistance. In 2015,
300,000 (of the estimated 450,000 cases) MDR-TB cases were
reported, yet only 24% received second-line DST (WHO 2015).
Molecular tests for detecting drug resistance such as the Geno-
type®MTBDRsl assay (henceforth calledMTBDRsl) have shown
promise for the diagnosis of drug-resistantTB.These tests are rapid
(around five hours), and genotypic, as they detect the presence
of mutations associated with drug resistance. MTBDRsl belongs
to a category of molecular genetic tests called line probe assays.
MTBDRsl version 1.0 was the first commercial line probe assay
for detection of resistance to second-line TB drugs and, since the
beginning of 2016, is no longer available. MTBDRsl version 2.0
was released in 2015. MTBDRsl version 2.0 detects the mutations
associated with FQ and SLID resistance detected by MTBDRsl
version 1.0, as well as additional mutations (described below). We
have included a glossary of genetic terms in Appendix 1. The draft
of this updated Cochrane review informed the WHO Guideline
Development Group that met February to March 2016 to make
recommendations about the use of this test. The WHO policy
guidance, “The use of molecular line probe assays for the detec-
tion of resistance to second-line anti-tuberculosis drugs”, was pub-
lished in May 2016 (WHO 2016).
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Target condition being diagnosed
We considered the following target conditions.
1. Fluoroquinolone (FQ) resistance.
2. Second-line injectable drug (SLID) resistance.
3. XDR-TB.
Index test(s)
The index test is MTBDRsl versions 1.0 and 2.0 (Hain Life
Sciences 2015; Table 1). MTBDRsl detects specific mutations as-
sociated with resistance to the FQs (including ofloxacin, mox-
ifloxacin, levofloxacin, and gatifloxacin) and SLIDs (including
kanamycin, amikacin, and capreomycin) in M. tuberculosis com-
plex species. Version 1.0 detects mutations in the gyrA quinolone
resistance-determining region (codons 88, 90, 91, 94) and rrs
(codons 1401, 1402, 1484).Version2.0 additionally detectsmuta-
tions in the gyrB quinolone resistance-determining region (codons
538, 540) and the eis promoter region (codons -37, -14, -12, -
10, -2) (Hain Life Sciences 2015a). As mutations in these regions
may cause additional resistance to the FQs or SLIDs respectively,
MTBDRsl version 2.0 should have heightened sensitivity for re-
sistance to these drug classes. Mutations in some regions (for ex-
ample, the eis promoter region) may be responsible for causing
resistance to one drug in a class more than other drugs within
that class. For example, the eis C14T mutation is associated with
kanamycin resistance in M. tuberculosis strains from Eastern Eu-
rope (Gikalo 2012). MTBDRsl version 1.0 also detects mutations
in embB that may encode for resistance to ethambutol. As this is
a first-line drug and was omitted from MTBDRsl version 2.0, we
did not determine the accuracy for ethambutol resistance.
For the FQs, the presence of mutations in each of the genes probed
by MTBDRsl has high but imperfect concordance with resistance
to all drugs within that drug class. For example, a mutation in the
gyrA gene may mean a strain is resistant to each of the FQs (for
example, ofloxacin and moxifloxacin) (Sirgel 2012a). The same
holds true for the rrs gene and the two aminoglycosides, kanamycin
and amikacin (Sirgel 2012b). Evidence is mixed regarding the level
of concordance between resistance to the two aminoglycosides and
capreomycin arising from mutations in the rrs gene. MTBDRsl
reports on the presence of mutations within these genes (as well
as gyrB and the eis promoter for MTBDRsl version 2.0), which
are associated with resistance to a class of drugs. The presence of
mutation(s) in these regions does not necessarily imply resistance
to all the drugs within that class.
For MTBDRsl version 1.0, the manufacturer recommended that
if the patient specimen (usually sputum) is smear-positive, the
assay be performed on the specimen (direct testing) and if smear-
negative, the assay be performed on the culture isolate grown from
the patient specimen (indirect testing). The manufacturer states
that MTBDRsl version 2.0 may be performed on a smear-positive
or smear-negative specimen without the need for culture.
The assay procedure involves the following steps: 1. decontami-
nation of the specimen; 2. isolation and amplification of DNA; 3.
detection of the amplification products by reverse hybridisation;
and 4. visualisation using a streptavidin-conjugated alkaline phos-
phatase colour reaction. The observed bands, each corresponding
to a probe, can be used to determine the drug susceptibility pro-
file of the analysed specimen. The assay can be completed in five
hours.
Figure 1 shows the line probe assay strips used for MTBDRsl ver-
sion 1.0 or version 2.0. A band for the detection of theM. tubercu-
losis complex (the ”TUB“ band) is included, as well as two internal
controls (conjugate and amplification controls) and a control for
each gene locus (MTBDRsl version 2.0: gyrA, gyrB, rrs, eis). The
two internal controls plus each gene locus control should be pos-
itive; otherwise the assay cannot be evaluated for that particular
drug. A result can be indeterminate for one locus but valid for
another (on the basis of a gene-specific locus control failing). A
template is supplied by the manufacturer to help read the strips,
where the banding patterns are scored by eye, transcribed, and re-
ported. In high-volume settings, the GenoScan®, an automated
reader, can be incorporated to interpret the banding patterns auto-
matically and give a suggested interpretation. If the operator agrees
with the interpretation, the results are automatically uploaded,
thereby reducing possible transcription errors.
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Figure 1. Comparison of version 1.0 and version 2.0 of the GenoType® MTBDRsl test (adapted from Hain
Life Sciences 2015).
Clinical pathway
Figure 2 illustrates the clinical pathway. Depending on the setting,
DST is either performed on all patients with confirmed TB or
on patients who are clinically suspected of having drug-resistant
TB (for example, if the patients’ symptoms have failed to improve
on first-line therapy, or if they still have M. tuberculosis bacilli in
their sputum after an extended period of treatment). DST for
resistance to the second-line drugs is usually only performed if
resistance to the first-line drugs is confirmed. Specifically, a pa-
tient with suspected drug-resistant TB provides a specimen (usu-
ally sputum), which is examined by smear microscopy. If smear-
positive, MTBDRsl version 1.0 or version 2.0 can be performed
directly on the specimen. If smear-negative, MTBDRsl version
1.0 should not be performed directly on the specimen, but rather
on the culture isolate. MTBDRsl version 2.0 may be performed
directly on a smear-negative specimen. A molecular test for first-
line drug resistance (for example, the MTBDRplus assay) may be
performed prior to testing withMTBDRsl if resistance to the first-
line drugs is yet to be confirmed. Phenotypic DST may still be
performed on culture-positive isolates.
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Figure 2. Clinical pathway. A patient to be evaluated for drug-resistant tuberculosis (TB) provides a
specimen (usually sputum), which is examined by smear microscopy. If smear-positive, MTBDRsl version 1.0 or
version 2.0 can be performed directly on the specimen. If smear-negative, MTBDRsl version 1.0should not be
performed directly on the specimen, but rather on the culture isolate. Version 2.0 may be performed directly
on a smear-negative specimen. A molecular test for first-line drug resistance (for example, the MTBDRplus
assay) may be performed prior to testing with MTBDRsl if resistance to the first-line drugs is yet to be
confirmed. Phenotypic (culture-based) drug susceptibility testing (DST) may still be performed on culture-
positive isolates.
Prior test(s)
Patients who received MTBDRsl testing may have first received
smear microscopy, Xpert®MTB/RIF or another nucleic acid am-
plification test, and culture to diagnose TB and Xpert® MTB/
RIF,MTBDRplus, or an alternative line-probe assay to detect first-
line drug resistance.
Role of index test(s)
The role of MTBDRsl would be as the initial test, replacing cul-
ture-based DST, for detecting second-line drug resistance.
Alternative test(s)
We are aware of several additional line probe assays marketed for
genotypic testing for second-line drug resistance: TB Resistance
Module Fluoroquinolones/Ethambutol and TB Resistance
Module Kanamycin/Amikacin/Capreomycin/Streptomycin (Au-
toimmun Diagnostika GmbH (AID) Strassberg); MolecuTech
REBA MTB-FQ®, MolecuTech REBA MTB-KM®, and Mole-
cuTech REBA MTB-XDR® (YD diagnostics, Seoul); and NiPro
LiPA FQ (NiPro Co, Osaka) (Boyle 2015). For a comprehensive
review of these tests, we refer the reader to the Tuberculosis Diag-
nostics Technology and Market Landscape report (Boyle 2015).
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Rationale
Second-line TB drugs are used to treat patients with TB that is
resistant to the most effective and widely used first-line drugs. To
ensure that themost appropriate and least toxic drugs are provided
to patients as quickly as possible, it is critical to know whether a
patient has resistance to FQs alone, resistance to SLIDs alone, or
resistance to both FQs and SLIDs (XDR-TB) as this will guide the
selection of drugs. The conventional method for the diagnosis of
drug resistance (culture-based DST) is vulnerable to contamina-
tion and loss of viability, meaning that the TB bacteria sometimes
cannot be regrown and a culture isolate is hence not available for
DST. Culture-based DST is also slow and can take several months.
The resulting diagnostic delay results in unnecessary morbidity,
mortality, and increased transmission, which is a major driver of
new TB cases. There is a need for rapid assays to improve time-to-
diagnosis and new molecular assays, such as the MTBDRsl assay,
present a promising potential solution.
O B J E C T I V E S
To assess and compare the diagnostic accuracy ofMTBDRsl for: 1.
fluoroquinolone resistance, 2. SLID resistance, and 3. extensively
drug-resistant tuberculosis, as an indirect test on aM. tuberculosis
isolate grown from culture or as a direct test on a patient speci-
men. The populations of interest were people with MDR-TB or
rifampicin-resistant TB, which is considered a proxy for MDR-
TB in high burden settings, WHO 2011.
Secondary objectives
We planned to investigate heterogeneity in relation to the type
of reference standard (culture-based drug susceptibility testing
(DST) compared with sequencing, culture-based DST and se-
quencing, and culture-based DST followed by sequencing of dis-
crepant results) and resistance to individual drugs within a drug
class (for example, ofloxacin, moxifloxacin, levofloxacin, and gat-
ifloxacin within the FQ class). We also prespecified in the proto-
col investigations of heterogeneity in relation to human immun-
odeficiency virus (HIV) status, condition of the specimen (fresh
or frozen, volume of specimen), patient population (patients sus-
pected of having MDR-TB or XDR-TB), and whether World
HealthOrganization (WHO)-recommended critical drug concen-
trations were used for the culture-based DST reference standard.
Subsequent to the published protocol, we added an investigation
of heterogeneity in relation to microscopy smear grade.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all studies that determined the diagnostic accuracy of
the index test in comparison with a defined reference standard, in-
cluding case-control designs.We only included studies fromwhich
we could extract data on true positives (TP), false positives (FP),
false negatives (FN), and true negatives (TN). We excluded un-
published studies reported only in abstracts and conference pro-
ceedings.
Participants
We included patients of any age who had rifampicin-resistant TB
or MDR-TB or may have had resistance to any of the second-line
TB drugs, irrespective of background burden of drug resistance
and patient population.
Index tests
The index test was MTBDRsl version 1.0 or version 2.0.
Target conditions
We considered the following target conditions.
1. Fluoroquinolone (FQ) resistance.
2. Second-line injectable drug (SLID) resistance.
3. XDR-TB.
Reference standards
We included studies that used one or more of the following refer-
ence standards.
1. Culture-based drug susceptibility testing (DST): solid
culture or a liquid culture.
2. Sequencing of the gyrA or rrs genes (MTBDRsl version 1.0)
or additionally the gyrB and eis promoter regions (MTBDRsl
version 2.0).
3. A composite reference standard with two components:
culture-based DST and sequencing of the same samples. If a
specimen was resistant according to culture-based DST or had a
mutation, we classified the specimen as having the target
condition. If both culture-based DST and sequencing indicated
susceptibility, we classified the specimen as not having the target
condition.
4. Two reference standards used sequentially: culture-based
DST followed by selective testing by sequencing of samples with
discrepant results. Discrepant results may be either index test
positive/culture-based DST negative or index test negative/
culture-based DST positive.
There are strengths and limitations to each of the reference stan-
dards. Culture-based DST is the accepted reference standard, but
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it is considered to be imperfect and is dependent on the drug
concentration threshold used to define resistance. Sequencing is
considered to be more accurate than culture-based DST; however,
this is only if it targets all known resistance-determining regions,
which are not fully known for the FQs and the SLIDs. There-
fore, targeted sequencing may miss mutations that cause drug re-
sistance.
We carried out separate analyses for the different reference stan-
dards, which we have described below. In our primary analysis we
used culture-based DST as the reference standard. We expected all
or nearly all included studies to report results using this reference
standard.
Search methods for identification of studies
We attempted to identify all relevant studies regardless of language
and publication status (published, unpublished, in press, and on-
going).
Electronic searches
Vittoria Lutje (VL), the Information Specialist for the Cochrane
Infectious Diseases Group (CIDG), performed literature searches
up to 21 September 2015 without language restrictions. To iden-
tify all relevant studies, she searched the following databases using
the search terms and strategy described in Appendix 2: CIDG Spe-
cialized Register; MEDLINE (PubMed, 1966 to 21 September
2015); Embase OVID (1980 to 21 September 2015); Science Ci-
tation Index Expanded (SCI-EXPANDED, 1900 to 21 September
2015, Conference Proceedings Citation Index-Science (CPCI-S,
1990 to 21 September 2015), and BIOSIS Previews (1926 to 21
September 2015; all three fromWeb of Science); LILACS (http:/
/lilacs.bvsalud.org/en/; 1982 to 21 September 2015); and SCO-
PUS (1995 to21September 2015). She also searched the ISRCTN
registry (http://isrctn.com) and the search portal of the World
Health Organization International Clinical Trials Registry Plat-
form (ICTRP; http://apps.who.int/trialsearch/) to identify ongo-
ing trials, and ProQuest Dissertations & Theses A&I to iden-
tify relevant dissertations (all websites accessed on 21 September
2015). We searched MEDION in the previous version of the re-
view, Theron 2014, but this database was unavailable in Septem-
ber 2015.
Searching other resources
We reviewed reference lists of included articles and any relevant re-
view articles identified through the above methods. We contacted
researchers at FIND and other experts in the field of TB diagnos-
tics for information on ongoing or unpublished studies.
Data collection and analysis
Selection of studies
Two review authors (GT and JP) independently scrutinized titles
and abstracts identified by electronic literature searches to identify
potentially eligible studies. We selected all citations identified as
suitable during this screen for full-text review.The same two review
authors then independently reviewed full-text papers for study
eligibility using the predefined inclusion and exclusion criteria.
For full-text articles, we resolved any discrepancies by discussion
with a third review author (KRS).Wemaintained a list of excluded
studies and their reasons for exclusion, and recorded these details
in the ’Characteristics of excluded studies’ table and prepared a
PRISMA diagram.
Data extraction and management
We developed a standardized data extraction form and piloted
the form with two of the included studies. Based upon the pilot,
we finalized the form. Then two review authors (GT and JP)
independently extracted data on the following characteristics and
resolved any discrepancies by discussion.
1. Details of study: first author; publication year; country
where testing was performed; specimen country origin; setting
(primary care laboratory, hospital laboratory, reference
laboratory); study design; manner of participant selection;
number of participants enrolled; number of participants for
whom results available; industry sponsorship.
2. Characteristics of participants: age; HIV status; smear
status; history of TB; known MDR-TB, pre-XDR-TB (defined
as MDR-TB and resistance to a FQ or SLID, but not to drugs
from both classes), or XDR-TB status.
3. Target conditions: resistance to FQ and SLID drug classes
and XDR-TB.
4. Resistances to individual drugs: ofloxacin, moxifloxacin,
levofloxacin, gatifloxacin, amikacin, kanamycin, and
capreomycin.
5. Reference standards: type; percentage of patients whose
reference standard was ’uninterpretable’ (for example,
contaminated, sequencing failed).
6. Details of specimen: type (such as expectorated sputum,
induced sputum or culture isolate); condition (fresh or frozen);
definition of a positive smear; type of testing (direct testing or
indirect testing); smear grade (negative, scanty, 1+, 2+, 3+).
7. Details of outcomes: the number of TP, FP, FN, and TN
results; number of indeterminate assay results.
8. Intra-reader and inter-reader variability.
9. Time to treatment initiation: defined as the time from
specimen collection until patient starts treatment.
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10. Time to diagnosis: defined as the time from specimen
collection until there is an available TB result in lab or clinic, if
the assay was performed in a clinic.
We assigned country income status (high, middle or low) as clas-
sified by the World Bank List of Economies (World Bank 2015).
We contacted authors of primary studies for missing data or clari-
fications. We assigned smear grade according to theWHO defini-
tion (WHO 2014). We entered all data into a database manager
(Microsoft Excel 2014).
For one study that tested the same panel of TB isolates in mul-
tiple centres, we selected one centre that provided results in the
middle range (neither the best nor the worst results) (Ignatyeva
2012). One study included extrapulmonary specimens, which we
excluded from the analysis (Barnard 2012). Whenever possible,
we extracted data that used a single patient as the unit of analysis
(one MTBDRsl result per one specimen from one patient).
When culture-based DST was performed using more than one
drug from the FQs (ofloxacin, moxifloxacin, levofloxacin, or gati-
floxacin) or SLIDs (amikacin, kanamycin or capreomycin), we ex-
tracted TP, FP, FN, and TN values for each drug and for each class
overall. If the reference standard indicated resistance for at least
one drug in that class, we classified the sample as resistant to that
class of drugs. We did not require reference standard DST results
for all drugs in a class in order to classify a sample as resistant or
susceptible.
In the 2 x 2 tables of TP, FP, FN, and TN, we based the results
of the index test on categorical assay results defined by the visual
readout of the MTBDRsl strip.
Possible results for the GenoType® MTBDRsl assay (as
defined by the product manual)
1. Sensitive to either FQs or SLIDs (referred to as
’aminoglycosides/cyclic peptides’), or both (conjugation and
amplification bands present;Mycobacterium tuberculosis
complex-specific control (TUB) band present; gene locus band
present; all wild type (wt) bands for each gene present; no
mutation bands present). In the case of susceptibility to both
drug classes, the test would indicate susceptibility for each, rather
than having a single composite readout specifying XDR-TB.
2. Resistant to either FQs or SLIDs, or both (conjugation and
amplification bands present; TUB band present; gene locus band
present; all, none or some wt bands for each gene present; all,
none or some mutation bands present with similar intensity to
amplification control). In the case of resistance to both drug
classes, the test would indicate resistance for each, rather than
having a composite readout.
3. Indeterminate (faint bands) or no result (no conjugation or
amplification bands present, no locus band present for the gene
of interest).
4. No TB (negative for MTB complex irrespective of locus
control band).
5. No result (failure of any one of the control bands, as well as
the TUB band).
No studies reported on the number of ’no TB’ or ’no result’ results
obtained fromMTBDRsl, therefore we only extracted the number
and percentage of ’indeterminate’ results.
Assignment of results to the fluoroquinolones, second-line
injectable drugs, or both categories
We were able to report accuracy estimates for individual drugs
within the drug classes when that drug was used as part of the cul-
ture-based DST reference standard. For determining resistance to
the drug class, we used the following approach. For a culture-based
DST reference standard, one study might have used detection of
ofloxacin resistance and another study, detection of moxifloxacin
resistance to confirm an MTBDRsl FQ-resistant result. In such a
scenario, if culture-based DST is positive for resistance to one of
the drugs in the drug class and theMTBDRsl result is concordant,
we classified the index test result as a true positive for resistance to
the FQs. We adopted the same approach for the SLIDs.
For sequencing as a reference standard, if the index test reported
resistance to FQs and the presence of mutations known to be
associated with drug resistance to the FQs was confirmed in the
same regions of the genome targeted by MTBDRsl, we recorded
the test result as concordant and classified the index test as a true
positive for resistance to the FQs. We adopted the same approach
for the SLIDs.
Assessment of methodological quality
We appraised the quality of the included studies with the Qual-
ity Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool
(Whiting 2011; Appendix 3). QUADAS-2 consists of four do-
mains: patient selection, index test, reference standard, and flow
and timing. We assessed all domains for risk of bias and the first
three domains for concerns regarding applicability. We used sig-
nalling questions in each domain to form judgments about the risk
of bias.One review author (GT) piloted the tool with two included
studies and finalized the tool based on experience gained from the
pilot testing. Three review authors (GT, JP, and KRS) then inde-
pendently assessed the methodological quality of included studies
with the finalized tool and finalized judgments by discussion.
Statistical analysis and data synthesis
We performed descriptive analyses for key variables (such as coun-
try income status) of the primary studies using Stata (Stata 2015),
and displayed key study characteristics in the ’Characteristics of
included studies’ table.
We analysed data separately for MTBDRsl version 1.0 and version
2.0. We used the reference standard culture-based DST in our pri-
mary analyses. We stratified these analyses first by target condition
and second by type of MTBDRsl testing (indirect testing or direct
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testing). Within each stratum (for example, FQ resistance by in-
direct testing), we plotted estimates of the studies’ observed sen-
sitivities and specificities in forest plots with 95% confidence in-
tervals (CIs) and in receiver operating characteristic (ROC) space
using Review Manager (RevMan) (RevMan 2014). Where ade-
quate data were available, we combined data using meta-analysis.
We performedmost meta-analyses by fitting the bivariate random-
effects model (Macaskill 2010; Reitsma 2005), using Stata with
the metandi and xtmelogit commands (Stata 2015). In situations
with few studies, we performed meta-analysis where appropriate
by reducing the bivariate model to two univariate random-effects
logistic regressionmodels by assuming no correlation between sen-
sitivity and specificity. When we observed little or no heterogene-
ity on forest plots and summary receiver operating characteristic
(SROC) plots, we further simplified the models into fixed-effect
models by eliminating the random-effects parameters for sensi-
tivity or specificity, or both sensitivity and specificity (Takwoingi
2015).
We compared results from studies of direct testing with results
from studies of indirect testing by adding a covariate for the type of
testing to themodel.We assessed the significance of the differences
in sensitivity and specificity estimates between studies in which
MTBDRsl was performed by direct testing or indirect testing by a
likelihood ratio test comparing models with and without covari-
ate terms. Where data were sufficient, we performed comparative
analyses including only those studies thatmade direct comparisons
between test evaluations with the same participants. Otherwise,
we included all studies with available data. Comparative studies
are preferred to non-comparative studies when deriving evidence
of diagnostic test accuracy (Takwoingi 2013).
Approach to uninterpretable (indeterminate) MTBDRsl
results
We excluded indeterminate test results from the analyses for de-
termination of sensitivity and specificity. We determined the per-
centage of indeterminate MTBDRsl results among the primary
studies for each target condition and summarized these findings
separately for indirect and direct testing when available, according
to culture-based reference standard.
Investigations of heterogeneity
Within each stratum (for example, SLID resistance, indirect test-
ing), we investigated heterogeneity through visual examination of
forest plots of sensitivity and specificity. Then, if sufficient studies
were available, we explored the possible influence of the following
prespecified categorical covariates: reference standard (culture, se-
quencing, culture and sequencing, culture followed by sequenc-
ing); resistance to the following drugs: ofloxacin, moxifloxacin,
levofloxacin, gatifloxacin, amikacin, kanamycin, and capreomycin
(we excluded resistance to ciprofloxacin because this drug is infre-
quently used in DST); and drug concentration used for culture-
based DST (WHO-recommended critical concentration used or
a different concentration used). In addition, for this updated re-
view, we added an investigation of heterogeneity in relation to
microscopy smear grade. We assessed the significance of the dif-
ference in test accuracy (for example, between studies using cul-
ture versus those using sequencing as the reference standard) by a
likelihood ratio test comparing models with and without covariate
terms.
We had planned to investigate the effect of HIV status, the condi-
tion of the specimen (fresh or frozen), sample volume, and popu-
lation (patients thought to have MDR-TB or XDR-TB) on sum-
mary estimates of sensitivity and specificity in a meta-regression
analysis by adding covariate terms to the bivariate model. How-
ever, there were insufficient data for these additional analyses.
Sensitivity analyses
For our primary analyses using the culture-based DST reference
standard, we performed sensitivity analyses for QUADAS-2 items
to explore whether the accuracy estimates were robust with respect
to the methodological quality of the studies. We included the
following signalling questions.
1. Was a consecutive or random sample of patients/specimens
enrolled?
2. Was a case-control design avoided?
3. Were the index test results interpreted without knowledge
of the results of the reference standard?
4. Was the test applied in the manner recommended by the
manufacturer (index test domain, low concern about
applicability)?
Assessment of reporting bias
We did not undertake a formal assessment of publication bias of
data included in this review using methods such as funnel plots
or regression tests because such techniques have been unhelpful
for determining publication bias within diagnostic test accuracy
studies (Macaskill 2010).
Other analyses
We had intended to summarize data on intra- and inter-reader
variability; however inter-reader variability was the only informa-
tion described in the included studies. We had also intended to
summarize two patient outcomes, time-to-diagnosis, and time-to-
treatment initiation; however time-to-diagnosis was the only out-
come described in the included studies.
Assessment of the quality of evidence (certainty of
the evidence)
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We assessed the quality of evidence (also called certainty of
the evidence or confidence in effect estimates) using the Grad-
ing of Recommendations Assessment, Development and Eval-
uation (GRADE) approach (Balshem 2011; GRADE 2013),
and GRADEpro Guideline Development Tool (GDT) software
(GRADEpro GDT 2015). In the context of a systematic review,
the ratings of the certainty of the evidence reflect the extent of
our confidence that the estimates of the effect (including test ac-
curacy and associations) are correct. As recommended, we rated
the quality of evidence as either high (not downgraded), moderate
(downgraded by one level), low (downgraded by two levels), or
very low (downgraded by more than two levels) for five domains:
risk of bias, indirectness, inconsistency, imprecision, and publi-
cation bias. For each outcome, the quality of evidence started as
high when there were high quality observational studies (cross-sec-
tional or cohort studies) that enrolled participants with diagnostic
uncertainty. If we found a reason for downgrading, we used our
judgement to classify the reason as either serious (downgraded by
one level) or very serious (downgraded by two levels).
Three review authors (GT, JP, and KRS) discussed judgments and
applied GRADE in the following way.
1. Risk of bias: we used QUADAS-2 to assess risk of bias.
2. Indirectness: we considered indirectness from the
perspective of test accuracy. We used QUADAS-2 for concerns
of applicability and looked for important differences between the
populations studied (for example, in the spectrum of disease),
the setting, and the review questions.
3. Inconsistency: GRADE recommends downgrading for
unexplained inconsistency in sensitivity and specificity estimates.
We carried out prespecified analyses to investigate potential
sources of heterogeneity and did not downgrade the quality of
the evidence when we felt we could explain inconsistency in the
accuracy estimates.
4. Imprecision: we considered a precise estimate to be one that
would allow a clinically meaningful decision. We considered the
width of the CI, and asked ourselves, “Would we make a
different decision if the lower or upper boundary of the CI
represented the truth?” In addition, we worked out projected
ranges for TP, FN, TN, and FP for a given TB prevalence and
made judgements on imprecision from these calculations.
5. Publication bias: we rated publication bias as undetected
(not serious) because of the comprehensiveness of the literature
search and extensive outreach to TB researchers to identify
studies.
R E S U L T S
Results of the search
We identified 27 unique studies that met the inclusion criteria of
this review. All studies but two (Fan 2011, written in Chinese and
Chikamatsu 2012, written in Japanese) were written in English.
ForMTBDRsl version1.0,we included 26 studies: 21 studies from
Theron 2014, the original Cochrane review (Ajbani 2012; Barnard
2012; Brossier 2010a; Chikamatsu 2012; Fan 2011; Ferro 2013;
Hillemann 2009; Huang 2011; Ignatyeva 2012; Jin 2013; Kiet
2010; Kontsevaya 2011; Kontsevaya 2013; Lacoma 2012; Lopez-
Roa 2012; Miotto 2012; Said 2012; Surcouf 2011; Tukvadze
2014; van Ingen 2010; Zivanovic 2012) and five new studies (
Catanzaro 2015; Kambli 2015a; Kambli 2015b; Simons 2015;
Tomasicchio 2016). For MTBDRsl version 2.0, we included one
study (Tagliani 2015). Figure 3 shows the flow of studies in the
review. We recorded the excluded studies and the reasons for their
exclusion in the ’Characteristics of excluded studies’ table.
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Figure 3. Study flow diagram for searches run from January 2014 to 21 September 2015.
Methodological quality of included studies
Figure 4 and Figure 5 show risk of bias and applicability con-
cerns for each of the 27 included studies. In the patient selec-
tion domain, we judged that 17 studies (63%) had low risk of
bias (Ajbani 2012; Barnard 2012; Catanzaro 2015; Ferro 2013;
Huang 2011 Jin 2013; Kambli 2015a; Kambli 2015b; Kontsevaya
2011; Kontsevaya 2013; Lacoma 2012; Said 2012; Simons 2015;
Surcouf 2011; Tagliani 2015; Tukvadze 2014; Zivanovic 2012).
We judged that one study (4%) had unclear risk of bias because
the manner of patient selection was unclear (Chikamatsu 2012).
We judged that nine studies had high risk of bias for the following
reasons.
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Figure 4. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies.
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Figure 5. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.For direct testing of smear-positive specimens, Miotto 2012 and Tomasicchio 2016 had
low risk of bias in the patient selection domain.
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1. There was a case-control design (four studies: Brossier
2010a; Hillemann 2009; Ignatyeva 2012; Kiet 2010).
2. There was a cross-sectional design for samples used in direct
testing and case-control design for samples used in indirect
testing (two studies: Miotto 2012; Tomasicchio 2016).
3. Enrolment was by convenience (three studies: Fan 2011;
Lopez-Roa 2012; van Ingen 2010).
Regarding applicability (patient characteristics and setting), we
judged that 21 studies (78%) had low concern and six studies
had high concern (Brossier 2010a; Hillemann 2009; Ignatyeva
2012; Kiet 2010; Miotto 2012; van Ingen 2010). In the in-
dex test domain, we judged that 18 studies (67%) had low risk
of bias (Ajbani 2012; Barnard 2012; Hillemann 2009; Huang
2011; Ignatyeva 2012; Jin 2013; Kambli 2015a; Kambli 2015b;
Kontsevaya 2011; Kontsevaya 2013; Lacoma 2012; Miotto 2012;
Said 2012; Simons 2015; Tagliani 2015; Tomasicchio 2016; van
Ingen 2010; Zivanovic 2012); seven (26%) studies had unclear
risk of bias because information about blinding was not re-
ported (Brossier 2010a; Catanzaro 2015; Fan 2011; Ferro 2013;
Lopez-Roa 2012; Surcouf 2011; Tukvadze 2014); and two stud-
ies had high risk of bias because the index test results were not
interpreted without knowledge of the reference standard results
(Chikamatsu 2012; Kiet 2010). Regarding applicability of the in-
dex test, we judged that 24 studies (89%) had low concern, one
study (4%) had high concern (Catanzaro 2015), and two studies
had unclear concern (Brossier 2010a; Tukvadze 2014).
In the reference standard domain, we judged that only three stud-
ies (11%) had low risk of bias (Kambli 2015b; Lopez-Roa 2012;
Tomasicchio 2016) because these studies used the WHO-recom-
mended critical concentration for each drug included in the cul-
ture-based drug susceptibility testing (DST) reference standard;
18 studies (67%) had unclear risk of bias (Ajbani 2012; Barnard
2012; Catanzaro 2015; Hillemann 2009; Huang 2011; Ignatyeva
2012; Fan 2011; Ferro 2013; Kambli 2015a; Kontsevaya 2011;
Kontsevaya 2013;Miotto 2012; Said 2012; Simons 2015; Surcouf
2011; Tagliani 2015; Tukvadze 2014; Zivanovic 2012), because
these studies used the World Health Organization (WHO)-rec-
ommended critical concentration for some, but not all of the drugs
included in the culture-based DST reference standard; and six
studies had high risk of bias (Brossier 2010a; Chikamatsu 2012;
Jin 2013; Kiet 2010; Lacoma 2012; van Ingen 2010) because these
studies did not use WHO-recommended critical concentrations
for any of the drugs included in the culture-based DST reference
standard. Regarding applicability of the reference standard, we
judged that all studies had low concern. In the flow and timing
domain, we judged that 26 studies (96%) had low risk of bias and
one study had unclear risk of bias because we could not account
for all patients in the analyses (Ferro 2013).
We noted industry involvement in eight studies (30%) and this
included the following.
1. Donation of MTBDRsl (five studies: Ferro 2013;
Hillemann 2009; Miotto 2012; Surcouf 2011; Tagliani 2015).
2. Preferred pricing of MTBDRsl (one study: Barnard 2012).
3. Financial support for non-test related study costs (one
study: Said 2012).
4. Involvement in the design, analysis or manuscript
production (one study: Ajbani 2012).
Findings
We presented key characteristics of the 27 included studies in the
’Characteristics of included studies’ table. Of 26 studies report-
ing specimen country origin, 15 studies (58%) evaluated patients
from low- or middle-income countries. The median sample size
(interquartile range) was 95 (44 to 176).
MTBDRsl version 1.0
Table 2 (indirect testing) and Table 3 (direct testing) show the
number of studies that evaluated MTBDRsl version 1.0, accord-
ing to the reference standard and target condition. We did not
identify any studies that evaluated the accuracy of MTBDRsl for
gatifloxacin resistance.
I. Fluoroquinolone resistance detection
A. Estimates of the diagnostic accuracy of MTBDRsl using
culture-based DST as a reference standard
1. Indirect testing
Nineteen studies (2223 participants, 869 (39.1%) confirmed cases
of fluoroquinolone (FQ)-resistant TB) evaluated MTBDRsl by
indirect testing for detection of FQ resistance (Figure 6). Sensitiv-
ity estimates ranged from 57% to 100% and specificity estimates
ranged from 77% to 100%. The pooled sensitivity and specificity
(95% CI) were 85.6% (79.2% to 90.4%) and 98.5% (95.7% to
99.5%) (Table 4).
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Figure 6. Forest plots of MTBDRsl sensitivity and specificity for fluoroquinolone (FQ) resistance, the test
performed indirectly or directly against culture-based drug susceptibility (DST) as a reference standard. TP =
true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95%
confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and
specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered
by decreasing sensitivity.
2. Direct testing
Nine studies (1771 participants, 519 (29.3%) confirmed cases of
FQ-resistant TB) evaluated MTBDRsl by direct testing for de-
tection of FQ resistance, (Figure 6). Sensitivity estimates ranged
from 33% to 100% and specificity estimates ranged from 91%
to 100%. The pooled sensitivity and specificity (95% CI) were
86.2% (74.6% to 93.0%) and 98.6% (96.9% to 99.4%) (Table
4).
3. Comparison of indirect versus direct testing
(a) Diagnostic accuracy
Based on analysis of all data, there was no evidence of a statisti-
cally significant difference in MTBDRsl version 1.0 accuracy for
FQ resistance between indirect and direct testing (smear-positive
specimen) when using culture-based DST as a reference standard
(P values for differences in sensitivity and specificity of 0.932 and
0.333, respectively) (Table 4). Direct within-study comparisons
were not possible because no studies performedMTBDRsl testing
on specimens and isolates from the same patients.
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(b) Indeterminate rates
MTBDRsl version 1.0: for indirect testing for culture-confirmed
resistance to FQs, of 14 studies that reported indeterminate
MTBDRsl results, eight of 2065 results (0.4%) were indetermi-
nate (seven culture-DST resistant and one culture-DST sensitive).
For direct testing on a smear-positive specimen, of nine studies
that reported indeterminate MTBDRsl results, 147 of 2059 re-
sults (7.1%)were indeterminate (68 culture-DST resistant, 73 sus-
ceptible, and six whose culture phenotypic status was unknown).
The indeterminate rates for direct testing for each smear-grade
(smear-negative, scanty, 1+, 2+, 3+) were 61/190 (32.1%), 28/133
(21.1%), 35/272 (12.9%), 19/211 (9.0%), and 44/388 (11%),
respectively.
B. Investigations of heterogeneity
1. Indirect testing
(a) Individual drugs within the drug class
Wepresent accuracy estimates forMTBDRslby indirect testing for
detection of resistance to ofloxacin, moxifloxacin, and levofloxacin
in Table 5 and Appendix 4.
For detection of ofloxacin resistance by indirect testing, sensitivity
estimates ranged from 70% to 100% and specificity estimates
ranged from 91% to 100%. The pooled sensitivity and specificity
(95% CI) were 85.2% (78.5% to 90.1%) and 98.5% (95.6% to
99.5%), (13 studies, 1927 participants).
For detection of moxifloxacin resistance by indirect testing, sen-
sitivity estimates ranged from 57% to 100% and specificity esti-
mates from 77% to 100%. The pooled sensitivity and specificity
(95% CI) were 94.0% (82.2% to 98.1%) and 96.6% (85.2% to
99.3%), (six studies, 419 participants).
We identified two studies for detection of levofloxacin resistance
by indirect testing. Sensitivity and specificity estimates (95% CI)
were 80%(56%to94%) and96%(80%to100%) forChikamatsu
2012, and 100% (96% to 100%) and 100% (88% to 100%) for
Kambli 2015b. We did not determine summary estimates because
there were only two studies and the sensitivity was variable.
(b) Drug concentration used in culture-based DST
Appendix 5 shows ofloxacin, levofloxacin, and moxifloxacin drug
concentrations used in culture-based DST in relation to the
WHO-recommended critical concentrations.
Ofloxacin: eight studies used the WHO-recommended critical
concentration of ofloxacin (Fan 2011; Huang 2011; Ignatyeva
2012; Kambli 2015a; Lopez-Roa 2012; Miotto 2012; Said 2012;
Tomasicchio 2016), whereas two did not (Brossier 2010a; Kiet
2010). Two studies used two different types of culture medium
but only used the WHO-recommended critical concentration
of ofloxacin for one type of culture medium (Hillemann 2009;
Zivanovic 2012). Jin 2013 used a non-WHO recommended con-
centration for one type of culture medium and no recommended
concentration existed for the other culture type. There was no
evidence of a statistically significant difference in MTBDRsl ver-
sion 1.0 accuracy for ofloxacin resistance between studies that did
or did not use the WHO-recommended critical concentration (P
values for differences in sensitivity and specificity of 0.960 and
0.904, respectively).
Moxifloxacin: Ferro 2013 used the WHO-recommended criti-
cal concentration for low-level moxifloxacin resistance whereas
Lacoma 2012 used the concentration recommended for high-level
resistance. Four studies did not use the recommended critical con-
centration of moxifloxacin (Fan 2011; Kambli 2015a; Simons
2015; van Ingen 2010).
Levofloxacin: one study used the WHO-recommended critical
concentration (Kambli 2015b), and one study (Chikamatsu 2012)
used a culturemedia type for which a recommended concentration
does not exist.
Comparisons between accuracy estimates for moxifloxacin and
levofloxacin according to critical concentration were not possible
given the small number of studies.
(c) Type of reference standard
We present MTBDRsl accuracy estimates for detection of FQ
resistance against different reference standards in Table 6 and
Appendix 6.
Reference standard is sequencing
Using sequencing, MTBDRsl version 1.0 sensitivity estimates
ranged from 85% to 100% and specificity estimates ranged from
92% to 100%. Based on comparative studies, the pooled sensitiv-
ity and specificity (95% CI) were 99.3% (81.2% to 100.0%) and
99.3% (90.8% to 100.0%), (six studies, 873 participants). There
was evidence of a significantly higher sensitivity using sequencing
as the reference standard compared with culture-based DST (P
value < 0.001), but not specificity (P value of 0.735).
Reference standard is culture-basedDST and sequencing (i.e. both
investigations performed on all isolates)
Using culture and sequencing, MTBDRsl version 1.0 sensitiv-
ity estimates ranged from 74% to 91% and specificity estimates
ranged from 99% to 100%. Based on comparative studies, the
pooled sensitivity and specificity (95% CI) were 82.0% (77.7%
to 85.6%) and 99.8% (98.5% to 100.0%), (seven studies, 1211
participants). There was no evidence of a statistically significant
difference using both culture-based DST and sequencing as the
reference standard compared with culture-based DST (P values
for differences in sensitivity and specificity of 0.664 and 0.070,
respectively).
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Reference standard is culture-based DST followed by sequencing
of discrepant index test-culture-based DST results
Using sequencing of discrepant results,MTBDRsl version 1.0 sen-
sitivity estimates ranged from 73% to 100% and specificity es-
timates ranged from 94% to 100%. The pooled sensitivity and
specificity (95% CI) were 83.7% (74.2% to 90.8%) and 99.7%
(98.4% to 100.0%), (three studies, 427 participants). We did not
performwithin study comparisons between accuracy estimates us-
ing this reference standard and culture-based DST given the small
number of studies in the former group.
2. Direct testing
(a) Individual drugs within the drug class
We present accuracy estimates for MTBDRsl version 1.0 by direct
testing for detection of resistance to ofloxacin and moxifloxacin
in Table 5 and Appendix 7. We did not identify any studies that
performed direct testing for detection for levofloxacin resistance.
For detection of ofloxacin resistance by direct testing, MTBDRsl
version 1.0 sensitivity estimates ranged from 79% to 100% and
specificity estimates ranged from 98% to 100%, (seven studies,
1667 participants). The pooled sensitivity and specificity (95%
CI) were 90.9% (84.7% to 94.7%) and 98.9% (97.8% to 99.4%).
Based on all data, there was no evidence of a statistically signif-
icant difference between indirect and direct testing for ofloxacin
resistance (P values for differences in sensitivity and specificity of
0.180 and 0.161, respectively).
For detection of moxifloxacin resistance by direct testing,
Catanzaro 2015 reportedMTBDRsl version 1.0 sensitivity of 96%
and specificity of 99% and Ajbani 2012 reported a sensitivity of
92% and specificity of 98%. The pooled sensitivity and specificity
(95% CI) were 95.0% (92.1% to 96.9%) and 99.0% (95% CI
97.5% to 99.6%), (two studies, 821 participants). Based on all
data, there was no evidence of a statistically significant difference
between indirect and direct testing for moxifloxacin resistance (P
values for differences in sensitivity and specificity of 0.820 and
0.365, respectively).
(b) Drug concentration used in culture-based DST
Appendix 5 shows ofloxacin andmoxifloxacin drug concentrations
used in culture-basedDST in relation to theWHO-recommended
critical concentrations.
Ofloxacin: five studies used theWHO-recommended critical con-
centration of ofloxacin (Ajbani 2012; Barnard 2012: Catanzaro
2015; Miotto 2012; Tomasicchio 2016), whereas one study did
not (Tukvadze 2014). Hillemann 2009, which used two types of
culture medium, used the recommended concentration for one
culture type and a non-recommended concentration for the other.
Moxifloxacin: neither study used theWHO-recommended critical
concentration of moxifloxacin (Ajbani 2012; Catanzaro 2015).
Comparisons between accuracy estimates according to whether or
not WHO-recommended critical drug concentrations were used
for culture-based reference testingwere not possible given the small
number of studies.
(c) Stratification by smear grade
There were limited data on MTBDRsl version 1.0 accuracy for
individual FQ drugs by smear grade. Figure 7 presents the forest
plots for ofloxacin resistance by smear grade.
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Figure 7. Forest plots of MTBDRsl sensitivity and specificity for ofloxacin resistance by smear grade, using
culture-based drug susceptibility testing (DST) as a reference standard. TP = true positive; FP = false positive;
FN = false negative; TN = true negative. Between brackets are the 95% confidence intervals (CIs) of sensitivity
and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95%
CI (black horizontal line). The individual studies are ordered by decreasing sensitivity.
(d) Type of reference standard
Reference standard is sequencing
No studies performed direct MTBDRsl version 1.0 testing and
used sequencing as a reference standard.
Reference standard is culture-basedDST and sequencing (i.e. both
investigations performed on all isolates)
No studies performed direct MTBDRsl version 1.0 testing and
used both culture-based DST and sequencing (performed on all
isolates) as a reference standard.
Reference standard is culture-based DST followed by sequencing
of discrepant index test-culture-based DST results
Two studies (685 participants) reported MTBDRsl version 1.0
sensitivity and specificity when performed directly for the detec-
tion of resistance to FQs, with culture-based DST and sequencing
performed only on discrepant results as a reference standard. The
reported sensitivity and specificity (95% CI) were 91% (84% to
96%) and 98% (92% and 100%) for Ajbani 2012, and 96% (88%
to 100%) and 99% (98% to 100%) for Barnard 2012.
II. Second-line injectable drug resistance detection
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A. Estimates of the diagnostic accuracy of MTBDRsl using
culture-based DST as a reference standard
1. Indirect testing
Sixteen studies (1921 participants, 575 (29.9%) confirmed cases
of second-line injectable drug (SLID)-resistant TB) evaluated
MTBDRsl version 1.0 by indirect testing for detection of SLID
resistance (Figure 8). Sensitivity estimates ranged from 25% to
100% and specificity estimates ranged from 86% to 100%. The
pooled sensitivity and specificity (95% CI) were 76.5% (63.3%
to 86.0%) and 99.1% (97.3% to 99.7%) (Table 4).
Figure 8. Forest plots of MTBDRsl sensitivity and specificity for SLID resistance, the test performed
indirectly or directly against culture-based drug susceptibility testing (DST) as a reference standard. TP = true
positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95%
confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and
specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered
by decreasing sensitivity.
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2. Direct testing
Eight studies (1639 participants, 348 (21.2%) confirmed cases of
FQ-resistantTB) evaluatedMTBDRsl version 1.0 by direct testing
for detection of SLID resistance (Figure 8). For individual stud-
ies, sensitivity estimates ranged from 9% to 100% and specificity
estimates ranged from 58% to 100%. The pooled sensitivity and
specificity (95% CI) were 87.0% (38.1% to 98.6%) and 99.5%
(93.6% to 100.0%) (Table 4).
3. Comparison of indirect versus direct testing
(a) Diagnostic accuracy
Based on analysis of all data, there was no evidence of a statistically
significant difference in MTBDRsl version 1.0 accuracy for SLID
resistance between indirect and direct testing when using culture-
based DST as a reference standard (P values for differences in
sensitivity or specificity of 0.547 and 0.664, respectively) (Table
4). Direct within-study comparisons were not possible because no
studies performed MTBDRsl testing on specimens and isolates
from the same patients.
(b) Indeterminate rates
For indirect testing for culture-confirmed resistance to SLIDs, of
10 studies that reported indeterminate MTBDRsl version 1.0 re-
sults, seven (0.5%) of 1316 results were indeterminate (two cul-
ture-DST resistant and five culture-DST sensitive). For direct test-
ing on a smear-positive specimen, of four studies that reported in-
determinate MTBDRsl results, 219 (13.5%) of 1627 results were
indeterminate (34 were culture-DST resistant, 165 were culture-
DST susceptible, and 20 whose culture phenotypic status was un-
known). The indeterminate rates for direct testing for each smear-
grade (smear-negative, scanty, 1+, 2+, 3+) were 76/180 (42.2%),
35/91 (38.5%), 47/213 (22.1%), 29/200 (14.5%), and 70/364
(19.2%), respectively.
B. Investigations of heterogeneity
1. Indirect testing
(a) Individual drugs within the drug class
We present accuracy estimates for MTBDRsl version 1.0 by in-
direct testing for detection of resistance to amikacin, kanamycin,
and capreomycin in Table 5 and Figure 9.
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Figure 9. Forest plots of MTBDRsl sensitivity and specificity for the detection of resistance to amikacin,
kanamycin, and capreomycin, the test performed indirectly against culture-based drug susceptibility testing
(DST) as a reference standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative.
Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows
the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The
individual studies are ordered by decreasing sensitivity.
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For detection of amikacin resistance by indirect testing,MTBDRsl
version 1.0 sensitivity estimates ranged from 75% to 100% and
specificity estimates ranged from 95% to 100%. The pooled sen-
sitivity and specificity (95% CI) were 84.9% (79.2% to 89.1%)
and 99.1% (97.6% to 99.6%), (11 studies, 1301 participants).
For detection of kanamycin resistance by indirect testing,
MTBDRsl version 1.0 sensitivity estimates ranged from 25% to
100% and specificity estimates ranged from 86% to 100%. The
pooled sensitivity and specificity (95% CI) were 66.9% (44.1%
to 83.8%) and 98.6% (96.1% to 99.5%), (nine studies, 1342 par-
ticipants).
For detection of capreomycin resistance by indirect testing),
MTBDRsl version 1.0 sensitivity estimates ranged from 21% to
100% and specificity estimates from 86% to 100%. The pooled
sensitivity and specificity (95%CI)were 79.5% (58.3% to 91.4%)
and 95.8% (93.4% to 97.3%), (10 studies, 1406 participants).
(b) Drug concentration used in culture-based DST
Appendix 5 shows amikacin, kanamycin, and capreomycin drug
concentrations used in culture-based DST in relation to the
WHO-recommended critical concentrations.
Amikacin: five studies used the WHO-recommended critical
concentration of amikacin (Fan 2011; Ignatyeva 2012; Miotto
2012; Lopez-Roa 2012; Tomasicchio 2016), whereas three did not
(Brossier 2010a; Ferro 2013; van Ingen 2010). Hillemann 2009
and Zivanovic 2012, which each used two types of culture me-
dia, used the WHO-recommended concentration for one culture
type and a non-recommended concentration for the other type.
Huang 2011 also used two types of culture media and used the
WHO-recommended concentration for one culture type and for
the other culture type, no recommended concentration exists. Be-
tween studies that used and did not use theWHO-recommended
critical concentration for amikacin, there was evidence of a statis-
tically significant difference in specificity (P value < 0.001), but
not sensitivity (P value = 0.063).
Kanamycin: two studies used the WHO-recommended critical
concentration of kanamycin (Ferro 2013; Huang 2011 for both
types of culture media), whereas seven did not (Brossier 2010a;
Ignatyeva 2012; Jin 2013; Kiet 2010; Lacoma 2012;Miotto 2012;
Said 2012).
Capreomycin: four studies used the WHO-recommended critical
concentration of capreomycin (Hillemann 2009 for both culture
types; Ignatyeva 2012;Miotto 2012; Zivanovic 2012 for both cul-
ture types), and three did not (Brossier 2010a; Said 2012; van
Ingen 2010). Huang 2011 used two types of culture media and
used theWHO-recommended concentration for one culture type
and for the other culture type, no recommended concentration ex-
ists. Lacoma 2012 used a culture type for which no recommended
concentration exists and Jin 2013 did not report the critical con-
centration used. There was no evidence of a statistically signifi-
cant difference inMTBDRsl version 1.0 accuracy for capreomycin
resistance between studies that used and did not use the WHO-
recommended critical concentration (P values for differences in
sensitivity and specificity of 0.161 and 0.625, respectively).
Comparisons between accuracy estimates for kanamycin according
to critical concentration were not possible given the small number
of studies.
(c) Type of reference standard
WepresentMTBDRsl version 1.0 accuracy estimates for detection
of SLID resistance against different reference standards in Table 6
and Appendix 8.
Reference standard is sequencing
Using sequencing, MTBDRsl version 1.0 sensitivity estimates
ranged from 62% to 100% and specificity estimates ranged from
96% to 100%, (seven studies, 962 participants). We restricted
the meta-analysis to comparative studies (six studies, 873 par-
ticipants). The pooled sensitivity and specificity (95% CI) were
97.0% (77.0% to 99.7%) and 99.5% (94.5% to 100.0%). There
was evidence of a significantly higher sensitivity using sequencing
as the reference standard compared with culture-based DST (P
value of 0.034), but not specificity (P value of 0.456).
Reference standard is culture-basedDST and sequencing (i.e. both
investigations performed on all isolates)
Using culture and sequencing, MTBDRsl version 1.0 sensitiv-
ity estimates ranged from 30% to 85% and specificity estimates
ranged from 99% to 100%, (seven studies, 1491 participants).
We restricted the meta-analysis to comparative studies (six stud-
ies, 1159 participants). The pooled sensitivity and specificity
(95% CI) were 61.3% (45.8% to 74.8%) and 99.9% (99.0% to
100.0%). There was no evidence of a statistically significant dif-
ference in accuracy using culture and sequencing as the reference
standard compared with culture-based DST (P values for differ-
ences in sensitivity and specificity of 0.458 and 0.203, respec-
tively).
Reference standard is culture-based DST followed by sequencing
of discrepant index test-culture-based DST results
Using sequencing of discrepant results,MTBDRsl version 1.0 sen-
sitivity estimates ranged from 34% to 100% and specificity es-
timates ranged from 95% to 100%, (three studies, 619 partici-
pants). We did not determine summary estimates because there
were only three studies and the sensitivity was variable.
2. Direct testing
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(a) Individual drugs within the drug class
We present MTBDRsl accuracy estimates for detection of resis-
tance to amikacin, kanamycin, and capreomycin by direct testing
against a phenotypic culture-based reference standard in Figure
10.
Figure 10. Forest plots of MTBDRsl sensitivity and specificity for resistance to amikacin, kanamycin, and
capreomycin, the test performed directly against culture-based drug susceptibility testing (DST) as a reference
standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Between brackets are
the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and
specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered
by decreasing sensitivity.
For detection of amikacin resistance by direct testing, MTBDRsl
version 1.0 sensitivity estimates ranged from 64% to 100% and
specificity estimates ranged from 88% to 100%. The pooled sen-
sitivity and specificity (95% CI) were 91.9% (71.5% to 98.1%)
and 99.9% (95.2% to 100.0%), (six studies, 1491 participants).
Based on all data, there was no evidence of a statistically signif-
icant difference in accuracy between indirect and direct testing
for amikacin resistance (P values for differences in sensitivity of
specificity 0.338 and 0.213, respectively).
For detection of kanamycin resistance by direct testing, MTBDRsl
version 1.0 sensitivity estimates ranged from 9% to 100% and
specificity estimates ranged from 90% to 100%. The pooled sen-
sitivity and specificity (95% CI) were 78.7% (11.9% to 99.0%)
and 99.7% (95% CI 93.8% to 100.0%), (five studies, 1020 par-
ticipants). Based on all data, there was no evidence of a statistically
significant difference in accuracy between indirect and direct test-
ing for kanamycin resistance (P values for differences in sensitivity
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of specificity 0.836 and 0.445, respectively).
For detection of capreomycin resistance by direct testing,
MTBDRsl version 1.0 sensitivity estimates ranged from 57% to
100% and specificity estimates ranged from 88% to 100%. The
pooled sensitivity and specificity (95% CI) were 76.6% (61.1%
to 87.3%) and 98.2% (92.5% to 99.6%), (five studies, 1027 par-
ticipants). Based on all data, there was no evidence of a statisti-
cally significant difference in accuracy between indirect and direct
testing for capreomycin resistance (P values for differences in sen-
sitivity and specificity of 0.841 and 0.353, respectively).
(b) Drug concentration used in culture-based
Amikacin: all six studies in this category used the WHO-rec-
ommended critical concentration (Ajbani 2012; Barnard 2012;
Catanzaro 2015; Kontsevaya 2013; Miotto 2012; Tomasicchio
2016).
Kanamycin: three studies used the WHO-recommended criti-
cal concentration for kanamycin (Ajbani 2012; Catanzaro 2015;
Tukvadze 2014), whereas two did not (Kontsevaya 2013; Miotto
2012).
Capreomycin: all five studies used the WHO-recommended crit-
ical concentration (Ajbani 2012; Catanzaro 2015; Kontsevaya
2013; Miotto 2012; Tukvadze 2014).
Comparisons between accuracy estimates according to whether or
not WHO-recommended critical drug concentrations were used
for culture-based reference testing were not possible.
(c) Stratification by smear grade
There were limited data on MTBDRsl version 1.0 accuracy for
individual SLID drugs by smear grade. Figure 11 presents the
forest plots for amikacin resistance by smear grade.
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Figure 11. Forest plots of MTBDRsl sensitivity and specificity for detection of amikacin resistance by smear
grade, using culture-based drug susceptibility testing (DST) as a reference standard. TP = true positive; FP =
false positive; FN = false negative; TN = true negative. Between brackets are the 95% confidence intervals
(CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue
square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing sensitivity.
(d) Type of reference standard
Reference standard is sequencing
No studies performed direct MTBDRsl version 1.0 testing and
used sequencing as a reference standard.
Reference standard is culture-basedDST and sequencing (i.e. both
investigations performed on all isolates)
No studies performed direct MTBDRsl version 1.0 testing and
used both culture-based DST and sequencing (performed on all
isolates) as a reference standard.
Reference standard is culture-based DST followed by sequencing
of discrepant index test culture-based DST results
We identified two studies, both of which reported perfect sensi-
tivity and specificity (95% CI): 100% (85% to 100%) and 100%
(97% to 100%) for Ajbani 2012, and 100% (92% to 100%) and
100% (98% to 100%) for Barnard 2012, respectively.
III. XDR-TB detection
A. Estimates of the diagnostic accuracy of MTBDRsl using
culture-based DST as a reference standard
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1. Indirect testing
Eight studies (880 participants, 173 (19.7%) confirmed cases of
XDR-TB) evaluated MTBDRsl version 1.0 by indirect testing for
detection of XDR-TB, (Figure 12). Sensitivity estimates ranged
from 20% to 100% and specificity estimates ranged from 96%
to 100%. The pooled sensitivity and specificity (95% CI) were
70.9% (42.9% to 88.8%) and 98.8% (96.1% to 99.6%).
Figure 12. Forest plots of MTBDRsl sensitivity and specificity for the detection of XDR-TB, the test
performed indirectly and directly against culture-based drug susceptibility testing (DST) as a reference
standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Between brackets are
the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and
specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered
by decreasing sensitivity.
2. Direct testing
Six studies (1420 participants, 143 (10.1%) confirmed cases of
XDR-TB) evaluated MTBDRsl version 1.0 by direct testing for
detection of XDR-TB, (Figure 12). Sensitivity estimates ranged
from 14% to 92% and specificity estimates ranged from 82%
to 100%. The pooled sensitivity and specificity (95% CI ) were
69.4% (38.8% to 89.0%) and 99.4% (95.0% to 99.3%).
3. Comparison of indirect versus direct testing
(a) Diagnostic accuracy
Based on analysis of all data, there was no evidence of a statistically
significant difference inMTBDRsl version 1.0 accuracy for XDR-
TB between indirect and direct testing when using culture-based
DST as a reference standard (P values for differences in sensitivity
and specificity of 0.916 and 0.387, respectively) (Table 4). Direct
within-study comparisons were not possible because no studies
performedMTBDRsl version1.0 testing on specimens and isolates
from the same patients.
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(b) Indeterminate rates
For indirect testing for XDR-TB, of the six studies that reported
version 1.0 results, one (0.2%) of 554 was indeterminate (one cul-
ture DST sensitive). For direct testing on a smear-positive speci-
men, of seven studies that reported indeterminate MTBDRsl re-
sults, 224 (13.5%) of 1665 results were indeterminate (27 cul-
ture-DST resistant, 186 culture-DST susceptible, and 11 of un-
known phenotypic culture status). The indeterminate rates for di-
rect testing for each smear-grade (smear-negative, scanty, 1+, 2+,
3+) were 81/183 (44.2%), 39/186 (21.0%), 53/225 (23.5%), 33/
301 (11.0%), and 82/177 (46.3%).
B. Investigations of heterogeneity
1. Indirect testing
(a) Drugs used in the culture-based DST
One of the eight studies that performed indirect testing for XDR-
TB and used culture-based DST as a reference standard used
ofloxacin and kanamycin (Kiet 2010). Two studies used ofloxacin,
amikacin, and capreomycin (Hillemann 2009; Zivanovic 2012).
One study used ofloxacin, amikacin, and kanamycin (Miotto
2012). One study used levofloxacin, amikacin, kanamycin, and
capreomycin (Chikamatsu 2012). One study used ofloxacin,
amikacin, kanamycin, and capreomycin (Ignatyeva 2012). One
study used ofloxacin, kanamycin, and capreomycin (Jin 2013).
One study used moxifloxacin, amikacin, and ofloxacin (van Ingen
2010).
As all but two studies used a different combination of drugs, we
did not compare test performance according to drugs used in the
culture-based DST.
(b) Drug concentration used in culture-based DST
Ofloxacin: two studies in this category used the WHO-recom-
mended critical concentration for ofloxacin (Ignatyeva 2012;
Miotto 2012), and two did not (Jin 2013; Kiet 2010). Two stud-
ies used two different types of culture but only used the WHO-
recommended critical concentration of ofloxacin for one type of
culture (Hillemann 2009; Zivanovic 2012).
Moxifloxacin: van Ingen 2010 used moxifloxacin but did not use
the WHO-recommended critical concentration.
Levofloxacin: for the study that used levofloxacin (Chikamatsu
2012), the WHO does not recommend a critical concentration
for the type of culture used (Ogawa culture).
Amikacin: for the six studies that used amikacin, two used
the WHO-recommended critical concentration (Ignatyeva 2012;
Miotto 2012), one did not report the concentration used (
Chikamatsu 2012), and one used a type of culture-based testing
(Middlebrook 7H10 media) for which the WHO did not spec-
ify a recommended critical concentration (van Ingen 2010). Two
studies used two types of culture medium, one of which was done
at a recommended concentration and the other not (Hillemann
2009;Zivanovic 2012).
Kanamycin: of the five studies that used kanamycin, four did not
use the WHO-recommended critical concentration (Ignatyeva
2012; Jin 2013; Kiet 2010; Miotto 2012), and one did not report
the concentration used (Chikamatsu 2012).
Capreomycin: of the seven studies that used capreomycin, four
used the WHO-recommended critical concentration (Hillemann
2009 for both culture types; Ignatyeva 2012; Miotto 2012;
Zivanovic 2012 for both culture types), whereas one study did not
(van Ingen 2010); and two studies did not report the concentra-
tion used (Chikamatsu 2012; Jin 2013).
We did not compare MTBDRsl version 1.0 accuracy according to
drug concentrations used in the culture-based DST because there
were few studies that used the same drugs and the same critical
concentrations.
(c) Type of reference standard
WepresentMTBDRsl version 1.0 accuracy estimates for detection
of XDR-TB against different reference standards in Table 6 and
Figure 13.
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Figure 13. Forest plots of MTBDRsl sensitivity and specificity for extensively drug-resistant tuberculosis
(XDR-TB), the test performed indirectly against three different reference standards. TP = true positive; FP =
false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence
intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the
study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing
sensitivity.
Reference standard is sequencing
For individual studies (four studies, 630 participants), MTBDRsl
version 1.0 sensitivity estimates in all four studies were 100% and
specificity estimates ranged from 95% to 100%. We restricted
the meta-analysis to comparative studies (three studies, 541 par-
ticipants). Using a fixed-effect model, the pooled sensitivity and
specificity (95% CI) were 100% (94.6% to 100.0%) and 97.9%
(96.3% to 98.8%).
Reference standard is culture-basedDST and sequencing (i.e. both
investigations performed on all isolates)
We identified two studies with 435 participants. MTBDRsl ver-
sion 1.0 sensitivity and specificity estimates (95% CI) were 56%
(45% to 67%) and 99% (96% to 100%) for Jin 2013, and 71%
(44% to 90%) and 99% (95% to 100%) for Miotto 2012. We
did not perform a meta-analysis.
Reference standard is culture-based DST followed by sequencing
of discrepant index test-culture-based DST results
No studies performed indirect MTBDRsl version 1.0 testing for
XDR-TB and used culture-based DST and sequencing for dis-
crepant results as a reference standard.
2. Direct testing
(a) Drugs used in the culture-based DST
Two of the six studies that performed direct testing for XDR-
TB and used culture-based DST as a reference standard used
ofloxacin and amikacin (Barnard 2012; Tomasicchio 2016). Two
studies used ofloxacin, moxifloxacin, amikacin, kanamycin, and
capreomycin (Catanzaro 2015; Kontsevaya 2013). One study
used ofloxacin, amikacin, kanamycin, and capreomycin (Miotto
2012). One study used ofloxacin, kanamycin, and capreomycin
(Tukvadze 2014).
As all but two studies used a different combination of drugs, we
did not compare test performance according to drugs used in the
culture-based DST.
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(b) Drug concentration used in culture-based DST
Ofloxacin: five studies in this category used the WHO-rec-
ommended critical concentration for ofloxacin (Barnard 2012;
Catanzaro 2015; Kontsevaya 2013; Miotto 2012; Tomasicchio
2016), whereas one did not (Tukvadze 2014).
Moxifloxacin: neither study used the WHO-recommended criti-
cal concentration for moxifloxacin (Catanzaro 2015; Kontsevaya
2013).
Amikacin: four studies in this category used the WHO-recom-
mended critical concentration for amikacin (Catanzaro 2015;
Kontsevaya 2013; Miotto 2012; Tomasicchio 2016), whereas on
study did not (Barnard 2012).
Kanamycin: two studies used the WHO-recommended critical
concentration for kanamycin (Catanzaro 2015; Tukvadze 2014),
whereas two studies did not (Kontsevaya 2013; Miotto 2012).
Capreomycin: all four studies in this category used the WHO-
recommended critical concentration for capreomycin (Catanzaro
2015; Kontsevaya 2013; Miotto 2012; Tukvadze 2014).
We did not compare test accuracy according to drug concentra-
tions used in the culture-based DST because there were few stud-
ies using the same drugs and the same critical concentrations.
(c) Type of reference standard
Reference standard is sequencing
No studies performed direct MTBDRsl version 1.0 testing for
XDR-TB and used sequencing as a reference standard.
Reference standard is culture-basedDST and sequencing (i.e. both
investigations performed on all isolates)
No studies performed direct MTBDRsl version 1.0 testing and
used both culture-based DST and sequencing (performed on all
isolates) as a reference standard.
Reference standard is culture-based DST followed by sequencing
of discrepant index test-culture-based DST results
We identified two studies that used culture-based DST and per-
formed sequencing only on discrepant results (Barnard 2012;
Miotto 2012). These studies both reported sensitivities of 92%
and specificities of 100%.
Sensitivity analyses
We have presented the MTBDRsl version 1.0 sensitivity analyses
(using culture-based DST as the reference standard) for the FQs
(Table 7) and the SLIDs (Table 8). The sensitivity analyses made
no difference to any of the findings.
MTBDRsl version 2.0
I. Fluoroquinolone resistance detection
A. Estimates of the diagnostic accuracy of MTBDRsl using
culture-based DST as a reference standard
1. Indirect testing
By indirect testing, MTBDRsl version 2.0 sensitivity and speci-
ficity (95% CI) were 84% (73% to 91%) and 100% (98% to
100%) (Tagliani 2015; Figure 14).
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Figure 14. Forest plots of MTBDRsl version 2.0 sensitivity and specificity for the detection of resistance to
the fluoroquinolones (FQs) and second-line injectable drugs (SLIDs) and extensively drug-resistant
tuberculosis (XDR-TB), the test performed indirectly and directly against culture-based drug susceptibility
testing (DST) as a reference standard. TP = true positive; FP = false positive; FN = false negative; TN = true
negative. Between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure
shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
2. Direct testing
By direct testing, MTBDRsl version 2.0 sensitivity and specificity
(95% CI) were 97% (83% to 100%) and 98% (93% to 100%)
on a smear-positive specimen and 80% (28% to 99%) and 100%
(40% to 100%) on a smear-negative specimen (Tagliani 2015;
Figure 15).
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Figure 15. Forest plots of MTBDRsl version 2.0 sensitivity and specificity for the detection of resistance to
the fluoroquinolones (FQs) and second-line injectable drugs (SLIDs) and extensively drug-resistant
tuberculosis (XDR-TB), the test performed directly on smear-positive and smear-negative specimens against
culture-based drug susceptibility testing (DST) as a reference standard. TP = true positive; FP = false positive;
FN = false negative; TN = true negative. Between brackets are the 95% confidence intervals (CIs) of sensitivity
and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95%
CI (black horizontal line).
3. Drug concentration used in culture-based DST
Ofloxacin: Tagliani 2015 used the WHO-recommended critical
concentration.
Moxifloxacin: Tagliani 2015 used the WHO-recommended crit-
ical concentration for low-level moxifloxacin resistance.
Levofloxacin: Tagliani 2015 used the WHO-recommended criti-
cal concentration.
4. Indeterminate rates
For both indirect and direct testing for culture-confirmed resis-
tance to FQs, Tagliani 2015 reported zero indeterminate results.
II. SLID resistance detection
A. Estimates of the diagnostic accuracy of MTBDRsl using
culture-based DST as a reference standard
1. Indirect testing
For MTBDRsl version 2.0 performed by indirect testing, sensitiv-
ity and specificity (95% CI) were 86% (80% to 91%) and 90%
(81% to 96%) (Figure 14; Tagliani 2015).
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2. Direct testing
By direct testing, sensitivity and specificity (95% CI) were 89%
(72% to 98%) and 90% (84% to 95%) on a smear-positive spec-
imen and 80% (28% to 99%) and 100% (40% to 100%) on a
smear-negative specimen (Figure 15; Tagliani 2015).
3. Drug concentration used in culture-based DST
Amikacin: Tagliani 2015 used the WHO-recommended critical
concentration of amikacin.
Kanamycin: Tagliani 2015 used the WHO-recommended critical
concentration of kanamycin.
Capreomycin: Tagliani 2015 used the WHO-recommended crit-
ical concentration of capreomycin.
4. Indeterminate rates
For both indirect and direct testing for culture-confirmed resis-
tance to SLIDs, Tagliani 2015 reported zero indeterminate results.
III. XDR-TB detection
A. Estimates of the diagnostic accuracy of MTBDRsl using
culture-based DST as a reference standard
1. Indirect testing
For MTBDRsl version 2.0 performed by indirect testing, sensitiv-
ity and specificity (95% CI) were 80% (66% to 91%) and 96%
(82% to 98%) (Figure 14; Tagliani 2015).
2. Direct testing
By direct testing, sensitivity and specificity (95% CI) were 79%
(49% to 95%) and 97% (93% to 99%) on a smear-positive spec-
imen and 50% (1% to 99%) and 100% (59% to 100%) on a
smear-negative specimen (Figure 15; Tagliani 2015).
3. Indeterminate rates
Tagliani 2015 reported zero indeterminate results for both indirect
and direct testing for XDR-TB.
Comparison of the accuracy of version 1.0 and 2.0
As we identified only one study that evaluated MTBDRsl version
2.0, we could not compare the accuracy of MTBDRsl version 1.0
and 2.0.
Other analyses
We did not identify any reports on intra-reader variability. One
study described inter-reader variability and reported high concor-
dance > 95% (Ignatyeva 2012).
Regarding patient outcomes, only four studies described the effect
of MTBDRsl on time-to-diagnosis. Lopez-Roa 2012 reported the
test to have a time-to-diagnosis of eight hours, compared to DST
using the agar proportion method (21 days) or the MGIT 960
method (eight days). Said 2012 stated that MTBDRsl had a me-
dian time-to-diagnosis of two days, compared to 11 days for the
agar proportion method. Tukvadze 2014 noted a median time-to-
diagnosis using MTBDRsl of 10 days, versus 70 to 104 days for
culture-based DST. Barnard 2012 reported MTBDRsl to have a
median turn-around-time of one day (after the diagnosis of first-
line resistance), whereas the median turn-around-time for pheno-
typic culture-based DST was 31 days.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Participants: pat ients with rif ampicin-resistant or MDR-TB
Prior testing: pat ients who received MTBDRsl test ing may have f irst received smear microscopy, Xpert® MTB/ RIF or other nucleic acid amplif icat ion test, and culture to
diagnose TB and Xpert® MTB/ RIF, MTBDRplus version 2.0 or an alternat ive line-probe assay to detect f irst-line drug resistance
Role: The role of MTBDRsl would be as the init ial test, replacing culture-based drug suscept ibility test ing, for detect ing second-line drug resistance
Settings: intermediate or central level laboratories
Index (new) test: MTBDRsl version 1.0.* The test was performed by direct test ing on smear-posit ive specimens
Reference standard: culture-based drug suscept ibility test ing
Studies: cross-sect ional studies
Limitations: most included studies did not consistent ly use the World Health Organizat ion (WHO)-recommended concentrat ions for drugs in the culture-based reference
standard
Pooled sensitivity (95% CI): 87.0% (38.1% to 98.6%)
Pooled specificity (95% CI): 99.5% (93.6% to 100.0%)
Test result Number of results per 1000 patients tested (95% CI) Number of participants
(studies)
Quality of the evidence (GRADE)
Prevalence of 5% Prevalence of 10% Prevalence of 15%
True positives
(pat ients correct ly diag-
nosed with SLID resistance)
44 (19 to 49) 87 (38 to 99) 131 (57 to 148) 348
(8)
⊕⊕©©1,2,3,4
low
False negatives
(pat ients incorrect ly classi-
f ied as not having SLID re-
sistance)
6 (1 to 31) 13 (1 to 62) 19 (2 to 93)
True negatives
(pat ients correct ly classi-
f ied as not having SLID re-
sistance)
945 (889 to 950) 896 (842 to 900) 846 (796 to 850) 8
(1291)
⊕⊕⊕©1,2
moderate
3
8
G
e
n
o
T
y
p
e
®
M
T
B
D
R
sl
a
ssa
y
fo
r
re
sista
n
c
e
to
se
c
o
n
d
-lin
e
a
n
ti-tu
b
e
rc
u
lo
sis
d
ru
g
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
A
u
th
o
rs.
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
False positives
(pat ients incorrect ly classi-
f ied as having SLID resis-
tance)
5 (0 to 61) 4 (0 to 58) 4 (0 to 54)
Abbreviat ions: CI: conf idence interval; DST: drug suscept ibility test ing; FQ: f luoroquinolone; GRADE: Grading of Recommenda-
t ions, Assessment, Development and Evaluat ion; SLID: second-line injectable drug; TB: tuberculosis; XDR-TB: extensively
drug-resistant TB.
By indirect test ing, MTBDRsl sensit ivity and specif icity (95%CI) were 76.5% (63.3% to 86.0%) and 99.1% (97.3% to 99.7%).
* This systematic review mainly evaluated MTBDRsl version 1.0, which has recent ly been replaced with version 2.0. We
considered the f indings in this review to be applicable to the current version of the test.
1We used QUADAS-2 to assess risk of bias. All studies used consecut ive or random sampling. In six studies, the reader of the
index test was blinded to results of the reference standard in two studies information about blinding to the reference standard
was not reported. Fif ty per cent of the studies used crit ical concentrat ions for the culture-based DST reference standard that
dif f ered f rom the concentrat ions recommended by the WHO. We downgraded one level.
2We considered indirectness (applicability) f rom the perspect ive of diagnost ic accuracy and had low concern. We did not
downgrade.
3For individual studies, sensit ivity est imates ranged f rom 9% to 100%. We thought heterogeneity could be explained in part by
the use of dif f erent drugs, crit ical concentrat ions, and types of culture media in the reference standard and likely presence
of eis mutat ions in pat ients in Eastern Europe. We did not downgrade for inconsistency and considered this in the context of
other factors, in part icular imprecision.
4The wide CI around true posit ives and false negat ives may lead to dif ferent decisions depending on which conf idence lim its
are assumed. We downgraded one level.
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Participants: pat ients with rif ampicin-resistant or MDR-TB
Prior testing: pat ients who received MTBDRsl test ing may have f irst received smear microscopy, Xpert® MTB/ RIF or other nucleic acid amplif icat ion test, and culture to
diagnose TB and Xpert® MTB/ RIF, MTBDRplus version 2.0 or an alternat ive line-probe assay to detect f irst-line drug resistance
Role: The role of MTBDRsl would be as the init ial test, replacing culture-based drug suscept ibility test ing, for detect ing second-line drug resistance
Settings: intermediate or central level laboratories
Index (new) test: MTBDRsl version 1.0.* The test was performed by direct test ing on smear-posit ive specimens
Reference standard: culture-based drug suscept ibility test ing
Studies: cross-sect ional studies
Limitations: most included studies did not consistent ly use the World Health Organizat ion (WHO)-recommended concentrat ions for drugs in the culture-based reference
standard
Pooled sensitivity (95% CI): 69.4% (38.8% to 89.0%)
Pooled specificity (95% CI): 99.4% (95.0% to 99.3%)
Test result Number of results per 1000 patients tested (95% CI) Number of participants
(studies)
Quality of the evidence (GRADE)
Prevalence of 1% Prevalence of 5% Prevalence of 10%
True positives
(pat ients correct ly diag-
nosed with XDR-TB)
7 (4 to 9) 35 (19 to 45) 69 (39 to 89) 143
(6)
⊕⊕©©1,2,3,4
low
False negatives
(pat ients incorrect ly classi-
f ied as not having XDR-TB)
3 (1 to 6) 15 (5 to 31) 31 (11 to 61)
True negatives
(pat ients correct ly classi-
f ied as not having XDR-TB)
980 (941 to 983) 941 (903 to 943) 891 (855 to 894) 1277
(6)
⊕⊕⊕©1,2
moderate
False positives
(pat ients incorrect ly classi-
f ied as having XDR-TB)
10 (7 to 49) 9 (7 to 47) 9 (6 to 45)
Abbreviat ions: CI: conf idence interval; DST: drug suscept ibility test ing; FQ: f luoroquinolone; GRADE: Grading of Recommen-
dat ions, Assessment, Development and Evaluat ion; SLID: second-line injectable drug; TB: tuberculosis; WHO: World Health
Organizat ion; XDR-TB: extensively drug-resistant TB.
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By indirect test ing, MTBDRsl sensit ivity and specif icity (95%CI) were 70.9% (42.9% to 88.7%) and 98.8% (96.1% to 99.6%).
* This systematic review mainly evaluated MTBDRsl version 1.0, which has recent ly been replaced with version 2.0. We
considered the f indings in this review to be applicable to the current version of the test.
1We used QUADAS-2 to assess risk of bias. All studies used consecut ive sampling. In four studies, the reader of the test was
blinded to results of the reference standard and in two studies information about blinding was not reported. Most studies
used crit ical concentrat ions for the phenotypic culture-based DST reference standard that dif f ered f rom the concentrat ions
recommended by the WHO. We downgraded the evidence by one level.
2We considered indirectness (applicability) f rom the perspect ive of diagnost ic accuracy and had low concern. We did not
downgrade.
3For individual studies, sensit ivity est imates ranged f rom 14% to 92%. We thought heterogeneity could be explained in part by
the use of dif f erent drugs, crit ical concentrat ions, and types of culture media in the reference standard and likely presence
of eis mutat ions in pat ients in Eastern Europe. We did not downgrade for inconsistency and considered this in the context of
other factors, in part icular imprecision.
4The wide CI for true posit ives and false negat ives may lead to dif ferent decisions depending on which conf idence lim its are
assumed. We downgraded one level.
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D I S C U S S I O N
This updated systematic review summarizes the current litera-
ture and includes 27 studies and integrates six new studies: five
new studies for MTBDRsl version 1.0 identified since the original
Cochrane review (Theron 2014), and one study for MTBDRsl
version 2.0. For MTBDRsl version 1.0, the findings in this up-
dated review are consistent with those reported in the previous ver-
sion of the review. We have presented the average sensitivities and
specificities of MTBDRsl version 1.0 for detection of resistance to
fluoroquinolones (FQs) and second-line injectable drugs (SLIDs)
and for extensively drug-resistant tuberculosis (XDR-TB) in the
’Summary of findings’ tables (Summary of findings 1; Summary
of findings 2; Summary of findings 3) and Table 4 Table 5, and
Table 6
We found that, whenwe comparedMTBDRsl version1.0 accuracy
according to whether the test was performed directly or indirectly,
the sensitivities were similar for FQ resistance and SLID resistance.
When used indirectly on a culture isolate, MTBDRsl had higher
pooled sensitivity for detection of FQ resistance (85.6%) than for
detection of SLID resistance (76.5%). When used directly on a
smear-positive specimen,MTBDRsl had similar pooled sensitivity
for FQ resistance (86.2%) and SLID resistance (87.0%); however
the pooled sensitivity for SLID resistance was imprecise (95%
confidence interval (CI) 38.1% to 98.8%). When SLID resistance
was analysed for individual drugs, the pooled sensitivity (direct
testing) was highest for amikacin (92.0%). For detection of XDR-
TB the pooled sensitivity of MTBDRsl was 70.9% by indirect
testing and 69.4% by direct testing. For detection of resistance to
FQs and SLIDs and XDR-TB by either indirect or direct testing,
MTBDRsl pooled specificity was high (> 98%).
We compared the accuracy of MTBDRsl version 1.0 against dif-
ferent reference standards comprised of culture-based drug sus-
ceptibility testing (DST) (the traditional reference standard) or
sequencing. We looked at MTBDRsl version 1.0 accuracy against
each type of reference standard alone or in combination (where
all specimens received both culture-based DST and sequencing).
When used indirectly on a culture isolate for detection of FQ
resistance, MTBDRsl version 1.0 had higher pooled sensitivity
against sequencing than against culture-based DST (99.3% versus
82.4%). This suggests that MTBDRsl is sensitive for detecting
FQ resistance caused by mutations in gyrA (the only gene that is
targeted by MTBDRsl for detection of FQ resistance). However,
against culture-basedDST,MTBDRsl sensitivity for FQ resistance
was only 82.4% suggesting that just less than one in five cases may
be caused by mutations outside of gyrA, such as in gyrB, a gene
which is not targeted by MTBDRsl version 1.0. An alternative
explanation is that the proportion of bacilli harbouring the mu-
tation is below the threshold of detection by MTBDRsl but not
below the threshold of detection of the phenotypic test.
Similarly, we found higher pooled sensitivity for SLID resistance
when MTBDRsl version 1.0 was evaluated against sequencing
rather than culture-basedDST (97.0%versus 74.6%). In this case,
both sequencing and MTBDRsl only target the rrs gene for resis-
tance to SLIDs. This approach can potentiallymissmutations out-
side of this region that are responsible for SLID resistance. Using
culture-based DST (sensitivity 74.6%), it appears that around one
in four cases of SLID-resistant TB may be caused by mutations
outside of rrs. The prevalence of these non-rrs mutations, which
can occur in regions such as tlyA, eis, and gidB (Georghiou 2012),
appears to be most pronounced for kanamycin given the reduced
sensitivity (66.9%) of MTBDRsl for resistance to this drug com-
pared to the other SLIDs (sensitivity of 84.9% and 79.5% for
amikacin and capreomycin, respectively,MTBDRsl performed in-
directly against culture-based DST). The sensitivity of MTBDRsl
for SLID resistance, and in particular kanamycin resistance, is
likely to vary according to the genetic background ofM. tuberculo-
sis strains, where some may have a greater frequency of resistance-
causing mutations that fall outside of rrs and different levels of
cross-resistance within the SLIDs. As in the case of the FQs, the
mutation-harbouring bacilli may fall below the limit of detection
of MTBDRsl.
We are aware of two systematic reviews of MTBDRsl (Feng
2013; WHO 2013). Feng 2013 (11 published studies) deter-
mined MTBDRsl sensitivity and specificity for resistance to sec-
ond-line anti-TB drugs using a fixed-effect meta-analysis model,
rather than fitting the bivariate random-effects model currently
recommended. Accuracy estimates for resistance to kanamycin and
capreomycin resistance were substantially lower than the ones we
found. As in our review, WHO 2013 (11 published and seven
unpublished studies) used a random-effects meta-analysis model
and arrived at similar summary estimates. Our review included
additional studies not included in these previous reviews. Key
questions remain regarding test accuracy and potential sources of
heterogeneity, including risk of bias, type of testing (indirect ver-
sus direct testing), and reference standard (for example, culture-
based DST versus genetic sequencing). We addressed several of
these questions in this review. Although we intended to investigate
whether the observed test accuracy varied between studies accord-
ing to HIV infection status, specimen condition (frozen versus
fresh), specimen type (induced sputum or extrapulmonary speci-
men), the drug concentration used in culture-based DST (studies
that used theWorld Health Organization (WHO)-recommended
concentrations versus those that did not) or population (patients
suspected of having MDR-TB or XDR-TB), there were unfortu-
nately insufficient data to perform these additional analyses for
each target condition. We were also unable to examine sources of
heterogeneity for detection of XDR-TB due to insufficient data.
We also had limited data to investigate the influence of smear grade
on accuracy estimates.
Summary of main results
Themain results are presented in the ’Summary of findings’ tables.
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1. When performed indirectly on a culture isolate, MTBDRsl
version 1.0 sensitivity for FQ resistance was 85.6% compared
with 86.2% when performed directly on a smear-positive
specimen; the specificities for indirect testing (98.5%) and direct
testing (98.6%) were high.
2. When performed indirectly, MTBDRsl version 1.0
sensitivity for SLID resistance was 76.5% compared with 87.0%
when performed directly on a smear-positive specimen; the
specificities for indirect testing (99.1%) and direct testing
(99.5%) were high.
3. When performed indirectly, MTBDRsl version 1.0
sensitivity for XDR-TB was 70.9% compared with 69.4%
performed directly on a smear-positive specimen; the specificities
for indirect testing (98.8%) and direct testing (98.0%) were high.
4. For MTBDRsl version 1.0, we found no evidence of a
statistically significant difference in accuracy between indirect
testing and direct testing on a smear-positive specimen for FQ
resistance, SLID resistance, or XDR-TB.
5. We had insufficient data to estimate summary diagnostic
accuracy of MTBDRsl version 2.0 (smear-positive or smear-
negative specimens) or compare accuracy of the two versions.
Application of the meta-analysis to a hypothetical
cohort
In the ’Summary of findings’ tables we have summarized the re-
viewfindings forMTBDRsl version 1.0 by applying the results to a
hypothetical cohort of 1000 individuals with rifampicin-resistant
TB or MDR-TB thought to have resistance to a FQ, or SLID, or
both (Summary of findings 1; Summary of findings 2; Summary
of findings 3). We have presented several scenarios, based on the
prevalence of drug-resistant TB suggested by the WHO of 5%,
10%, and 15% for FQ and SLID resistance and 1%, 5%, and
10% for XDR-TB. We chose these thresholds based on the find-
ings from global surveillance of second-line resistance among pa-
tients with rifampicin-resistance TB or MDR-TB from 75 coun-
tries (WHO 2015). The consequences of false positive (FP) re-
sults are likely patient anxiety, morbidity from additional testing,
possible delays in further diagnostic evaluation, and prolonged
and unnecessary treatment with drugs that may have lower bacte-
ricidal activity than second-line regimens and often have serious
side effects. The consequences of false negative (FN) results are an
increased risk of patient morbidity and mortality, and continued
risk of community transmission of drug-resistant TB.
MTBDRsl version 1.0, direct testing (smear-positive
specimen) for fluoroquinolone resistance
By direct testing (smear-positive specimen), the test detected 86%
of people with FQ resistance and rarely gave a positive result for
people without resistance. In a population of 1000 people, where
150 have FQ resistance,MTBDRslwill correctly identify 129 peo-
ple with FQ resistance andmiss 21 people. In this same population
of 1000 people, where 850 people do not have FQ resistance, the
test will correctly classify 838 people as not having FQ resistance
and misclassify 12 people as having resistance.
MTBDRsl version 1.0, direct testing (smear-positive
specimen) for SLID resistance
By direct testing (smear-positive specimen), the test detected 87%
of people with SLID resistance and rarely gave a positive result for
people without resistance. In a population of 1000 people, where
150 have SLID resistance, MTBDRsl will correctly identify 131
people with SLID resistance andmiss 19 people. In this same pop-
ulation of 1000 people, where 850 do not have SLID resistance,
the test will correctly classify 846 people as not having SLID re-
sistance and misclassify four people as having resistance.
MTBDRsl version 1.0, direct testing (smear-positive
specimen) for XDR-TB
By direct testing (smear-positive specimen), the test detected 69%
of people with XDR-TB and rarely gave a positive result for people
without resistance. In a population of 1000 people, where 100
have XDR-TB, MTBDRsl will correctly identify 69 people with
XDR-TB and miss 31 people. In this same population of 1000
people, where 900 do not have XDR-TB, the test will correctly
classify 891 people as not having SLID resistance and misclassify
nine people as having resistance.
Strengths and weaknesses of the review
The results of this review are based on strict and careful literature
searches, study inclusion, and data extraction. The strength of this
review is that it allows an assessment of differentmethods of testing
(indirect versus direct) and different reference standards.
Completeness of evidence
This is a reasonably complete data set. We included any non-
English studies we found from which we could obtain accuracy
data. However, we acknowledge that we may have missed some
studies despite the comprehensive search.
Accuracy of the reference standards used
For our primary analysis, we used culture-based DST. This was
the most frequently deployed reference standard in the included
studies. Although considered to be the best reference standard for
drug-resistant TB, culture-basedDST is not 100%accurate for de-
tection of drug resistance, in particular with respect to detection of
second-line drug resistance. We also determined MTBDRsl accu-
racy using sequencing (gene sequencing of loci known to be associ-
ated with drug resistance) and both sequencing and culture-based
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DST as reference standards. Many TB experts consider sequenc-
ing to be the best available reference standard, provided it encom-
passes all the possible resistance-determining regions. In addition,
we determined the accuracy of MTBDRsl against a fourth refer-
ence standard, where sequencing was only performed as part of an
analysis for culture-DST-MTBDRsl discrepant results. However,
in most cases we were unable to determine summary estimates due
to the small number of studies and therefore were unable to com-
pare MTBDRsl accuracy estimates using this reference standard
with those obtained using culture-based DST, or sequencing, or
both, as the reference standard. MTBDRsl accuracy was generally
greater when measured against a reference standard that included
genetic testing. However, such genetic testing was only limited to
the genes the MTBDRsl targeted and did not detect mutations
outside of these genes that may cause phenotypic drug resistance.
Quality and quality of reporting of the included
studies
We judged that greater than 50% of studies had low risk of bias for
the patient selection, index test, and flow and timing domains. We
judged that only three studies (11%) had low risk of bias for the
reference standard domain because these studies used the WHO-
recommended critical concentrations for every drug in the culture-
based DST reference standard whereas the other studies did not.
Regarding applicability, we had low concern for all QUADAS-
2 domains. In general, studies were fairly well reported, though
we corresponded with almost all study authors for additional data
and missing information. However, accuracy data for individual
drugs and smear grades was not well reported and blinding was
not reported in a minority of studies. We strongly encourage fu-
ture studies to follow the recommendations in the Standards for
Reporting Diagnostic Accuracy (STARD) statement to improve
the quality of reporting (Bossuyt 2015).
Interpretability of subgroup analyses
We investigated potential sources of heterogeneity in the different
reference standards used and the individual drugs in the FQ and
SLID drug classes.We performed statistical testing and provided P
values where appropriate. Where data were sufficient, we derived
accuracy estimates from comparative studies of test accuracy in
which the same set of studies was used for each test evaluation.
Where data from comparative accuracy studies were limited, we
used all relevant data. For some subgroups (for example, people
living with HIV), there were insufficient data to perform an anal-
ysis.
Completeness and relevance of the review
There are now several commercially-available tests in addition to
MTBDRsl for detection of resistance beyondMDR-TB. These in-
clude TB Resistance Module Fluoroquinolones/Ethambutol and
TB Resistance Module Kanamycin/Amikacin/Capreomycin/
Streptomycin (Autoimmun Diagnostika GmbH (AID) Strass-
berg); MolecuTech REBAMTB-FQ®, MolecuTech REBAMTB-
KM®, and MolecuTech REBA MTB-XDR® (YD diagnostics,
Seoul); and NiPro LiPA FQ (NiPro Co, Osaka). Our review is the
most complete analysis of the diagnostic accuracy of theMTBDRsl
test to date.
Unpublished data
We did not include unpublished data.
Applicability of findings to the review question
We had low concern about the applicability of the included stud-
ies to our review question as assessed by QUADAS-2. This review
mainly evaluated MTBDRsl version 1.0 which has recently been
replaced with version 2.0. We reasoned that with the addition of
new probes targeting more resistance-causing mutations, the sen-
sitivity of MTBDRsl version 2.0 would be expected to be the same
or higher than that of MTBDRsl version 1.0 and the specificity
to remain the same or decrease slightly because of the small like-
lihood that at least one of the probes may misprime (resulting in
an increase in false-positive results). Therefore the findings of this
review should be considered applicable to the test. However, it is
important to note that this review assessed sensitivity and speci-
ficity in research settings. Although the patient characteristics and
settings matched our review question inmost cases, as studies were
carried out under research conditions, it is possible that the accu-
racy of MTBDRsl may be lower in routine practice settings.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In people with rifampicin-resistant or multidrug-resistant tuber-
culosis,MTBDRslperformedon a culture isolate or smear-positive
specimen may be useful in detecting second-line drug resistance.
MTBDRsl performed on a smear-positive specimen correctly clas-
sified around six in seven people as having fluoroquinolone or
SLID resistance, although the sensitivity estimates for SLID resis-
tance varied. The test rarely gave a positive result for people with-
out drug resistance. However, when second-line drug resistance
is not detected (MTBDRsl result is negative), conventional DST
can still be used to evaluate patients for resistance to the fluoro-
quinolones or SLIDs.
An enhancement of MTBDRsl version 2.0 in comparison to ver-
sion 1.0 is that, according to the manufacturer, the test may be
performed on a smear-negative specimen with high diagnostic ac-
curacy, although we had insufficient data to investigate this.
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Implications for research
Future studies should evaluate MTBDRsl version 2.0 in particu-
lar on smear-negative specimens and in different laboratory set-
tings and populations (for example, in HIV-positive people). Test
accuracy should be determined and compared using strains from
different geographical regions, as these are likely to have different
frequencies of resistance-causing mutations that fall outside of the
genes targeted by MTBDRsl (and therefore MTBDRsl will likely
have different sensitivities for each drug class in these strains). Such
future research should include as a reference standard sequencing
that targets all known resistance-determining mutations and not
just those detectable using MTBDRsl. Future molecular tests for
FQ and SLID resistance should have more genetic targets than
gyrA, gyrB, eis, and rrs. Studies are needed todetermine inter-reader
variability of the test. Although we recognize that WHO-recom-
mended critical concentrations for individual drugs may change
over time, researchers should consider incorporating these critical
concentrations into their culture-based reference standards. Stud-
ies are also needed to assess the effect of MTBDRsl implemen-
tation on time-to-treatment, patient health outcomes, and cost-
effectiveness.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ajbani 2012
Study characteristics
Patient sampling Cross-sectional design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: India.
2. World Bank classification of country: middle.
3. Type of lab: hospital.
4. Type of patients: confirmed multidrug-resistant tuberculosis (MDR-TB) patients.
5. Patients were smear-positive.
Index tests 1. Manufacturer involvement: yes, in design, analysis, or manuscript production.
2. Type of testing: direct.
3. Type of specimens: smear-positive.
4. Specimen treatment: NALC-NaOH.
5. Specimen condition: frozen.
6. Duration of freezing: < 1 year.
Target condition and reference
standard(s)
1. Culture (liquid; MGIT 960) used for fluoroquinolone (FQ), second-line injectable drug
(SLID).
2. FQ drugs: ofloxacin (2 µg/mL) and moxifloxacin (0.25 µg/mL).
3. SLIDs: amikacin (1 µg/mL), capreomycin (2.5 µg/mL), and kanamycin (2.5 µg/mL).
4. Discrepant analysis: yes, with sequencing.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes Also performed discrepant analysis; in this analysis, not all patients received both culture-based drug
susceptibility testing (DST) and genetic sequencing reference standards
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Ajbani 2012 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Barnard 2012
Study characteristics
Patient sampling Cross-sectional design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: South Africa.
2. World Bank classification of country: middle.
3. Type of lab: reference.
4. Type of patients: confirmed MDR-TB patients, confirmed rifampicin-monoresistant
patients, confirmed isoniazid-monoresistant patients.
5. Patients were smear-positive.
Index tests 1. Manufacturer involvement: yes, reduced price.
2. Type of testing: direct.
3. Type of specimens: smear-positive.
4. Specimen treatment: NALC-NaOH.
5. Specimen condition: fresh.
6. Tested after storage at room temperature or refrigerated within 48 hours of collection.
Target condition and reference
standard(s)
1. Culture (solid; AP (agar proportion) method on 7H11) used for FQ, SLID.
2. FQ drugs: ofloxacin (2 µg/mL).
3. SLIDs: amikacin (4 µg/mL).
4. Discrepant analysis: yes, with sequencing.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes 1. Reported performance on extrapulmonary tuberculosis specimens.
2. Reported on the utility of the index test on specimens that were culture-contaminated (and
hence could not receive a phenotypic DST).
3. Reported on time-to-result.
4. Also performed discrepant analysis; in this analysis, not all patients received both culture-
based DST and genetic sequencing reference standards.
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Barnard 2012 (Continued)
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Brossier 2010a
Study characteristics
Patient sampling Case-control design with unknown mechanism of enrolment of participants, prospective data col-
lection
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Brossier 2010a (Continued)
Patient characteristics and set-
ting
1. Country of origin: France.
2. World Bank classification of country: high.
3. Type of lab: reference.
4. Type of patients: confirmed MDR-TB patients, confirmed extensively drug resistant
tuberculosis (XDR-TB) patients, confirmed drug-susceptible TB patients.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
Target condition and reference
standard(s)
1. Culture (solid; agar proportion method on LJ (Lo
wenstein-Jensen) and sequencing used for FQ, SLID.
2. FQ drugs: ofloxacin (2 µg/mL).
3. SLIDs: amikacin (20 µg/mL), kanamycin (20 µg/mL), capreomycin (20 µg/mL).
4. Genes sequenced for FQ: gyrA and gyrB.
5. Genes sequenced for SLIDs: rrs.
6. Discrepant analysis: no.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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Brossier 2010a (Continued)
If a threshold was used, was it
pre-specified?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Catanzaro 2015
Study characteristics
Patient sampling Prospective, cross-sectional study that enrolled consecutively
Patient characteristics and set-
ting
1. Country of origin: Manila, the Philippines; Mumbai, India; Chisinau, Moldova; and Port
Elizabeth, South Africa.
2. World Bank classification of country: low- and middle-income.
3. Type of lab: unknown.
4. Type of patients: patients failing TB therapy or possible MDR-TB.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
3. The test was applied to pooled sputum specimens.
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Catanzaro 2015 (Continued)
Target condition and reference
standard(s)
1. Culture (MGIT (Mycobacteria Growth Indicator Tube) 960).
2. FQ drugs: ofloxacin (2 µg/mL) moxifloxacin (0.25 µg/mL).
3. SLIDs: amikacin (1 µg/mL), kanamycin (2.5 µg/mL), capreomycin (2.5 µg/mL).
4. Discrepant analysis: no.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes The test was applied to pooled sputum specimens
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
Yes
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Catanzaro 2015 (Continued)
of the results of the index tests?
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Chikamatsu 2012
Study characteristics
Patient sampling Cross-sectional design with unknown mechanism of enrolment of participants, unknown direction
of data collection
Patient characteristics and set-
ting
1. Country of origin: Japan.
2. World Bank classification of country: high.
3. Type of lab: reference.
4. Type of patients: unknown.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
Target condition and reference
standard(s)
1. Culture (solid; Ogawa solid culture for FQs, unclear for SLIDs) and sequencing used for FQ,
SLID.
2. FQ drugs: levofloxacin (1 µg/mL).
3. SLIDs: amikacin (unknown concentration), kanamycin (unknown concentration),
capreomycin (unknown concentration).
4. Genes sequenced for FQ: gyrA.
5. Genes sequenced for SLIDs: rrs.
6. Discrepant analysis: no.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes
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Chikamatsu 2012 (Continued)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
No
If a threshold was used, was it
pre-specified?
Yes
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Chikamatsu 2012 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Fan 2011
Study characteristics
Patient sampling Cross-sectional design with enrolment of participants by convenience, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: China.
2. World Bank classification of country: middle.
3. Type of lab: research.
4. Type of patients: confirmed MDR-TB patients and confirmed XDR-TB patients.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
Target condition and reference
standard(s)
1. Culture (liquid; MGIT 960).
2. FQ drugs: ofloxacin (2 µg/mL), moxifloxacin (0.25 µg/mL).
3. SLIDs: amikacin (1 µg/mL).
4. Discrepant analysis: no.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Fan 2011 (Continued)
High Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Ferro 2013
Study characteristics
Patient sampling Cross-sectional design with random enrolment of participants, prospective data collection
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Ferro 2013 (Continued)
Patient characteristics and set-
ting
1. Country of origin: Colombia.
2. World Bank classification of country: middle.
3. Type of lab: reference.
4. Type of patients: confirmed drug-susceptible TB patients, MDR-TB patients, MDR-TB
patients with some known second-line resistance and XDR-TB patients.
Index tests 1. Manufacturer involvement: yes, donation of test.
2. Type of testing: indirect.
Target condition and reference
standard(s)
1. Culture-based DST (solid, 7H10).
2. FQ drugs: moxifloxacin 2 µg/mL.
3. SLIDS: amikacin 5 µg/mL, kanamycin 5 µg/mL.
4. No XDR-TB information reported.
5. There was no discrepant analysis.
Flow and timing Not all participants were accounted for in the analyses. Uninterpretable results reported: yes
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
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Ferro 2013 (Continued)
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Hillemann 2009
Study characteristics
Patient sampling Case-control design with the consecutive enrolment of participants, prospective data collection for
clinical specimens, retrospective for culture isolates
Patient characteristics and set-
ting
1. Country of origin: Germany.
2. World Bank classification of country: high.
3. Type of lab: reference.
4. Type of patients: confirmed XDR-TB patients, confirmed drug-susceptible TB patients.
5. The specimens tested were smear positive and smear negative.
Index tests 1. Manufacturer involvement: yes, donation of tests.
2. Type of testing: direct and indirect.
3. Type of specimens: smear-positive.
4. Specimen treatment: NALC-NaOH.
5. Specimen condition: frozen.
6. Duration of freezing: > 1 year.
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Hillemann 2009 (Continued)
Target condition and reference
standard(s)
1. Culture (liquid and solid; MGIT 960 and LJ) and sequencing used for FQ, SLID.
2. FQ drugs: ofloxacin (2 µg/mL for MGIT and LJ).
3. SLIDs: amikacin 1 µg/mL for MGIT and 40.0 µg/mL for LJ; capreomycin 2.5 µg/mL for
MGIT and 40.0 µg/mL for LJ.
4. Genes sequenced for FQ: gyrA.
5. Genes sequenced for SLIDs: rrs.
6. Discrepant analysis: no.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Yes
High High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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Hillemann 2009 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Huang 2011
Study characteristics
Patient sampling Cross-sectional design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: China.
2. World Bank classification of country: middle.
3. Type of lab: reference.
4. Type of patients: confirmed MDR-TB patients.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
Target condition and reference
standard(s)
1. Culture (solid; 7H11 and liquid: MGIT 960) and sequencing used for FQ, SLID.
2. FQ drugs: ofloxacin (2 µg/mL).
3. SLIDs (for 7H11): amikacin (6 µg/mL), kanamycin (6 µg/mL) and capreomycin (10 µg/mL).
4. Genes sequenced for FQ: gyrA and gyrB.
5. Genes sequenced for SLIDs: rrs and eis.
6. Discrepant analysis: no.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes
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Huang 2011 (Continued)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Ignatyeva 2012
Study characteristics
Patient sampling Case-control design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Estonia.
2. World Bank classification of country: high.
3. Type of lab: reference.
4. Type of patients: confirmed MDR-TB patients, confirmed XDR-TB patients and confirmed
drug-susceptible TB patients.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
Target condition and reference
standard(s)
1. Culture (liquid; MGIT 960) used for FQ, SLID.
2. FQ drugs: ofloxacin (2 µg/mL).
3. SLIDs: amikacin (1 µg/mL), kanamycin (5 µg/mL), and capreomycin (2.5 µg/mL).
Flow and timing Uninterpretable results reported: yes
Comparative
Notes Other findings: the interpretability of the Genotype® MTBDRsl assay was high, varying between
98.0% and 100% for the first reading and between 95.5% and 100% for the second reading (Table
3)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
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Did the study avoid inappropri-
ate exclusions?
Yes
High High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Study characteristics
Patient sampling Cross-sectional design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: China.
2. World Bank classification of country: middle.
3. Type of lab: reference.
4. Type of patients: confirmed MDR-TB patients and confirmed XDR-TB patients.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
Target condition and reference
standard(s)
1. Culture (solid; LJ) and BacT/ALERT 3D and sequencing used for FQ, SLID.
2. FQ drugs: ofloxacin (5 and 50 µg/mL).
3. SLIDs: kanamycin (10 µg/mL), capreomycin unknown.
4. Genes sequenced for FQ: gyrA.
5. Genes sequenced for SLIDs: rrs.
6. Discrepant analysis: no.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Jin 2013 (Continued)
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Kambli 2015a
Study characteristics
Patient sampling Cross-sectional study that enrolled consecutively
Patient characteristics and set-
ting
1. Country of origin: India.
2. World Bank classification of country: middle.
3. Type of lab: reference.
4. Type of patients: confirmed MDR-TB patients.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
Target condition and reference
standard(s)
MGIT 960
FQ drugs: ofloxacin (2 µg/mL), moxifloxacin (0.25 µg/mL)
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Flow and timing Uninterpretable results reported: no
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
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Kambli 2015a (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Kambli 2015b
Study characteristics
Patient sampling Cross-sectional study that enrolled consecutively
Patient characteristics and set-
ting
1. Country of origin: India.
2. World Bank classification of country: middle.
3. Type of lab: reference.
4. Type of patients: confirmed MDR-TB cases.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
Target condition and reference
standard(s)
MGIT 960
Levofloxacin (1.5 µg/mL)
Flow and timing Uninterpretable results reported: no
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Kambli 2015b (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Kiet 2010
Study characteristics
Patient sampling Case-control design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Vietnam.
2. World Bank classification of country: middle.
3. Type of lab: reference.
4. Type of patients: confirmed MDR-TB patients with FQ resistance, confirmed FQ
monoresistant patients.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
Target condition and reference
standard(s)
1. Culture (solid; LJ) used for FQ, SLID.
2. FQ drugs: ofloxacin (2 µg/mL).
3. SLIDs: kanamycin (20 µg/mL), not World Health Organization (WHO)-recommended
critical concentrations for LJ solid culture.
4. Discrepant analysis: yes.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes Also performed discrepant analysis; in this analysis, not all patients received both culture-based DST
and genetic sequencing reference standards
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Yes
High High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
No
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Kiet 2010 (Continued)
If a threshold was used, was it
pre-specified?
Yes
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Kontsevaya 2011
Study characteristics
Patient sampling Cross-sectional design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: UK.
2. World Bank classification of country: high.
3. Type of lab: reference.
4. Type of patients: confirmed MDR-TB patients.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
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Target condition and reference
standard(s)
1. Culture (liquid; MGIT 960) used for FQ.
2. FQ drugs: ofloxacin (2 µg/mL), moxifloxacin (0.25 µg/mL).
3. Discrepant analysis: no.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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Kontsevaya 2011 (Continued)
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Kontsevaya 2013
Study characteristics
Patient sampling Cross-sectional design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Russia.
2. World Bank classification of country: high.
3. Type of lab: unknown.
4. Type of patients: confirmed MDR-TB cases.
5. Median age: 35.
6. All HIV-infected.
7. Previous TB: 38/90.
8. Male: 71/90.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: direct.
3. Type of specimens: smear-positive.
4. Specimen treatment: unknown.
5. Specimen condition: unknown.
6. Duration of freezing: unknown.
Target condition and reference
standard(s)
1. Culture (liquid; MGIT 960) used for FQ, SLID.
2. FQ drugs: ofloxacin (2 µg/mL) and moxifloxacin (0.25 µg/mL).
3. SLIDs: kanamycin (5 µg/mL), amikacin (1 µg/mL), and capreomycin (2.5 µg/mL).
4. Discrepant analysis: no.
Flow and timing Uninterpretable results reported: no
Comparative
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Notes Other findings: analysis of test performance stratified according to sputum smear positivity showed
that the test readability for individual drugs and their drug groups ranged from 80.0% to 100.0%,
with the lowest for specimens graded 1 (Table 5). Within this group of specimens, lower readability
rates were observed for the AG/CP group of drugs (20.0% of tests failed), with higher readability
rates for FQ and ethambutol. Similar trends were observed in specimens graded 2 and 3 (Figure 1).
Total agreement between the molecular assay and phenotypic DST was the highest (84.1%) for
FQs and lowest (23.5%) for the injectable drugs
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
79GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Kontsevaya 2013 (Continued)
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Lacoma 2012
Study characteristics
Patient sampling Cross-sectional design, all samples that received the reference standard were enrolled, prospective
data collection
Patient characteristics and set-
ting
1. Country of origin: Spain.
2. World Bank classification of country: high.
3. Type of lab: hospital.
4. Type of patients: confirmed MDR-TB cases.
5. Smear-positive patients whose specimens were tested directly: 49/54.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: direct and indirect.
3. Type of specimens: smear-positive and smear negative.
4. Specimen treatment: NALC-NaOH.
5. Specimen condition: frozen.
6. Duration of freezing: > 1 year.
Target condition and reference
standard(s)
1. Culture (liquid; BACTEC460TB) used for FQ, SLID.
2. FQ drugs: moxifloxacin (0.5 µg/mL).
3. SLIDs: kanamycin (5 µg/mL) and capreomycin (1.25 µg/mL).
4. Discrepant analysis: yes (for indirect testing only).
Flow and timing Uninterpretable results reported: yes
Comparative
Notes Also performed discrepant analysis; in this analysis, not all patients received both culture-based DST
and genetic sequencing reference standards
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Lacoma 2012 (Continued)
Were all patients included in the
analysis?
Yes
Low
Lopez-Roa 2012
Study characteristics
Patient sampling Cross-sectional designwith convenience-based enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Spain.
2. World Bank classification of country: high.
3. Type of lab: hospital.
4. Type of patients: confirmed MDR-TB patients.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
Target condition and reference
standard(s)
1. Culture (solid, agar proportion): 7H11 (FQ) and 7H10 (SLID).
2. FQ drugs: ofloxacin 2 µg/mL on 7H11.
3. SLIDs: amikacin 4 µg/mL on 7H10.
4. Discrepant analysis: yes.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes For diagnostic accuracy, MGIT 960 was used, but MTBDRsl data were presented (and thus ex-
tracted) using the agar proportion method in 7H10 or 7H11 as a reference standard.
Other findings: the turnaround time for agar proportion, MGIT 960 and GenoType® MTBDRsl
were, respectively, 21 days, 8 days, and 8 hours. Also performed discrepant analysis; in this analysis,
not all patients received both culture-based DST and genetic sequencing reference standards
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
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Lopez-Roa 2012 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
High Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Miotto 2012
Study characteristics
Patient sampling Isolates: case-control design with consecutive enrolment of participants, prospective data collection
Specimens: cross-sectional design with consecutive enrolment of participants, prospective data col-
lection
Patient characteristics and set-
ting
1. Country of origin: Unclear.
2. World Bank classification of country: Unclear.
3. Type of lab: hospital.
4. Type of patients: confirmed MDR-TB cases, confirmed XDR-TB cases, confirmed MDR-
TB patients with some known second-line resistance.
Index tests 1. Manufacturer involvement: yes, donation of test.
2. Type of testing: direct and indirect.
3. Type of specimens: smear-positive.
4. Specimen treatment: NALC-NaOH.
5. Specimen condition: frozen.
6. Duration of freezing: > 1 year.
Target condition and reference
standard(s)
1. Culture (liquid, MGIT 960) and sequencing used for FQ, SLID.
2. FQ drugs: ofloxacin (2 µg/mL).
3. SLIDs: amikacin (1.0 µg/mL), kanamycin (5.0 µg/mL), and capreomycin (2.5 µg/mL).
4. Discrepant analysis: yes for XDR-TB, with sequencing.
5. Genes for FQ: gyrA.
6. Genes for SLIDs: rrs.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes Other findings: negative predictive value for SLID is higher in Beijing strains
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Yes
High High
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Miotto 2012 (Continued)
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Said 2012
Study characteristics
Patient sampling Cross-sectional design with consecutive-based enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: South Africa.
2. World Bank classification of country: middle.
3. Type of lab: research.
4. Type of patients: confirmed MDR-TB patients.
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Index tests 1. Manufacturer involvement: yes, financial support.
2. Type of testing: indirect.
Target condition and reference
standard(s)
1. Culture (solid; 7H11).
2. FQ drugs: ofloxacin (2 µg/mL).
3. SLIDs: kanamycin (5 µg/mL) and capreomycin (10 µg/mL). Not the WHO critical
concentrations for SLIDs.
4. Discrepant analysis: no.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes Other findings: turnaround times for DST ranged from 6 to 21 days (median 11) for the agar
proportion method and from 2 to 3 days (median 2) for the MTBDRsl assay. DST results of the
MTBDRsl assay as compared to the agar proportion method are shown in Table 2
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
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Said 2012 (Continued)
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Simons 2015
Study characteristics
Patient sampling Retrospective, cross-sectional study with consecutive sampling
Patient characteristics and set-
ting
1. Country of origin: the Netherlands.
2. World Bank classification of country: high.
3. Type of lab: research.
4. Type of patients: confirmed MDR-TB patients.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
Target condition and reference
standard(s)
1. Culture (liquid; MGIT 960 and 7H10).
2. FQ drugs: moxifloxacin 0.5 µg/mL for MGIT and 1 µg/mL for 7H10.
3. SLIDs: amikacin 1.0 µg/mL for MGIT and 5 µg/mL for 7H10; and capreomycin 2.5 µg/
mL for MGIT and 10 µg/mL for 7H10.
Flow and timing Uninterpretable results reported: yes
Comparative
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Simons 2015 (Continued)
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Simons 2015 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Surcouf 2011
Study characteristics
Patient sampling Cross-sectional design with consecutive-based enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Cambodia.
2. World Bank classification of country: low.
3. Type of lab: unknown.
4. Type of patients: confirmed MDR-TB cases.
Index tests 1. Manufacturer involvement: yes, donation of tests.
2. Type of testing: indirect.
Target condition and reference
standard(s)
1. Sequencing used for reference standard.
2. FQ genes: gyrA.
3. SLID genes: rrs.
4. Discrepant analysis: no.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes Other findings: spoligotyping results showed that most MDR strains belonged to the Beijing family
(57/101, 56%) or were Beijing like (2/101, 2%). This percentage is higher in MDR FQ-R strains
(10/14, 71%). This confirms that Beijing strains are more prone to accumulate antibiotic resistance
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Surcouf 2011 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Tagliani 2015
Study characteristics
Patient sampling Cross-sectional design with consecutive-based enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Italy, Sweden, Germany, and Moldova.
2. World Bank classification of country: high and middle.
3. Type of lab: supranational reference laboratory.
4. Type of patients: confirmed MDR-TB patients.
Index tests 1. MTBDRsl version 2.0
2. Manufacturer involvement: yes, donation of tests.
3. Type of testing: direct and indirect.
Target condition and reference
standard(s)
1. Culture (liquid MGIT 960, solid: LJ proportion).
2. FQ drugs: MGIT: ofloxacin 2 µg/mL, levofloxacin 1.5 µg/mL, moxifloxacin 0.5 µg/mL; LJ:
ofloxacin 4 µg/mL.
3. SLIDs: amikacin 1 µg/mL, kanamycin 2.5 µg/mL, and capreomycin 2.5 µg/mL; LJ:
amikacin 30 µg/mL, kanamycin 30 µg/mL, and capreomycin 40 µg/mL.
4. Discrepant sequencing on false positive samples only.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Tagliani 2015 (Continued)
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
Low
Tomasicchio 2016
Study characteristics
Patient sampling Isolates: case-control design with consecutive enrolment of participants
Specimens: cross-sectional design with consecutive enrolment of participants
Patient characteristics and set-
ting
1. Country of origin: South Africa.
2. World Bank classification of country: middle.
3. Type of lab: reference laboratory.
4. Type of patients: confirmed MDR-TB patients and patients with confirmed second-line drug
resistance.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: direct and indirect.
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Tomasicchio 2016 (Continued)
Target condition and reference
standard(s)
1. Culture (liquid MGIT 960).
2. FQ drugs: ofloxacin 2 µg/mL.
3. SLIDs: amikacin 1 µg/mL.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes A case-control study design was used to evaluate culture isolates
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Yes
High Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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Tomasicchio 2016 (Continued)
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Tukvadze 2014
Study characteristics
Patient sampling Cross-sectional design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Georgia.
2. World Bank classification of country: middle.
3. Type of lab: reference.
4. Type of patients: confirmed MDR-TB patients.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: direct testing.
Target condition and reference
standard(s)
1. Culture based DST, LJ.
2. FQ: ofloxacin 2 µg/mL.
3. SLIDS: capreomycin 40 µg/mL; kanamycin 30 µg/mL.
4. There was no discrepant analysis.
5. All reported XDR-TB resistance.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Tukvadze 2014 (Continued)
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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van Ingen 2010
Study characteristics
Patient sampling Cross-sectional design with enrolment of participants by convenience, retrospective data collection
Patient characteristics and set-
ting
1. Country of origin: Netherlands
2. World Bank classification of country: high
3. Type of lab: reference
4. Type of patients: confirmed MDR-TB patients, confirmed MDR-TB patients with some
known second-line resistance.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
Target condition and reference
standard(s)
1. Culture (solid; 7H10).
2. FQ drugs: moxifloxacin (1 µg/mL).
3. SLIDs: amikacin (5 µg/mL) and capreomycin (10 µg/mL). WHO critical concentrations not
used for 7H10 solid culture.
4. Discrepant analysis: no.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes Relevant clinical information? unclear
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
High High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
96GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
van Ingen 2010 (Continued)
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Zivanovic 2012
Study characteristics
Patient sampling Cross-sectional design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Serbia.
2. World Bank classification of country: middle.
3. Type of lab: reference.
4. Type of patients: confirmed MDR-TB patients.
Index tests 1. Manufacturer involvement: no.
2. Type of testing: indirect.
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Zivanovic 2012 (Continued)
Target condition and reference
standard(s)
1. Culture (solid and liquid; LJ and MGIT 960).
2. FQ drugs: ofloxacin (2 µg/mL).
3. SLIDs: amikacin (1 µg/mL for MGIT and 40 µg/mL for LJ; capreomycin 2.5 µg/mL for
MGIT and 40.0 for LJ.
4. Discrepant analysis: no.
Flow and timing Uninterpretable results reported: yes
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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Zivanovic 2012 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Abbreviations: AP: agar proportion; DST: drug susceptibility testing; FQ: fluoroquinolone; LJ: Lo wenstein-Jensen; MGIT: My-
cobacteria Growth Indicator Tube; SLID: second-line injectable drug; TB: tuberculosis; XDR-TB: extensively drug-resistant TB.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aubry 2014 No cases with second-line resistance.
Babamahmoodi 2014 Not a diagnostic accuracy study.
Bantouna 2011 Conference abstract.
Bergvala 2010 Technical article. Not a diagnostic accuracy study.
Brossier 2010b Conference abstract.
Choi 2010 Technical article. Not a diagnostic accuracy study.
Fallico 2012 Conference abstract.
Felkel 2013 Technical article. No diagnostic data for fluoroquinolones (FQs), second-line injectable drugs (SLIDs), or
extensively drug-resistant tuberculosis (XDR-TB)
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(Continued)
Festoso 2011 Conference abstract.
Gkaravela 2012 Conference abstract.
Gomgnimbou 2015 Not a diagnostic accuracy study.
Iem 2013 Technical article. Only one case of second-line resistance.
Jang 2011 Conference abstract.
Karabela 2007 Conference abstract.
Kaswa 2014 Not a diagnostic accuracy study.
Kontos 2011 Conference abstract.
Kontos 2012 Conference abstract.
Lacoma 2015 Not a diagnostic accuracy study.
Lemus 2011 Conference abstract.
López-Roa 2010 Conference abstract.
Mindru 2013 Data insufficient for 2 x 2 tables.
Molina-Moya 2015 Test other than MTBDRsl.
Niehaus 2015 Not a diagnostic accuracy study.
Orikiriza 2015 Data insufficient for 2 x 2 tables.
Ouassa 2014 Not a diagnostic accuracy study.
Singh 2013 Technical article. No information on resistance to the pre-specified FQs and no cases susceptible to the
SLIDs
Tessema 2012a Technical article. No information on resistance to FQs, SLIDs, or XDR-TB
Tessema 2012b Technical article. No information on resistance to FQs, SLIDs, or XDR-TB
Totten 2011 Conference abstract.
Walker 2015 Not a diagnostic accuracy study.
Wedajo 2014 Not a diagnostic accuracy study.
Zhang 2011 Conference abstract.
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Abbreviations: FQ: fluoroquinolones; SLIDs: second-line injectable drugs; tuberculosis: TB; XDR-TB: extensively drug-resistant
tuberculosis.
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Indirect, FQ, culture 19 2223
2 Indirect, ofloxacin, culture 13 1927
3 Indirect, moxifloxacin, culture 6 419
4 Indirect, levofloxacin, culture 2 169
5 Indirect, ofloxacin, WHO
critical concentration used
8 1427
6 Indirect, ofloxacin, WHO
critical concentration not used
4 481
7 Indirect, SLID, culture 16 1921
8 Indirect, amikacin, culture 11 1301
9 Indirect, kanamycin, culture 9 1342
10 Indirect, capreomycin, culture 10 1406
11 Indirect, amikacin, WHO
critical concentration used
4 706
12 Indirect, capreomycin, WHO
critical concentration used
4 473
13 Indirect, amikacin, WHO
critical concentration not used
7 595
14 Indirect, capreomycin, WHO
critical concentration not used
6 933
15 Indirect, XDR, culture 8 880
16 Indirect, FQ, sequencing 7 974
17 Indirect, SLID, sequencing 7 962
18 Indirect, XDR, sequencing 4 630
19 Indirect, FQ, sequencing and
culture
7 1211
20 Indirect, SLID, sequencing and
culture
7 1491
21 Indirect, XDR, sequencing and
culture
2 435
22 Indirect, FQ, culture followed
by sequencing of discrepants
3 427
23 Indirect, SLID, culture
followed by sequencing of
discrepants
3 619
24 Direct, FQ, culture 9 1771
25 Direct, ofloxacin, culture 7 1667
26 Direct, moxifloxacin, culture 2 821
27 Ofloxacin, smear positive 4 963
28 Ofloxacin, smear negative 2 120
29 Ofloxacin, smear grade = scanty 2 65
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30 Ofloxacin, smear grade = 1+ 4 241
31 Ofloxacin, smear grade ≥ 2+ 4 647
32 Moxifloxacin, smear positive 2 821
33 Moxifloxacin, smear negative 1 91
34 Moxifloxacin, smear grade =
scanty
1 51
35 Moxifloxacin, smear grade = 1+ 2 197
36 Moxifloxacin, smear grade ≥
2+
2 593
37 Direct, SLID, culture 8 1639
38 Direct, amikacin, culture 6 1491
39 Direct, kanamycin, culture 5 1020
40 Direct, capreomycin, culture 5 1027
41 Amikacin, smear positive 4 809
42 Amikacin, smear negative 2 104
43 Amikacin, smear grade = scanty 3 57
44 Amikacin, smear grade= 1+ 4 222
45 Amikacin, smear grade ≥ 2+ 4 602
46 Kananycin, smear positive 3 806
47 Kanamycin, smear negative 1 73
48 Kanamycin, smear grade =
scanty
2 43
49 Kanamycin, smear grade = +1 3 193
50 Kanamycin, smear grade ≥ 2+ 3 564
51 Capreomycin, smear positive 3 806
52 Capreomycin, smear negative 1 73
53 Capreomycin, smear grade = 1+ 3 193
54 Capreomycin, smear grade =
scanty
2 43
55 Capreomycin, smear grade ≥
2+
3 564
56 Direct, XDR, culture 6 1420
57 Direct, FQ, culture followed by
sequencing of discrepants
2 685
58 Direct, SLID, culture followed
by sequencing of discrepants
2 666
59 Direct, XDR, culture followed
by sequencing of discrepants
2 570
60 V2, Indirect, FQ, culture 1 228
61 V2, Direct, FQ, smear positive 1 155
62 V2, Direct, FQ, smear negative 1 9
63 V2, Indirect, ofloxacin, culture 1 226
64 V2, Indirect, moxifloxacin,
culture
1 97
65 V2, Indirect, SLID, culture 1 228
66 V2, Direct, SLID, smear
positive
1 164
67 V2, Direct, SLID, smear
negative
1 9
68 V2, Indirect, amikacin, culture 1 226
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69 V2, Indirect, kanamycin,
culture
1 224
70 V2, Indirect, capreomycin,
culture
1 218
71 V2, Ofloxacin, smear positive 1 153
72 V2, Ofloxacin, smear negative 1 9
73 V2, Ofloxacin, smear grade =
scanty
1 38
74 V2, Ofloxacin, smear grade =
1+
1 56
75 V2, Ofloxacin, smear grade ≥
2+
1 49
76 V2, Moxifloxacin, smear
positive
1 22
77 V2, Moxifloxacin, smear grade
≥ 2+
1 8
78 V2, Levofloxacin, smear
positive
1 53
79 V2, Levofloxacin, smear grade
= scanty
1 25
80 V2, Levofloxacin, smear grade
= 1+
1 22
81 V2, Levofloxacin, smear grade
≥ 2+
1 6
82 V2, Amikacin, smear positive 1 155
83 V2, Amikacin, smear negative 1 9
84 V2, Amikacin, smear grade =
scanty
1 40
85 V2, Amikacin, smear grade =
1+
1 57
86 V2, Amikacin, smear grade ≥
2+
1 49
87 V2, Kanamycin, smear positive 1 155
88 V2, Kanamycin, smear negative 1 7
89 V2, Kanamycin, smear grade =
scanty
1 37
90 V2, Kanamycin, smear grade =
1+
1 55
91 V2, Kanamycin, smear grade ≥
2+
1 45
92 V2, Capreomycin, smear
positive
1 164
93 V2, Capreomycin, smear
negative
1 9
94 V2, Capreomycin, smear grade
= scanty
1 40
95 V2, Capreomycin, smear grade
= 1+
1 57
96 V2, Capreomycin, smear grade
≥ 2+
1 49
97 V2, Indirect, XDR, culture 1 228
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98 V2, Direct, XDR, smear
positive
1 164
99 V2, Direct, XDR, smear
negative
1 9
Test 1. Indirect, FQ, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 1 Indirect, FQ, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010a 21 1 3 27 0.88 [ 0.68, 0.97 ] 0.96 [ 0.82, 1.00 ]
Chikamatsu 2012 16 1 4 25 0.80 [ 0.56, 0.94 ] 0.96 [ 0.80, 1.00 ]
Fan 2011 49 3 3 39 0.94 [ 0.84, 0.99 ] 0.93 [ 0.81, 0.99 ]
Ferro 2013 3 8 0 62 1.00 [ 0.29, 1.00 ] 0.89 [ 0.79, 0.95 ]
Hillemann 2009 29 0 3 74 0.91 [ 0.75, 0.98 ] 1.00 [ 0.95, 1.00 ]
Huang 2011 63 0 11 160 0.85 [ 0.75, 0.92 ] 1.00 [ 0.98, 1.00 ]
Ignatyeva 2012 69 7 12 92 0.85 [ 0.76, 0.92 ] 0.93 [ 0.86, 0.97 ]
Jin 2013 111 11 26 113 0.81 [ 0.73, 0.87 ] 0.91 [ 0.85, 0.95 ]
Kambli 2015b 93 0 0 30 1.00 [ 0.96, 1.00 ] 1.00 [ 0.88, 1.00 ]
Kiet 2010 31 0 10 21 0.76 [ 0.60, 0.88 ] 1.00 [ 0.84, 1.00 ]
Kontsevaya 2011 25 0 4 19 0.86 [ 0.68, 0.96 ] 1.00 [ 0.82, 1.00 ]
Lacoma 2012 4 5 3 17 0.57 [ 0.18, 0.90 ] 0.77 [ 0.55, 0.92 ]
Lopez-Roa 2012 5 0 1 20 0.83 [ 0.36, 1.00 ] 1.00 [ 0.83, 1.00 ]
Miotto 2012 42 1 15 116 0.74 [ 0.60, 0.84 ] 0.99 [ 0.95, 1.00 ]
Said 2012 26 7 11 292 0.70 [ 0.53, 0.84 ] 0.98 [ 0.95, 0.99 ]
Simons 2015 6 0 1 67 0.86 [ 0.42, 1.00 ] 1.00 [ 0.95, 1.00 ]
Tomasicchio 2016 115 1 44 100 0.72 [ 0.65, 0.79 ] 0.99 [ 0.95, 1.00 ]
van Ingen 2010 5 0 0 21 1.00 [ 0.48, 1.00 ] 1.00 [ 0.84, 1.00 ]
Zivanovic 2012 5 0 0 14 1.00 [ 0.48, 1.00 ] 1.00 [ 0.77, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. Indirect, ofloxacin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 2 Indirect, ofloxacin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010a 21 1 3 27 0.88 [ 0.68, 0.97 ] 0.96 [ 0.82, 1.00 ]
Fan 2011 48 4 3 39 0.94 [ 0.84, 0.99 ] 0.91 [ 0.78, 0.97 ]
Hillemann 2009 29 0 3 74 0.91 [ 0.75, 0.98 ] 1.00 [ 0.95, 1.00 ]
Huang 2011 63 0 11 160 0.85 [ 0.75, 0.92 ] 1.00 [ 0.98, 1.00 ]
Ignatyeva 2012 69 7 12 92 0.85 [ 0.76, 0.92 ] 0.93 [ 0.86, 0.97 ]
Jin 2013 111 11 26 113 0.81 [ 0.73, 0.87 ] 0.91 [ 0.85, 0.95 ]
Kambli 2015a 93 0 2 28 0.98 [ 0.93, 1.00 ] 1.00 [ 0.88, 1.00 ]
Kiet 2010 31 0 10 21 0.76 [ 0.60, 0.88 ] 1.00 [ 0.84, 1.00 ]
Lopez-Roa 2012 5 0 1 20 0.83 [ 0.36, 1.00 ] 1.00 [ 0.83, 1.00 ]
Miotto 2012 42 1 15 116 0.74 [ 0.60, 0.84 ] 0.99 [ 0.95, 1.00 ]
Said 2012 26 7 11 292 0.70 [ 0.53, 0.84 ] 0.98 [ 0.95, 0.99 ]
Tomasicchio 2016 115 1 44 100 0.72 [ 0.65, 0.79 ] 0.99 [ 0.95, 1.00 ]
Zivanovic 2012 5 0 0 14 1.00 [ 0.48, 1.00 ] 1.00 [ 0.77, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 3. Indirect, moxifloxacin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 3 Indirect, moxifloxacin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Fan 2011 49 3 3 39 0.94 [ 0.84, 0.99 ] 0.93 [ 0.81, 0.99 ]
Ferro 2013 3 8 0 62 1.00 [ 0.29, 1.00 ] 0.89 [ 0.79, 0.95 ]
Kambli 2015a 93 0 2 28 0.98 [ 0.93, 1.00 ] 1.00 [ 0.88, 1.00 ]
Lacoma 2012 4 5 3 17 0.57 [ 0.18, 0.90 ] 0.77 [ 0.55, 0.92 ]
Simons 2015 6 0 1 67 0.86 [ 0.42, 1.00 ] 1.00 [ 0.95, 1.00 ]
van Ingen 2010 5 0 0 21 1.00 [ 0.48, 1.00 ] 1.00 [ 0.84, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. Indirect, levofloxacin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 4 Indirect, levofloxacin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Chikamatsu 2012 16 1 4 25 0.80 [ 0.56, 0.94 ] 0.96 [ 0.80, 1.00 ]
Kambli 2015b 93 0 0 30 1.00 [ 0.96, 1.00 ] 1.00 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
107GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Test 5. Indirect, ofloxacin, WHO critical concentration used.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 5 Indirect, ofloxacin, WHO critical concentration used
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Fan 2011 48 4 3 39 0.94 [ 0.84, 0.99 ] 0.91 [ 0.78, 0.97 ]
Huang 2011 63 0 11 160 0.85 [ 0.75, 0.92 ] 1.00 [ 0.98, 1.00 ]
Ignatyeva 2012 69 7 12 92 0.85 [ 0.76, 0.92 ] 0.93 [ 0.86, 0.97 ]
Kambli 2015a 93 0 2 28 0.98 [ 0.93, 1.00 ] 1.00 [ 0.88, 1.00 ]
Lopez-Roa 2012 5 0 1 20 0.83 [ 0.36, 1.00 ] 1.00 [ 0.83, 1.00 ]
Miotto 2012 42 1 15 116 0.74 [ 0.60, 0.84 ] 0.99 [ 0.95, 1.00 ]
Said 2012 26 7 11 292 0.70 [ 0.53, 0.84 ] 0.98 [ 0.95, 0.99 ]
Tomasicchio 2016 115 1 44 100 0.72 [ 0.65, 0.79 ] 0.99 [ 0.95, 1.00 ]
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Test 6. Indirect, ofloxacin, WHO critical concentration not used.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 6 Indirect, ofloxacin, WHO critical concentration not used
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010a 21 1 3 27 0.88 [ 0.68, 0.97 ] 0.96 [ 0.82, 1.00 ]
Hillemann 2009 29 0 3 74 0.91 [ 0.75, 0.98 ] 1.00 [ 0.95, 1.00 ]
Jin 2013 111 11 26 113 0.81 [ 0.73, 0.87 ] 0.91 [ 0.85, 0.95 ]
Kiet 2010 31 0 10 21 0.76 [ 0.60, 0.88 ] 1.00 [ 0.84, 1.00 ]
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Test 7. Indirect, SLID, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 7 Indirect, SLID, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010a 11 0 4 37 0.73 [ 0.45, 0.92 ] 1.00 [ 0.91, 1.00 ]
Chikamatsu 2012 10 0 8 28 0.56 [ 0.31, 0.78 ] 1.00 [ 0.88, 1.00 ]
Fan 2011 13 1 3 77 0.81 [ 0.54, 0.96 ] 0.99 [ 0.93, 1.00 ]
Ferro 2013 4 0 0 18 1.00 [ 0.40, 1.00 ] 1.00 [ 0.81, 1.00 ]
Hillemann 2009 40 0 6 60 0.87 [ 0.74, 0.95 ] 1.00 [ 0.94, 1.00 ]
Huang 2011 16 0 3 215 0.84 [ 0.60, 0.97 ] 1.00 [ 0.98, 1.00 ]
Ignatyeva 2012 37 2 55 87 0.40 [ 0.30, 0.51 ] 0.98 [ 0.92, 1.00 ]
Jin 2013 48 9 24 180 0.67 [ 0.55, 0.77 ] 0.95 [ 0.91, 0.98 ]
Kiet 2010 5 0 0 57 1.00 [ 0.48, 1.00 ] 1.00 [ 0.94, 1.00 ]
Lacoma 2012 5 3 0 19 1.00 [ 0.48, 1.00 ] 0.86 [ 0.65, 0.97 ]
Lopez-Roa 2012 3 1 1 21 0.75 [ 0.19, 0.99 ] 0.95 [ 0.77, 1.00 ]
Miotto 2012 60 0 24 90 0.71 [ 0.61, 0.81 ] 1.00 [ 0.96, 1.00 ]
Said 2012 7 4 21 300 0.25 [ 0.11, 0.45 ] 0.99 [ 0.97, 1.00 ]
Tomasicchio 2016 125 2 32 99 0.80 [ 0.72, 0.86 ] 0.98 [ 0.93, 1.00 ]
van Ingen 2010 6 0 0 21 1.00 [ 0.54, 1.00 ] 1.00 [ 0.84, 1.00 ]
Zivanovic 2012 4 0 0 15 1.00 [ 0.40, 1.00 ] 1.00 [ 0.78, 1.00 ]
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Test 8. Indirect, amikacin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 8 Indirect, amikacin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010a 10 0 0 42 1.00 [ 0.69, 1.00 ] 1.00 [ 0.92, 1.00 ]
Fan 2011 13 1 3 77 0.81 [ 0.54, 0.96 ] 0.99 [ 0.93, 1.00 ]
Ferro 2013 27 0 2 102 0.93 [ 0.77, 0.99 ] 1.00 [ 0.96, 1.00 ]
Hillemann 2009 39 0 7 60 0.85 [ 0.71, 0.94 ] 1.00 [ 0.94, 1.00 ]
Huang 2011 16 0 3 215 0.84 [ 0.60, 0.97 ] 1.00 [ 0.98, 1.00 ]
Ignatyeva 2012 37 4 9 130 0.80 [ 0.66, 0.91 ] 0.97 [ 0.93, 0.99 ]
Lopez-Roa 2012 3 1 1 21 0.75 [ 0.19, 0.99 ] 0.95 [ 0.77, 1.00 ]
Miotto 2012 58 2 7 107 0.89 [ 0.79, 0.96 ] 0.98 [ 0.94, 1.00 ]
Tomasicchio 2016 125 2 32 99 0.80 [ 0.72, 0.86 ] 0.98 [ 0.93, 1.00 ]
van Ingen 2010 6 0 0 21 1.00 [ 0.54, 1.00 ] 1.00 [ 0.84, 1.00 ]
Zivanovic 2012 4 0 0 15 1.00 [ 0.40, 1.00 ] 1.00 [ 0.78, 1.00 ]
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Test 9. Indirect, kanamycin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 9 Indirect, kanamycin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010a 10 0 3 39 0.77 [ 0.46, 0.95 ] 1.00 [ 0.91, 1.00 ]
Ferro 2013 4 0 0 18 1.00 [ 0.40, 1.00 ] 1.00 [ 0.81, 1.00 ]
Huang 2011 16 0 21 197 0.43 [ 0.27, 0.61 ] 1.00 [ 0.98, 1.00 ]
Ignatyeva 2012 37 4 50 89 0.43 [ 0.32, 0.54 ] 0.96 [ 0.89, 0.99 ]
Jin 2013 55 2 40 164 0.58 [ 0.47, 0.68 ] 0.99 [ 0.96, 1.00 ]
Kiet 2010 5 0 0 57 1.00 [ 0.48, 1.00 ] 1.00 [ 0.94, 1.00 ]
Lacoma 2012 5 3 0 19 1.00 [ 0.48, 1.00 ] 0.86 [ 0.65, 0.97 ]
Miotto 2012 56 2 19 95 0.75 [ 0.63, 0.84 ] 0.98 [ 0.93, 1.00 ]
Said 2012 7 4 21 300 0.25 [ 0.11, 0.45 ] 0.99 [ 0.97, 1.00 ]
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Test 10. Indirect, capreomycin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 10 Indirect, capreomycin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010a 9 1 2 40 0.82 [ 0.48, 0.98 ] 0.98 [ 0.87, 1.00 ]
Hillemann 2009 39 1 6 60 0.87 [ 0.73, 0.95 ] 0.98 [ 0.91, 1.00 ]
Huang 2011 10 6 4 214 0.71 [ 0.42, 0.92 ] 0.97 [ 0.94, 0.99 ]
Ignatyeva 2012 34 7 5 134 0.87 [ 0.73, 0.96 ] 0.95 [ 0.90, 0.98 ]
Jin 2013 49 8 75 129 0.40 [ 0.31, 0.49 ] 0.94 [ 0.89, 0.97 ]
Lacoma 2012 5 3 0 19 1.00 [ 0.48, 1.00 ] 0.86 [ 0.65, 0.97 ]
Miotto 2012 49 9 9 101 0.84 [ 0.73, 0.93 ] 0.92 [ 0.85, 0.96 ]
Said 2012 7 4 26 295 0.21 [ 0.09, 0.39 ] 0.99 [ 0.97, 1.00 ]
van Ingen 2010 5 1 0 21 1.00 [ 0.48, 1.00 ] 0.95 [ 0.77, 1.00 ]
Zivanovic 2012 4 0 0 15 1.00 [ 0.40, 1.00 ] 1.00 [ 0.78, 1.00 ]
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Test 11. Indirect, amikacin, WHO critical concentration used.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 11 Indirect, amikacin, WHO critical concentration used
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Fan 2011 13 1 3 77 0.81 [ 0.54, 0.96 ] 0.99 [ 0.93, 1.00 ]
Ignatyeva 2012 37 4 9 130 0.80 [ 0.66, 0.91 ] 0.97 [ 0.93, 0.99 ]
Miotto 2012 58 2 7 107 0.89 [ 0.79, 0.96 ] 0.98 [ 0.94, 1.00 ]
Tomasicchio 2016 125 2 32 99 0.80 [ 0.72, 0.86 ] 0.98 [ 0.93, 1.00 ]
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Test 12. Indirect, capreomycin, WHO critical concentration used.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 12 Indirect, capreomycin, WHO critical concentration used
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hillemann 2009 39 1 6 60 0.87 [ 0.73, 0.95 ] 0.98 [ 0.91, 1.00 ]
Ignatyeva 2012 34 7 5 134 0.87 [ 0.73, 0.96 ] 0.95 [ 0.90, 0.98 ]
Miotto 2012 49 9 9 101 0.84 [ 0.73, 0.93 ] 0.92 [ 0.85, 0.96 ]
Zivanovic 2012 4 0 0 15 1.00 [ 0.40, 1.00 ] 1.00 [ 0.78, 1.00 ]
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Test 13. Indirect, amikacin, WHO critical concentration not used.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 13 Indirect, amikacin, WHO critical concentration not used
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010a 10 0 0 42 1.00 [ 0.69, 1.00 ] 1.00 [ 0.92, 1.00 ]
Ferro 2013 27 0 2 102 0.93 [ 0.77, 0.99 ] 1.00 [ 0.96, 1.00 ]
Hillemann 2009 39 0 7 60 0.85 [ 0.71, 0.94 ] 1.00 [ 0.94, 1.00 ]
Huang 2011 16 0 3 215 0.84 [ 0.60, 0.97 ] 1.00 [ 0.98, 1.00 ]
Lopez-Roa 2012 3 1 1 21 0.75 [ 0.19, 0.99 ] 0.95 [ 0.77, 1.00 ]
van Ingen 2010 6 0 0 21 1.00 [ 0.54, 1.00 ] 1.00 [ 0.84, 1.00 ]
Zivanovic 2012 4 0 0 15 1.00 [ 0.40, 1.00 ] 1.00 [ 0.78, 1.00 ]
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Test 14. Indirect, capreomycin, WHO critical concentration not used.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 14 Indirect, capreomycin, WHO critical concentration not used
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010a 9 1 2 40 0.82 [ 0.48, 0.98 ] 0.98 [ 0.87, 1.00 ]
Huang 2011 10 6 4 214 0.71 [ 0.42, 0.92 ] 0.97 [ 0.94, 0.99 ]
Jin 2013 49 8 75 129 0.40 [ 0.31, 0.49 ] 0.94 [ 0.89, 0.97 ]
Lacoma 2012 5 3 0 19 1.00 [ 0.48, 1.00 ] 0.86 [ 0.65, 0.97 ]
Said 2012 7 4 26 295 0.21 [ 0.09, 0.39 ] 0.99 [ 0.97, 1.00 ]
van Ingen 2010 5 1 0 21 1.00 [ 0.48, 1.00 ] 0.95 [ 0.77, 1.00 ]
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Test 15. Indirect, XDR, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 15 Indirect, XDR, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Chikamatsu 2012 9 0 4 33 0.69 [ 0.39, 0.91 ] 1.00 [ 0.89, 1.00 ]
Hillemann 2009 10 0 4 92 0.71 [ 0.42, 0.92 ] 1.00 [ 0.96, 1.00 ]
Ignatyeva 2012 8 6 32 134 0.20 [ 0.09, 0.36 ] 0.96 [ 0.91, 0.98 ]
Jin 2013 46 4 37 174 0.55 [ 0.44, 0.66 ] 0.98 [ 0.94, 0.99 ]
Kiet 2010 3 0 0 62 1.00 [ 0.29, 1.00 ] 1.00 [ 0.94, 1.00 ]
Miotto 2012 8 6 5 155 0.62 [ 0.32, 0.86 ] 0.96 [ 0.92, 0.99 ]
van Ingen 2010 4 0 0 25 1.00 [ 0.40, 1.00 ] 1.00 [ 0.86, 1.00 ]
Zivanovic 2012 3 0 0 16 1.00 [ 0.29, 1.00 ] 1.00 [ 0.79, 1.00 ]
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Test 16. Indirect, FQ, sequencing.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 16 Indirect, FQ, sequencing
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010a 22 0 4 26 0.85 [ 0.65, 0.96 ] 1.00 [ 0.87, 1.00 ]
Chikamatsu 2012 17 0 0 29 1.00 [ 0.80, 1.00 ] 1.00 [ 0.88, 1.00 ]
Hillemann 2009 29 0 0 77 1.00 [ 0.88, 1.00 ] 1.00 [ 0.95, 1.00 ]
Huang 2011 63 0 0 171 1.00 [ 0.94, 1.00 ] 1.00 [ 0.98, 1.00 ]
Jin 2013 110 12 5 134 0.96 [ 0.90, 0.99 ] 0.92 [ 0.86, 0.96 ]
Miotto 2012 39 4 0 131 1.00 [ 0.91, 1.00 ] 0.97 [ 0.93, 0.99 ]
Surcouf 2011 14 0 0 87 1.00 [ 0.77, 1.00 ] 1.00 [ 0.96, 1.00 ]
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Test 17. Indirect, SLID, sequencing.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 17 Indirect, SLID, sequencing
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010a 10 0 4 38 0.71 [ 0.42, 0.92 ] 1.00 [ 0.91, 1.00 ]
Chikamatsu 2012 10 0 0 36 1.00 [ 0.69, 1.00 ] 1.00 [ 0.90, 1.00 ]
Hillemann 2009 40 0 0 66 1.00 [ 0.91, 1.00 ] 1.00 [ 0.95, 1.00 ]
Huang 2011 16 0 10 208 0.62 [ 0.41, 0.80 ] 1.00 [ 0.98, 1.00 ]
Jin 2013 49 8 1 203 0.98 [ 0.89, 1.00 ] 0.96 [ 0.93, 0.98 ]
Miotto 2012 58 2 0 114 1.00 [ 0.94, 1.00 ] 0.98 [ 0.94, 1.00 ]
Surcouf 2011 1 0 0 88 1.00 [ 0.03, 1.00 ] 1.00 [ 0.96, 1.00 ]
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Test 18. Indirect, XDR, sequencing.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 18 Indirect, XDR, sequencing
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hillemann 2009 14 0 0 92 1.00 [ 0.77, 1.00 ] 1.00 [ 0.96, 1.00 ]
Jin 2013 40 10 0 211 1.00 [ 0.91, 1.00 ] 0.95 [ 0.92, 0.98 ]
Miotto 2012 12 2 0 160 1.00 [ 0.74, 1.00 ] 0.99 [ 0.96, 1.00 ]
Surcouf 2011 1 0 0 88 1.00 [ 0.03, 1.00 ] 1.00 [ 0.96, 1.00 ]
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Test 19. Indirect, FQ, sequencing and culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 19 Indirect, FQ, sequencing and culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010a 22 0 4 26 0.85 [ 0.65, 0.96 ] 1.00 [ 0.87, 1.00 ]
Hillemann 2009 29 0 3 74 0.91 [ 0.75, 0.98 ] 1.00 [ 0.95, 1.00 ]
Huang 2011 63 0 11 160 0.85 [ 0.75, 0.92 ] 1.00 [ 0.98, 1.00 ]
Jin 2013 121 1 26 113 0.82 [ 0.75, 0.88 ] 0.99 [ 0.95, 1.00 ]
Kontsevaya 2011 25 0 4 19 0.86 [ 0.68, 0.96 ] 1.00 [ 0.82, 1.00 ]
Miotto 2012 42 1 15 116 0.74 [ 0.60, 0.84 ] 0.99 [ 0.95, 1.00 ]
Said 2012 33 0 11 292 0.75 [ 0.60, 0.87 ] 1.00 [ 0.99, 1.00 ]
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Test 20. Indirect, SLID, sequencing and culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 20 Indirect, SLID, sequencing and culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010a 10 0 4 38 0.71 [ 0.42, 0.92 ] 1.00 [ 0.91, 1.00 ]
Hillemann 2009 39 0 7 60 0.85 [ 0.71, 0.94 ] 1.00 [ 0.94, 1.00 ]
Huang 2011 16 0 21 197 0.43 [ 0.27, 0.61 ] 1.00 [ 0.98, 1.00 ]
Jin 2013 56 1 41 163 0.58 [ 0.47, 0.68 ] 0.99 [ 0.97, 1.00 ]
Miotto 2012 59 0 25 90 0.70 [ 0.59, 0.80 ] 1.00 [ 0.96, 1.00 ]
Said 2012 11 0 21 300 0.34 [ 0.19, 0.53 ] 1.00 [ 0.99, 1.00 ]
Surcouf 2011 11 0 26 295 0.30 [ 0.16, 0.47 ] 1.00 [ 0.99, 1.00 ]
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Test 21. Indirect, XDR, sequencing and culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 21 Indirect, XDR, sequencing and culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jin 2013 48 2 37 174 0.56 [ 0.45, 0.67 ] 0.99 [ 0.96, 1.00 ]
Miotto 2012 12 2 5 155 0.71 [ 0.44, 0.90 ] 0.99 [ 0.95, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 22. Indirect, FQ, culture followed by sequencing of discrepants.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 22 Indirect, FQ, culture followed by sequencing of discrepants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kiet 2010 31 0 0 31 1.00 [ 0.89, 1.00 ] 1.00 [ 0.89, 1.00 ]
Lacoma 2012 8 1 3 17 0.73 [ 0.39, 0.94 ] 0.94 [ 0.73, 1.00 ]
Lopez-Roa 2012 33 0 11 292 0.75 [ 0.60, 0.87 ] 1.00 [ 0.99, 1.00 ]
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Test 23. Indirect, SLID, culture followed by sequencing of discrepants.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 23 Indirect, SLID, culture followed by sequencing of discrepants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jin 2013 56 1 40 163 0.58 [ 0.48, 0.68 ] 0.99 [ 0.97, 1.00 ]
Lacoma 2012 7 1 0 19 1.00 [ 0.59, 1.00 ] 0.95 [ 0.75, 1.00 ]
Said 2012 11 0 21 300 0.34 [ 0.19, 0.53 ] 1.00 [ 0.99, 1.00 ]
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Test 24. Direct, FQ, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 24 Direct, FQ, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 96 1 9 64 0.91 [ 0.84, 0.96 ] 0.98 [ 0.92, 1.00 ]
Barnard 2012 49 9 5 453 0.91 [ 0.80, 0.97 ] 0.98 [ 0.96, 0.99 ]
Catanzaro 2015 229 1 10 411 0.96 [ 0.92, 0.98 ] 1.00 [ 0.99, 1.00 ]
Hillemann 2009 8 0 1 41 0.89 [ 0.52, 1.00 ] 1.00 [ 0.91, 1.00 ]
Kontsevaya 2013 15 2 12 61 0.56 [ 0.35, 0.75 ] 0.97 [ 0.89, 1.00 ]
Lacoma 2012 1 1 2 10 0.33 [ 0.01, 0.91 ] 0.91 [ 0.59, 1.00 ]
Miotto 2012 8 0 0 52 1.00 [ 0.63, 1.00 ] 1.00 [ 0.93, 1.00 ]
Tomasicchio 2016 38 0 10 34 0.79 [ 0.65, 0.90 ] 1.00 [ 0.90, 1.00 ]
Tukvadze 2014 21 1 5 111 0.81 [ 0.61, 0.93 ] 0.99 [ 0.95, 1.00 ]
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Test 25. Direct, ofloxacin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 25 Direct, ofloxacin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 96 1 9 64 0.91 [ 0.84, 0.96 ] 0.98 [ 0.92, 1.00 ]
Barnard 2012 49 9 5 453 0.91 [ 0.80, 0.97 ] 0.98 [ 0.96, 0.99 ]
Catanzaro 2015 228 2 9 412 0.96 [ 0.93, 0.98 ] 1.00 [ 0.98, 1.00 ]
Hillemann 2009 8 0 1 41 0.89 [ 0.52, 1.00 ] 1.00 [ 0.91, 1.00 ]
Miotto 2012 8 0 0 52 1.00 [ 0.63, 1.00 ] 1.00 [ 0.93, 1.00 ]
Tomasicchio 2016 38 0 10 34 0.79 [ 0.65, 0.90 ] 1.00 [ 0.90, 1.00 ]
Tukvadze 2014 21 1 5 111 0.81 [ 0.61, 0.93 ] 0.99 [ 0.95, 1.00 ]
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Test 26. Direct, moxifloxacin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 26 Direct, moxifloxacin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 96 1 8 65 0.92 [ 0.85, 0.97 ] 0.98 [ 0.92, 1.00 ]
Catanzaro 2015 226 4 9 412 0.96 [ 0.93, 0.98 ] 0.99 [ 0.98, 1.00 ]
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Test 27. Ofloxacin, smear positive.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 27 Ofloxacin, smear positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 96 1 9 64 0.91 [ 0.84, 0.96 ] 0.98 [ 0.92, 1.00 ]
Catanzaro 2015 228 2 9 412 0.96 [ 0.93, 0.98 ] 1.00 [ 0.98, 1.00 ]
Miotto 2012 8 0 0 52 1.00 [ 0.63, 1.00 ] 1.00 [ 0.93, 1.00 ]
Tomasicchio 2016 38 0 10 34 0.79 [ 0.65, 0.90 ] 1.00 [ 0.90, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 28. Ofloxacin, smear negative.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 28 Ofloxacin, smear negative
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Catanzaro 2015 6 1 1 83 0.86 [ 0.42, 1.00 ] 0.99 [ 0.94, 1.00 ]
Tomasicchio 2016 5 0 20 4 0.20 [ 0.07, 0.41 ] 1.00 [ 0.40, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 29. Ofloxacin, smear grade = scanty.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 29 Ofloxacin, smear grade = scanty
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Catanzaro 2015 8 0 0 43 1.00 [ 0.63, 1.00 ] 1.00 [ 0.92, 1.00 ]
Tomasicchio 2016 1 1 0 12 1.00 [ 0.03, 1.00 ] 0.92 [ 0.64, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 30. Ofloxacin, smear grade = 1+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 30 Ofloxacin, smear grade = 1+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 26 1 0 19 1.00 [ 0.87, 1.00 ] 0.95 [ 0.75, 1.00 ]
Catanzaro 2015 41 1 2 107 0.95 [ 0.84, 0.99 ] 0.99 [ 0.95, 1.00 ]
Miotto 2012 3 0 0 12 1.00 [ 0.29, 1.00 ] 1.00 [ 0.74, 1.00 ]
Tomasicchio 2016 3 2 0 24 1.00 [ 0.29, 1.00 ] 0.92 [ 0.75, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 31. Ofloxacin, smear grade ≥ 2+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 31 Ofloxacin, smear grade ≥ 2+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 70 0 9 45 0.89 [ 0.79, 0.95 ] 1.00 [ 0.92, 1.00 ]
Catanzaro 2015 179 1 7 262 0.96 [ 0.92, 0.98 ] 1.00 [ 0.98, 1.00 ]
Miotto 2012 3 0 0 33 1.00 [ 0.29, 1.00 ] 1.00 [ 0.89, 1.00 ]
Tomasicchio 2016 5 3 2 28 0.71 [ 0.29, 0.96 ] 0.90 [ 0.74, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 32. Moxifloxacin, smear positive.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 32 Moxifloxacin, smear positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 96 1 8 65 0.92 [ 0.85, 0.97 ] 0.98 [ 0.92, 1.00 ]
Catanzaro 2015 226 4 9 412 0.96 [ 0.93, 0.98 ] 0.99 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 33. Moxifloxacin, smear negative.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 33 Moxifloxacin, smear negative
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Catanzaro 2015 6 1 2 82 0.75 [ 0.35, 0.97 ] 0.99 [ 0.93, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 34. Moxifloxacin, smear grade = scanty.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 34 Moxifloxacin, smear grade = scanty
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Catanzaro 2015 7 1 0 43 1.00 [ 0.59, 1.00 ] 0.98 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 35. Moxifloxacin, smear grade = 1+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 35 Moxifloxacin, smear grade = 1+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 27 0 0 19 1.00 [ 0.87, 1.00 ] 1.00 [ 0.82, 1.00 ]
Catanzaro 2015 42 0 2 107 0.95 [ 0.85, 0.99 ] 1.00 [ 0.97, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
124GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Test 36. Moxifloxacin, smear grade ≥ 2+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 36 Moxifloxacin, smear grade ≥ 2+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 69 1 8 46 0.90 [ 0.81, 0.95 ] 0.98 [ 0.89, 1.00 ]
Catanzaro 2015 197 3 7 262 0.97 [ 0.93, 0.99 ] 0.99 [ 0.97, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 37. Direct, SLID, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 37 Direct, SLID, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 22 0 0 128 1.00 [ 0.85, 1.00 ] 1.00 [ 0.97, 1.00 ]
Barnard 2012 43 3 0 470 1.00 [ 0.92, 1.00 ] 0.99 [ 0.98, 1.00 ]
Catanzaro 2015 43 0 48 508 0.47 [ 0.37, 0.58 ] 1.00 [ 0.99, 1.00 ]
Kontsevaya 2013 6 0 59 12 0.09 [ 0.03, 0.19 ] 1.00 [ 0.74, 1.00 ]
Lacoma 2012 4 5 0 7 1.00 [ 0.40, 1.00 ] 0.58 [ 0.28, 0.85 ]
Miotto 2012 8 5 1 43 0.89 [ 0.52, 1.00 ] 0.90 [ 0.77, 0.97 ]
Tomasicchio 2016 35 0 13 38 0.73 [ 0.58, 0.85 ] 1.00 [ 0.91, 1.00 ]
Tukvadze 2014 19 1 47 71 0.29 [ 0.18, 0.41 ] 0.99 [ 0.93, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 38. Direct, amikacin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 38 Direct, amikacin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 22 0 0 128 1.00 [ 0.85, 1.00 ] 1.00 [ 0.97, 1.00 ]
Barnard 2012 43 3 0 470 1.00 [ 0.92, 1.00 ] 0.99 [ 0.98, 1.00 ]
Catanzaro 2015 43 0 6 550 0.88 [ 0.75, 0.95 ] 1.00 [ 0.99, 1.00 ]
Kontsevaya 2013 7 0 4 72 0.64 [ 0.31, 0.89 ] 1.00 [ 0.95, 1.00 ]
Miotto 2012 7 6 1 43 0.88 [ 0.47, 1.00 ] 0.88 [ 0.75, 0.95 ]
Tomasicchio 2016 35 0 13 38 0.73 [ 0.58, 0.85 ] 1.00 [ 0.91, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 39. Direct, kanamycin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 39 Direct, kanamycin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 22 0 0 128 1.00 [ 0.85, 1.00 ] 1.00 [ 0.97, 1.00 ]
Catanzaro 2015 43 0 44 512 0.49 [ 0.39, 0.60 ] 1.00 [ 0.99, 1.00 ]
Kontsevaya 2013 6 0 58 12 0.09 [ 0.04, 0.19 ] 1.00 [ 0.74, 1.00 ]
Miotto 2012 8 5 0 44 1.00 [ 0.63, 1.00 ] 0.90 [ 0.78, 0.97 ]
Tukvadze 2014 19 1 47 71 0.29 [ 0.18, 0.41 ] 0.99 [ 0.93, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 40. Direct, capreomycin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 40 Direct, capreomycin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 16 0 6 128 0.73 [ 0.50, 0.89 ] 1.00 [ 0.97, 1.00 ]
Catanzaro 2015 41 2 6 550 0.87 [ 0.74, 0.95 ] 1.00 [ 0.99, 1.00 ]
Kontsevaya 2013 5 2 2 74 0.71 [ 0.29, 0.96 ] 0.97 [ 0.91, 1.00 ]
Miotto 2012 7 6 0 44 1.00 [ 0.59, 1.00 ] 0.88 [ 0.76, 0.95 ]
Tukvadze 2014 13 7 10 108 0.57 [ 0.34, 0.77 ] 0.94 [ 0.88, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 41. Amikacin, smear positive.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 41 Amikacin, smear positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 22 0 0 128 1.00 [ 0.85, 1.00 ] 1.00 [ 0.97, 1.00 ]
Catanzaro 2015 43 3 0 470 1.00 [ 0.92, 1.00 ] 0.99 [ 0.98, 1.00 ]
Miotto 2012 7 6 1 43 0.88 [ 0.47, 1.00 ] 0.88 [ 0.75, 0.95 ]
Tomasicchio 2016 35 0 13 38 0.73 [ 0.58, 0.85 ] 1.00 [ 0.91, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 42. Amikacin, smear negative.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 42 Amikacin, smear negative
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Catanzaro 2015 3 0 1 69 0.75 [ 0.19, 0.99 ] 1.00 [ 0.95, 1.00 ]
Tomasicchio 2016 10 0 17 4 0.37 [ 0.19, 0.58 ] 1.00 [ 0.40, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 43. Amikacin, smear grade = scanty.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 43 Amikacin, smear grade = scanty
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Catanzaro 2015 1 0 0 41 1.00 [ 0.03, 1.00 ] 1.00 [ 0.91, 1.00 ]
Miotto 2012 0 0 0 1 0.0 [ 0.0, 0.0 ] 1.00 [ 0.03, 1.00 ]
Tomasicchio 2016 3 0 0 11 1.00 [ 0.29, 1.00 ] 1.00 [ 0.72, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 44. Amikacin, smear grade= 1+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 44 Amikacin, smear grade= 1+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 5 0 0 36 1.00 [ 0.48, 1.00 ] 1.00 [ 0.90, 1.00 ]
Catanzaro 2015 8 0 0 129 1.00 [ 0.63, 1.00 ] 1.00 [ 0.97, 1.00 ]
Miotto 2012 3 3 0 9 1.00 [ 0.29, 1.00 ] 0.75 [ 0.43, 0.95 ]
Tomasicchio 2016 1 0 0 28 1.00 [ 0.03, 1.00 ] 1.00 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 45. Amikacin, smear grade ≥ 2+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 45 Amikacin, smear grade≥ 2+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 17 0 0 92 1.00 [ 0.80, 1.00 ] 1.00 [ 0.96, 1.00 ]
Catanzaro 2015 34 0 6 380 0.85 [ 0.70, 0.94 ] 1.00 [ 0.99, 1.00 ]
Miotto 2012 2 3 1 29 0.67 [ 0.09, 0.99 ] 0.91 [ 0.75, 0.98 ]
Tomasicchio 2016 2 0 4 32 0.33 [ 0.04, 0.78 ] 1.00 [ 0.89, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 46. Kananycin, smear positive.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 46 Kananycin, smear positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 22 0 0 128 1.00 [ 0.85, 1.00 ] 1.00 [ 0.97, 1.00 ]
Catanzaro 2015 43 0 44 512 0.49 [ 0.39, 0.60 ] 1.00 [ 0.99, 1.00 ]
Miotto 2012 8 5 0 44 1.00 [ 0.63, 1.00 ] 0.90 [ 0.78, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 47. Kanamycin, smear negative.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 47 Kanamycin, smear negative
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Catanzaro 2015 3 0 6 64 0.33 [ 0.07, 0.70 ] 1.00 [ 0.94, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 48. Kanamycin, smear grade = scanty.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 48 Kanamycin, smear grade = scanty
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Catanzaro 2015 1 0 3 38 0.25 [ 0.01, 0.81 ] 1.00 [ 0.91, 1.00 ]
Miotto 2012 0 0 0 1 0.0 [ 0.0, 0.0 ] 1.00 [ 0.03, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 49. Kanamycin, smear grade = +1.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 49 Kanamycin, smear grade = +1
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 5 0 0 36 1.00 [ 0.48, 1.00 ] 1.00 [ 0.90, 1.00 ]
Catanzaro 2015 8 0 13 116 0.38 [ 0.18, 0.62 ] 1.00 [ 0.97, 1.00 ]
Miotto 2012 3 3 0 9 1.00 [ 0.29, 1.00 ] 0.75 [ 0.43, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 50. Kanamycin, smear grade ≥ 2+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 50 Kanamycin, smear grade ≥ 2+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 17 0 0 92 1.00 [ 0.80, 1.00 ] 1.00 [ 0.96, 1.00 ]
Catanzaro 2015 34 0 28 358 0.55 [ 0.42, 0.68 ] 1.00 [ 0.99, 1.00 ]
Miotto 2012 3 2 0 30 1.00 [ 0.29, 1.00 ] 0.94 [ 0.79, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 51. Capreomycin, smear positive.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 51 Capreomycin, smear positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 16 0 6 128 0.73 [ 0.50, 0.89 ] 1.00 [ 0.97, 1.00 ]
Catanzaro 2015 41 2 6 550 0.87 [ 0.74, 0.95 ] 1.00 [ 0.99, 1.00 ]
Miotto 2012 7 6 0 44 1.00 [ 0.59, 1.00 ] 0.88 [ 0.76, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 52. Capreomycin, smear negative.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 52 Capreomycin, smear negative
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Catanzaro 2015 3 0 1 69 0.75 [ 0.19, 0.99 ] 1.00 [ 0.95, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 53. Capreomycin, smear grade = 1+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 53 Capreomycin, smear grade = 1+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 4 1 0 36 1.00 [ 0.40, 1.00 ] 0.97 [ 0.86, 1.00 ]
Catanzaro 2015 8 0 0 129 1.00 [ 0.63, 1.00 ] 1.00 [ 0.97, 1.00 ]
Miotto 2012 3 3 0 9 1.00 [ 0.29, 1.00 ] 0.75 [ 0.43, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 54. Capreomycin, smear grade = scanty.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 54 Capreomycin, smear grade = scanty
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Catanzaro 2015 1 0 0 41 1.00 [ 0.03, 1.00 ] 1.00 [ 0.91, 1.00 ]
Miotto 2012 0 0 0 1 0.0 [ 0.0, 0.0 ] 1.00 [ 0.03, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 55. Capreomycin, smear grade ≥ 2+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 55 Capreomycin, smear grade≥ 2+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 12 5 0 92 1.00 [ 0.74, 1.00 ] 0.95 [ 0.88, 0.98 ]
Catanzaro 2015 32 2 6 380 0.84 [ 0.69, 0.94 ] 0.99 [ 0.98, 1.00 ]
Miotto 2012 2 3 0 30 1.00 [ 0.16, 1.00 ] 0.91 [ 0.76, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
134GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Test 56. Direct, XDR, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 56 Direct, XDR, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barnard 2012 24 2 2 488 0.92 [ 0.75, 0.99 ] 1.00 [ 0.99, 1.00 ]
Catanzaro 2015 35 0 12 523 0.74 [ 0.60, 0.86 ] 1.00 [ 0.99, 1.00 ]
Kontsevaya 2013 3 0 19 52 0.14 [ 0.03, 0.35 ] 1.00 [ 0.93, 1.00 ]
Miotto 2012 4 1 1 52 0.80 [ 0.28, 0.99 ] 0.98 [ 0.90, 1.00 ]
Tomasicchio 2016 23 7 3 31 0.88 [ 0.70, 0.98 ] 0.82 [ 0.66, 0.92 ]
Tukvadze 2014 7 2 10 119 0.41 [ 0.18, 0.67 ] 0.98 [ 0.94, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 57. Direct, FQ, culture followed by sequencing of discrepants.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 57 Direct, FQ, culture followed by sequencing of discrepants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 96 1 9 64 0.91 [ 0.84, 0.96 ] 0.98 [ 0.92, 1.00 ]
Barnard 2012 54 4 2 455 0.96 [ 0.88, 1.00 ] 0.99 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 58. Direct, SLID, culture followed by sequencing of discrepants.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 58 Direct, SLID, culture followed by sequencing of discrepants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 22 0 0 128 1.00 [ 0.85, 1.00 ] 1.00 [ 0.97, 1.00 ]
Barnard 2012 44 2 0 470 1.00 [ 0.92, 1.00 ] 1.00 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 59. Direct, XDR, culture followed by sequencing of discrepants.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 59 Direct, XDR, culture followed by sequencing of discrepants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barnard 2012 24 2 2 488 0.92 [ 0.75, 0.99 ] 1.00 [ 0.99, 1.00 ]
Miotto 2012 2 3 0 49 1.00 [ 0.16, 1.00 ] 0.94 [ 0.84, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 60. V2, Indirect, FQ, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 60 V2, Indirect, FQ, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 61 0 12 155 0.84 [ 0.73, 0.91 ] 1.00 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 61. V2, Direct, FQ, smear positive.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 61 V2, Direct, FQ, smear positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 29 3 1 122 0.97 [ 0.83, 1.00 ] 0.98 [ 0.93, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 62. V2, Direct, FQ, smear negative.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 62 V2, Direct, FQ, smear negative
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 4 0 1 4 0.80 [ 0.28, 0.99 ] 1.00 [ 0.40, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 63. V2, Indirect, ofloxacin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 63 V2, Indirect, ofloxacin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 61 0 11 154 0.85 [ 0.74, 0.92 ] 1.00 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 64. V2, Indirect, moxifloxacin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 64 V2, Indirect, moxifloxacin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 18 2 2 75 0.90 [ 0.68, 0.99 ] 0.97 [ 0.91, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 65. V2, Indirect, SLID, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 65 V2, Indirect, SLID, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 127 8 20 73 0.86 [ 0.80, 0.91 ] 0.90 [ 0.81, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 66. V2, Direct, SLID, smear positive.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 66 V2, Direct, SLID, smear positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 25 13 3 123 0.89 [ 0.72, 0.98 ] 0.90 [ 0.84, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 67. V2, Direct, SLID, smear negative.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 67 V2, Direct, SLID, smear negative
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 4 0 1 4 0.80 [ 0.28, 0.99 ] 1.00 [ 0.40, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 68. V2, Indirect, amikacin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 68 V2, Indirect, amikacin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 111 24 3 88 0.97 [ 0.93, 0.99 ] 0.79 [ 0.70, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 69. V2, Indirect, kanamycin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 69 V2, Indirect, kanamycin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 125 8 6 85 0.95 [ 0.90, 0.98 ] 0.91 [ 0.84, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 70. V2, Indirect, capreomycin, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 70 V2, Indirect, capreomycin, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 91 39 15 73 0.86 [ 0.78, 0.92 ] 0.65 [ 0.56, 0.74 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 71. V2, Ofloxacin, smear positive.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 71 V2, Ofloxacin, smear positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 28 4 2 119 0.93 [ 0.78, 0.99 ] 0.97 [ 0.92, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 72. V2, Ofloxacin, smear negative.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 72 V2, Ofloxacin, smear negative
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 4 0 1 4 0.80 [ 0.28, 0.99 ] 1.00 [ 0.40, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 73. V2, Ofloxacin, smear grade = scanty.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 73 V2, Ofloxacin, smear grade = scanty
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 9 3 0 26 1.00 [ 0.66, 1.00 ] 0.90 [ 0.73, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 74. V2, Ofloxacin, smear grade = 1+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 74 V2, Ofloxacin, smear grade = 1+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 11 1 1 43 0.92 [ 0.62, 1.00 ] 0.98 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 75. V2, Ofloxacin, smear grade ≥ 2+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 75 V2, Ofloxacin, smear grade≥ 2+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 6 0 1 42 0.86 [ 0.42, 1.00 ] 1.00 [ 0.92, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 76. V2, Moxifloxacin, smear positive.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 76 V2, Moxifloxacin, smear positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 11 0 1 10 0.92 [ 0.62, 1.00 ] 1.00 [ 0.69, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 77. V2, Moxifloxacin, smear grade ≥ 2+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 77 V2, Moxifloxacin, smear grade≥ 2+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 3 0 0 5 1.00 [ 0.29, 1.00 ] 1.00 [ 0.48, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 78. V2, Levofloxacin, smear positive.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 78 V2, Levofloxacin, smear positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 8 4 0 41 1.00 [ 0.63, 1.00 ] 0.91 [ 0.79, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 79. V2, Levofloxacin, smear grade = scanty.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 79 V2, Levofloxacin, smear grade = scanty
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 6 3 0 16 1.00 [ 0.54, 1.00 ] 0.84 [ 0.60, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 80. V2, Levofloxacin, smear grade = 1+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 80 V2, Levofloxacin, smear grade = 1+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 1 1 0 20 1.00 [ 0.03, 1.00 ] 0.95 [ 0.76, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 81. V2, Levofloxacin, smear grade ≥ 2+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 81 V2, Levofloxacin, smear grade≥ 2+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 1 0 0 5 1.00 [ 0.03, 1.00 ] 1.00 [ 0.48, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 82. V2, Amikacin, smear positive.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 82 V2, Amikacin, smear positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 25 13 1 116 0.96 [ 0.80, 1.00 ] 0.90 [ 0.83, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 83. V2, Amikacin, smear negative.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 83 V2, Amikacin, smear negative
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 4 0 0 5 1.00 [ 0.40, 1.00 ] 1.00 [ 0.48, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 84. V2, Amikacin, smear grade = scanty.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 84 V2, Amikacin, smear grade = scanty
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 6 5 0 29 1.00 [ 0.54, 1.00 ] 0.85 [ 0.69, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 85. V2, Amikacin, smear grade = 1+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 85 V2, Amikacin, smear grade = 1+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 11 5 0 41 1.00 [ 0.72, 1.00 ] 0.89 [ 0.76, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 86. V2, Amikacin, smear grade ≥ 2+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 86 V2, Amikacin, smear grade ≥ 2+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 8 3 1 37 0.89 [ 0.52, 1.00 ] 0.93 [ 0.80, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 87. V2, Kanamycin, smear positive.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 87 V2, Kanamycin, smear positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 20 12 1 122 0.95 [ 0.76, 1.00 ] 0.91 [ 0.85, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 88. V2, Kanamycin, smear negative.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 88 V2, Kanamycin, smear negative
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 3 0 0 4 1.00 [ 0.29, 1.00 ] 1.00 [ 0.40, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 89. V2, Kanamycin, smear grade = scanty.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 89 V2, Kanamycin, smear grade = scanty
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 5 4 0 28 1.00 [ 0.48, 1.00 ] 0.88 [ 0.71, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 90. V2, Kanamycin, smear grade = 1+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 90 V2, Kanamycin, smear grade = 1+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 10 5 0 40 1.00 [ 0.69, 1.00 ] 0.89 [ 0.76, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 91. V2, Kanamycin, smear grade ≥ 2+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 91 V2, Kanamycin, smear grade ≥ 2+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 5 3 1 36 0.83 [ 0.36, 1.00 ] 0.92 [ 0.79, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 92. V2, Capreomycin, smear positive.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 92 V2, Capreomycin, smear positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 22 14 2 126 0.92 [ 0.73, 0.99 ] 0.90 [ 0.84, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 93. V2, Capreomycin, smear negative.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 93 V2, Capreomycin, smear negative
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 4 0 1 4 0.80 [ 0.28, 0.99 ] 1.00 [ 0.40, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 94. V2, Capreomycin, smear grade = scanty.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 94 V2, Capreomycin, smear grade = scanty
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 6 5 0 29 1.00 [ 0.54, 1.00 ] 0.85 [ 0.69, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 95. V2, Capreomycin, smear grade = 1+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 95 V2, Capreomycin, smear grade = 1+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 10 6 0 41 1.00 [ 0.69, 1.00 ] 0.87 [ 0.74, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 96. V2, Capreomycin, smear grade ≥ 2+.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 96 V2, Capreomycin, smear grade ≥ 2+
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 6 3 2 38 0.75 [ 0.35, 0.97 ] 0.93 [ 0.80, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 97. V2, Indirect, XDR, culture.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 97 V2, Indirect, XDR, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 37 8 9 174 0.80 [ 0.66, 0.91 ] 0.96 [ 0.92, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 98. V2, Direct, XDR, smear positive.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 98 V2, Direct, XDR, smear positive
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 11 4 3 146 0.79 [ 0.49, 0.95 ] 0.97 [ 0.93, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 99. V2, Direct, XDR, smear negative.
Review: GenoType MTBDRsl assay for resistance to second-line anti-tuberculosis drugs
Test: 99 V2, Direct, XDR, smear negative
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tagliani 2015 1 0 1 7 0.50 [ 0.01, 0.99 ] 1.00 [ 0.59, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Characteristics of MTBDRsl versions 1.0 and 2.0
Detection Version 1.0: M. tuberculosis complex and resis-
tances to FQs, SLIDs, and ethambutol
Version 2.0: M. tuberculosis complex and resis-
tances to FQs and SLIDs
Samples Smear-positive specimens and culture isolates Smear-positive and smear-negative specimens and
culture isolates
FQ resistance Mutations in resistance determining region of the
gyrA gene
Mutations in resistance determining regions of the
gyrA and gyrB genes
SLID resistance Mutations in resistance determining region of the rrs
gene
Mutations in resistance determining region rrs gene
and the eis promoter region
Ethambutol resistance Mutations in the embB gene Not included
Abbreviations: FQ: fluoroquinolone; SLID: second-line injectable drug.
MTBDRsl reports on the presence of mutations within genes (gyrA and rrs for version 1.0 and, in addition, gyrB and the eis promoter
for version 2.0), which are associated with resistance to a class of drugs. The presence of mutation(s) in these regions does not necessarily
imply resistance to all the drugs within that class. Although specific mutations within these regions may be associated with different
levels of resistance to each drug within these classes, the extent of this poorly understood
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Table 2. Map of review showing the number of studies evaluating MTBDRsl version 1.0 by indirect testing, according to the
reference standard and target condition
Target condition, drug
resistance to...
Reference standard
Culture, n/N (%) Sequencing, n/N (%) Sequencing and culture,
n/N (%)
Culture followed by se-
quencing of discrepant re-
sults, n/N (%)
FQs 19/19 (100)1 7/19 (37) 7/19 (37) 3/19 (16)
Ofloxacin 13/19 (68) 0 0 0
Moxifloxacin 6/19 (32) 0 0 0
Levofloxacin 2/19 (11) 0 0 0
SLIDs 16/16 (100)1 7/16 (44) 7/16 (44) 3/16 (19)
Amikacin 11/16 (69) 0 0 0
Kanamycin 9/16 (56) 0 0 0
Capreomycin 10/16 (63) 0 0 0
XDR-TB 8/8 (100) 3/8 (38) 2/8 (25) 0
Abbreviations: FQ: fluoroquinolone; SLID: second-line injectable drug; TB: tuberculosis; XDR-TB: extensively drug-resistant TB.
1A total of 19, 16, and 8 studies were included that evaluatedMTBDRsl for FQ resistance, SLID resistance, and XDR-TB, respectively,
against culture-based DST. These form the denominators to generate percentages of studies that included a particular additional
reference standard.
Table 3. Map of review showing the number of studies evaluating MTBDRsl version 1.0 by direct testing, according to the
reference standard and target condition
Target condition, drug
resistance to...
Reference standard
Culture, n/N (%) Sequencing, n/N (%) Sequencing and culture,
n/N (%)
Culture followed by se-
quencing of discrepant re-
sults, n/N (%)
FQs 9/9 (100)1 0 0 2/9 (22)
Ofloxacin 7/9 (78) 0 0 2/9 (11)
Moxifloxacin 2/9 (22) 0 0 0
Levofloxacin 0 0 0 0
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Table 3. Map of review showing the number of studies evaluating MTBDRsl version 1.0 by direct testing, according to the
reference standard and target condition (Continued)
Gatifloxacin 0 0 0 0
SLIDs 8/8 (100)1 0 0 2/8 (25)
Amikacin 6/8 (75) 0 0 1/8 (13)
Kanamycin 5/8 (63) 0 0 0
Capreomycin 5/8 (63) 0 0 0
XDR-TB 6/6 (100) 0 0 2/6 (33)
Abbreviations: FQ: fluoroquinolone; SLID: second-line injectable drug; TB: tuberculosis; XDR-TB: extensively drug-resistant TB.
1We included a total of 9, 8, and 6 studies that evaluated MTBDRsl for detection of FQ resistance, SLID resistance, and XDR-TB,
respectively, against culture-based DST. These form the denominators to generate percentages of studies that included a particular
additional reference standard.
Table 4. Accuracy of MTBDRsl version 1.0 for resistance to FQs and SLIDs and XDR-TB, by type of testing, culture-based
DST reference standard
Pooled sensitivity
(95% CI)
Pooled specificity
(95% CI)
Pooled sensitivity
(95% CI)
Pooled specificity
(95% CI)
Pooled sensitivity
P value1
Pooled specificity
P value1
FQs, indirect testing
(19 studies, 2223 participants)
FQs, direct testing
(9 studies, 1771 participants)
0.932 0.333
85.6% (79.2 to 90.
4)
98.5% (95.7 to 99.
5)
86.2% (74.6 to 93.
0)
98.6% (96.9 to 99.
4)
SLIDs, indirect testing
(16 studies, 1921 participants)
SLIDs, direct testing
(8 studies, 1639 participants)
0.547 0.664
76.5% (63.3 to 86.
0)
99.1% (97.3 to 99.
7)
87.0% (38.1 to 98.
6)
99.5% (93.6 to 100.
0)
XDR-TB, indirect testing
(8 studies, 880 participants)
XDR-TB, direct testing
(6 studies, 1420 participants)
0.888 0.855
70.9% (42.9 to 88.
7)
98.8% (96.1 to 99.
6)
69.4% (38.8 to 89.
0)
99.4% (95.0 to 99.
3)
Abbreviations: CI: confidence interval; DST: drug susceptibility testing; FQ: fluoroquinolone; SLID: second-line injectable drug; TB:
tuberculosis; XDR-TB: extensively drug-resistant TB.
The accuracy estimates were derived from non-comparative studies of test accuracy in which different sets of studies were used. For
example, for FQ resistance, the set of studies used for indirect testing differed from that used for direct testing.
1Likelihood ratio test for evidence of a significant difference between accuracy estimates.
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Table 5. Accuracy of MTBDRsl version 1.0 for resistance to select FQ and SLID drugs, culture-based DST reference standard
Pooled sensitivity
(95% CI)
Pooled specificity
(95% CI)
Pooled sensitivity
(95% CI)
Pooled specificity
(95% CI)
Pooled sensitivity
P value1
Pooled specificity
P value1
Ofloxacin, indirect testing
(13 studies, 1927 participants)
Ofloxacin, direct testing
(7 studies, 1667 participants)
0.180 0.161
85.2% (78.5 to 90.
1)
98.5% (95.6 to 99.
5)
90.9% (84.7 to 94.
7)
98.9% (97.8 to 99.
4)
Moxifloxacin, indirect testing
(6 studies, 419 participants)
Moxifloxacin, direct testing
(2 studies, 821 participants)
0.820 0.365
94.0% (82.2 to 98.
1)
96.6% (85.2 to 99.
3)
95.0% (92.1 to 96.
9)
99.0% (97.5 to 99.
6)
Levofloxacin, indirect testing2
(2 studies, 169 participants)
Levofloxacin, direct testing
(0 studies, 0 participants)
Not applicable Not applicable
Not applicable Not applicable Not applicable Not applicable
Amikacin, indirect testing
(11 studies, 1301 participants)
Amikacin, direct testing
(6 studies, 1491 participants)
0.338 0.213
84.9% (79.2 to 89.
1)
99.1% (97.6 to 99.
6)
91.9% (71.5 to 98.
1)
99.9% (95.2 to 100.
0)
Kanamycin, indirect testing
(9 studies, 1342 participants)
Kanamycin, direct testing
(5 studies, 1020 participants
0.836 0.445
66.9% (44.1 to 83.
8)
98.6% (96.1 to 99.
5)
78.7% (11.9 to 99.
0)
99.7% (93.8 to 100.
0)
Capreomycin, indirect testing
(10 studies, 1406 participants
Capreomycin, direct testing
(5 studies, 1027 participants)
0.841 0.353
79.5% (58.3 to 91.
4)
95.8% (93.4 to 97.
3)
76.6% (61.1 to 87.
3)
98.2% (92.5 to 99.
6)
Abbreviations: CI: confidence interval; DST: drug susceptibility testing; FQ: fluoroquinolones; SLID: second-line injectable drug.
We derived the accuracy estimates from non-comparative studies of test accuracy in which different sets of studies were used. For
example, for ofloxacin resistance, the set of studies used for indirect testing differed from that used for direct testing.
1Likelihood ratio test for evidence of a significant difference between accuracy estimates.
2Sensitivity and specificity (95% confidence intervals (CIs)) were 80% (56 to 94) and 96% (80 to 100) for Chikamatsu 2012 and
100% (96 to 100) and 100% (88 to 100) for Kambli 2015b. We did not perform a meta-analysis.
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Table 6. Accuracy of MTBDRsl version 1.0 by indirect testing for FQ and SLID resistance and XDR-TB, by reference standard
Pooled sensitivity
(95% CI)
Pooled specificity
(95% CI)
Pooled sensitivity
(95% CI)
Pooled specificity
(95% CI)
Pooled sensitivity
P value1
Pooled specificity
P value1
FQ, culture
(6 studies, 873 participants)
FQ, sequencing
(6 studies, 873 participants)
< 0.001 0.735
82.4% (77.6 to 86.
3)
98.8% (94.3 to 99.
8)
99.3% (81.2 to 100.
0)
99.3%(90.8 to 100)
FQ, culture
(7 studies, 1211 participants)
FQ, sequencing and culture
(7 studies, 1211 participants)
0.664 0.070
81.8% (77.2 to 85.
7)
99.0% (95.0 to 99.
8)
82.0% (77.7 to 85.
6)
99.8%(98.5 to 100)
SLIDs, culture
(6 studies, 873 participants)
SLIDs sequencing
(6 studies, 873 participants)
0.034 0.456
74.6% (66.2 to 81.
5)
99.9% (71.8 to 100.
0)
97.0% (77.0 to 99.
7)
99.5% (94.5 to 100.
0)
SLIDs, culture
(6 studies, 1159 participants)
SLIDs, sequencing and culture
(6 studies, 1159 participants)
0.458 0.203
70.5% (52.0 to 84.
1)
99.8% (93.8 to 100.
0)
61.3% (45.8 to 74.
8%)
99.9% (99.0 to 100.
0)
XDR-TB, culture
(8 studies, 880 participants)
XDR-TB, sequencing2
(4 studies, 630 participants)
Could not deter-
mine
Could not deter-
mine
70.9% (42.9 to 88.
8)
98.8% (96.1 to 99.
6)
100% (94.6 to 100.
0)
97.9% (96.3 to 98.
8)
Abbreviations: CI: confidence interval; FQ: fluoroquinolones; SLID: second-line injectable drug; TB: tuberculosis; XDR-TB: exten-
sively drug-resistant TB.
For detection of FQ and SLID resistance, the accuracy estimates were derived from comparative studies of test accuracy in which the
same set of studies was used. For example, for FQ resistance, the set of studies using culture-based drug susceptibility testing (DST) as
a reference standard was the same as that using sequencing as a reference standard. For detection of XDR-TB, the accuracy estimates
were derived from non-comparative studies of test accuracy in which different sets of studies were used.
1Likelihood ratio test for evidence of a significant difference between accuracy estimates.
2Accuracy estimates were obtained with fixed-effect model.
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Table 7. Sensitivity analyses MTBDRsl version 1.0, fluoroquinolone resistance
Culture, indirect testing Culture, direct testing Pooled sensi-
tivity
P value1
Pooled speci-
ficity
P value1
Number of
studies (par-
ticipants)
Pooled sensi-
tivity
(95% CI)
Pooled speci-
ficity
(95% CI)
Number of
studies (par-
ticipants)
Pooled sensi-
tivity
(95% CI)
Pooled speci-
ficity
(95% CI)
All studies of fluoroquinolones
19 studies
(2223)
85.6% (79.2
to 90.4)
98.5% (95.7
to 99.5)
9 studies
(1771)
86.2% (74.6
to 93.0)
98.6% (96.9
to 99.4)
0.932 0.333
Was a consecutive or random sample of patients/specimens enrolled? Yes
14 studies
(1979)
84.1% (75.7
to 90.0)
99.0% (94.8
to 99.8)
9 studies
(1771)
86.2% (75.2
to 92.8)
98.9% (97.7
to 99.5)
0.725 0.506
Was a case-control design avoided? Yes
13 studies
(1389)
88.9 (79.4 to
94.3)
98.5% (93.4
to 99.7)
8 studies
(1721)
85.6% (72.4
to 93.1)
98.5% (96.9
to 99.3)
0.613 0.417
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
12 studies
(1796)
86.1% (75.9
to 92.5)
99.3% (94.4
to 99.9)
7 studies (982) 83.8% (68.5
to 92.5)
98.1% (96.4
to 99.0)
0.768 0.946
Was the test applied in the manner recommended by the manufacturer? Yes
18 studies
(2171)
85.6% (78.6
to 90.6)
98.6% (95.6
to 99.6)
7 studies (982) 83.8% (68.5
to 92.5)
98.1% (96.4
to 99.0)
0.736 0.652
Abbreviations: CI: confidence interval.
We derived the accuracy estimates from non-comparative studies of test accuracy in which different sets of studies were used.
1Likelihood ratio test for evidence of a significant difference between accuracy estimates.
Table 8. Sensitivity analyses MTBDRsl version 1.0, second-line injectable drug resistance
Culture, indirect testing Culture, direct testing Pooled sensi-
tivity
P value1
Pooled speci-
ficity
P value1
Number of
studies (par-
ticipants)
Pooled sensi-
tivity
(95% CI)
Pooled speci-
ficity
(95% CI)
Number of
studies (par-
ticipants)
Pooled sensi-
tivity
(95% CI)
Pooled speci-
ficity
(95% CI)
All studies of second-line injectable drugs
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Table 8. Sensitivity analyses MTBDRsl version 1.0, second-line injectable drug resistance (Continued)
16 studies
(1921)
76.5% (63.3
to 86.0)
99.1% (97.3
to 99.7)
8 studies
(1639)
87.0% (38.1
to 98.6)
99.5% (93.6
to 100.0)
0.547 0.664
Was a consecutive or random sample of patients/specimens enrolled? Yes
11 studies
(1869)
77.3% (58.9
to 89.0)
99.2% (96.4
to 99.8)
8 studies
(1639)
87.0% (38.1
to 98.6)
99.5% (93.6
to 100.0)
0.896 0.873
Was a case-control design avoided? Yes
10 studies
(1088)
80.2% (57.1
to 92.4)
98.6% (95.3
to 99.6)
8 studies
(1639)
87.0% (38.1
to 98.6)
99.5% (93.6
to 100.0)
0.822 0.889
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
10 studies
(1513)
75.4% (57.0
to 87.7)
99.0% (96.0
to 99.7)
6 studies (902) 96.1% (40.0
to 99.9)
99.2% (82.3
to 100.0)
0.471 0.573
Was the test applied in the manner recommended by the manufacturer? Yes
15 studies
(1869)
77.2% (62.6
to 87.2)
99.0% (97.1
to 99.7)
6 studies (902) 96.1% (40.0
to 99.9)
99.2% (82.3
to 100.0)
0.228 0.926
Abbreviations: CI: confidence interval.
We derived the accuracy estimates from non-comparative studies of test accuracy in which different sets of studies were used.
1Likelihood ratio test for evidence of a significant difference between accuracy estimates.
A P P E N D I C E S
Appendix 1. Glossary of terms
Amplification
Amplification is replication of a DNA fragment to generate copies. Both the original and the newly synthesized copies can be described
as the amplicons.
Codon
A codon is a sequence of three DNA or RNA bases that corresponds to a specific amino acid or a signal to start or stop transcription
or translation. The DNA in coding regions of the genome is read in groups of three bases (A, G, C, T).
Conjugate and amplification bands (controls)
The conjugate band is a control to make sure that the DNA probes immobilized on the MTBDRsl strip test can bind M. tuberculosis
DNA and that this is detectable, to ensure that the test is working properly. If this is not present, we will be unsure if the results of the
test are due to something going wrong with the test that prevents binding of the bands, or a real phenomenon. Hence, an MTBDRsl
test is indeterminate if the conjugate band is missing. Similarly, the amplification band is a control to make sure that the amplification
of M. tuberculosis DNA (which is done in order to bring target DNA sequences to a detectable level) was successful. If this band is
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absent, and we do not see any probes corresponding to mutations appearing, we cannot discount a failure to amplify DNA rather than
the presence of a susceptible strain.
Culture isolates
Culture isolates refers toM. tuberculosis cells from a clinical specimen that have been grown. For TB diagnosis, a volume of the clinical
specimen is processed and incubated under conditions that promote M. tuberculosis growth. The cells that are grown are referred to a
culture isolate.
Drug susceptibility testing
Drug susceptibility tests determine whetherM. tuberculosis cells are sensitive or resistant to antibiotics. Testing may be undertaken using
phenotypic or genotypic analyses. Phenotypic testing requires growth of TB in the presence of drugs that will inhibit the growth of a
sensitive organism or have no impact on growth of a resistant organism. Genotypic testing involves detecting predetermined mutations
in DNA that are known to make the organism resistant to a drug. When mutations causing drug resistance are not known, genotypic
DST is not useful. Genotype® MTBDRsl is a genotypic test.
DNA sequencing
DNA sequencing is a process to determine the nucleotide (A, G, C, T) sequence of fragments of DNA. By comparison of DNA
sequences from distinct TB isolates, variations known as mutations can be identified. Some mutations in M. tuberculosis are known to
cause drug resistance.
Hybridization
Hybridization is the process of allowing two nucleotide fragments to bind together if they share DNA sequences that are complementary.
Hybridisation reactions can be designed such that when one strand binds to another, the reaction may produce a detectable colour
change, which is what occurs in MTBDRsl.
Locus
A locus is the position of a genetic feature in the DNA sequence, like a genetic street address. Loci are standardized between genomes
by reference to a common reference genome, such as H37Rv for M. tuberculosis.
Promoter region
A promoter region is a sequence of DNA where the transcriptional machinery binds before transcribing the DNA into RNA that may
then be translated into an amino acid sequence.
Resistance-determining region
A region of theM. tuberculosis genome where mutations commonly cause resistance to a specific drug.
We have adapted these definitions from NIH 2015.
Appendix 2. Detailed search strategy
MEDLINE (PubMed)
1. MTBDR*.ti/ab.
2. Genotype MTBDR*.ti/ab
3. or/1-2
4. exp Tuberculosis, Pulmonary/
5. exp Tuberculosis, Multidrug-Resistant/
6. MDR-TB.ti/ab
7. XDR-TB.ti/ab
8. Mycobacterium tuberculosis/
9. TB.ti/ab
10. tuberculosis.ti/ab
11. or/4-10
12. 3 and 11
Embase (OVID)
1. tuberculosis.mp. or lung tuberculosis/ or Mycobacterium tuberculosis/ or multidrug resistant tuberculosis/
2. (MDR-TB or XDR-TB).mp.
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3. exp Mycobacterium tuberculosis/
4. 1 or 2 or 3
5. (MTBDR* or ”Genotype MTBDR*“).mp
6. 4 and 5
Web of Knowledge (SCI-expanded, Conference Proceedings science) and BIOSIS previews
Topic=(MTBDR*) AND Topic=(tuberculosis OR TB OR MDR-TB OR XDR-TB)
LILACS
(tuberculosis OR TB OR mycobacterium OR MDR-TB OR XDR-TB) (Words) AND (MTBDR$) (Wor
SCOPUS
(tuberculosis OR TB OR mycobacterium OR MDR-TB OR XDR-TB ) (title, abstract, keywords) AND (MTBDR*) (title, abstract,
keywords)
CIDG Specialized Register
(tuberculosis OR TB OR mycobacterium OR MDR-TB OR XDR-TB) AND (MTBDR*)
ProQuest Dissertations & Theses A&I search strategy
ab(tuberculosis) AND ab((diagnostic test* OR RDT* OR MTBDR*))
metaRegister of Controlled Trials (mRCT)
(tuberculosis OR TB OR mycobacterium OR MDR-TB OR XDR-TB) AND (MTBDR*)
World Health Organization International Clinical Trials Registry Platform
(tuberculosis OR TB OR mycobacterium OR MDR-TB OR XDR-TB) AND (MTBDR*)
Appendix 3. QUADAS-2 rules and interpretation
Domain 1: Patient selection
Risk of bias: could the selection of patients have introduced bias?
Signaling question 1: was a consecutive or random sample of patients enrolled?
We scored ’yes’ if the study enrolled a consecutive or random sample of eligible patients; ’no’ if the study selected patients by convenience;
and ’unclear’ if the study did not report the manner of patient selection or was not clearly reported.
Signaling question 2: was a case-control design avoided?
We scored ’yes’ if the study enrolled only TB patients with suspected resistance to second-line drugs, including patients with confirmed
multidrug-resistant tuberculosis (MDR-TB); ’no’ if the study enrolled TB patients with confirmed resistance to second-line drugs; and
’unclear’ for all other scenarios or if it was not clearly reported.
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Signaling question 3: did the study avoid inappropriate exclusions?
An inappropriate exclusion might occur if, after the laboratory technician runs the index and reference tests, he or she does not record
the test results in the study. This might occur if there were resource constraints as one might find in practice, but we did not expect
this to occur in the research studies included in this review. We scored ’yes’ for all studies.
Applicability: are there concerns that the included patients and setting do not match the review question?
We judged ’low’ concern if the selected specimens matched the review question, which reflects the way the test will be used in practice.
We judged ’high’ concern if the selected specimens or isolates did not represent those for whom the test will be used in practice, such
as in individuals who are not suspected of having drug-resistant TB. We judged ’unclear’ concern if we could not tell.
Domain 2: Index test
Risk of bias: could the conduct or interpretation of the index test have introduced bias?
Signaling question 1: were the index test results interpreted without knowledge of the results of the reference standard?
We scored this question ’yes’ if the reader of the assay was blinded to results of reference tests. We scored ’no’ if the reader of the assay
was not blinded to the results of reference tests. If the specimens were from a biobank (repository that stores biological specimens)
comprised of specimens with known second-line drug resistance and the identity of these specimens was known to the assay reader, we
also answered ’no’. We scored ’unclear’ if it was not stated in the paper or if the study authors failed to answer this question.
Signaling question 2: if a threshold was used, was it prespecified?
A threshold is prespecified in all versions of MTBDRsl. We answered this question ’yes’ for all studies.
Applicability: are there concerns that the index test, its conduct, or its interpretation differ from the review question?
Variations in test technology, execution, or interpretation may affect estimates of the diagnostic accuracy of a test. We judged the study
to be of ’low concern’ for applicability if the test was performed as recommended by the manufacturer. We judged the study to be of
’low concern’ for applicability if the test was performed as recommended by the manufacturer. We judged the study to be of ’high
concern’ when the test was applied differently than recommended by the manufacturer, for example when the test was applied to pooled
sputa, and we judged the study to be of ’unclear concern’ when we could not tell. When available, we selected the high level WHO-
recommended concentration for moxifloxacin because we felt this concentration was clinically meaningful.
Domain 3: Reference standard
Risk of bias: could the reference standard, its conduct or its interpretation have introduced bias?
Signaling question 1: is the reference standard likely to correctly classify the target condition?
Culture-based DST is not 100% accurate for detection of drug resistance, especially resistance to second-line drugs. However, it is
the test currently endorsed by WHO when performed using WHO-recommended critical drug concentrations (defined below WHO
2012). Therefore, for culture-based DST, we answered ’yes’ if study authors usedWHO critical concentrations for every test evaluation,
’no’ if study authors did not use critical concentrations (or if for the culture method used, WHO-recommended critical concentrations
did not exist) in any of their test evaluations, and ’unclear’ if study authors used critical concentrations in only some evaluations and not
others or the authors did not specify the critical concentrations used. We selected the WHO-recommended high level concentration
for moxifloxacin because we felt this concentration was clinically meaningful.
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We used the currently-recommended WHO critical concentrations as a benchmark for judging risk of bias (WHO 2012). For M.
tuberculosis, the antimicrobial susceptibility testing ’critical concentration’ is defined as “for each drug, the lowest concentration that
inhibits 95% (90% for pyrazinamide) of wild-type strains of M. tuberculosis that have not been exposed to the drug, but that simulta-
neously does not inhibit strains of M. tuberculosis that are considered resistant that are isolated from patients who are not responding
to therapy” (CSLI 2011). However, there is a lack of consensus about this definition (Ängeby 2012).
Genetic sequencing (gene sequencing of loci known to be associated with drug resistance) is considered by researchers in this field to
be the best reference standard for testing for the presence of drug resistance. Although sequencing may not be performed for all regions
of the TB genome associated with resistance, we consider this to be a concern about the setting in which the test is applied, rather than
a concern about risk of bias.
Signaling question 2: were the reference standard results interpreted without knowledge of the results of the index test?
We scored ’yes’ if the reference test provided an automated result (for example, MGIT 960 DST), blinding was explicitly stated, or it
was clear that the reference test was performed at a separate laboratory, or performed by different people, or both. We scored ’no’ if the
study stated that the reference standard result was interpreted with knowledge of the MTBDRsl assay result. We scored ’unclear’ if it
was not stated in the paper or if the authors failed to answer this question.
Applicability: are there concerns that the target condition as defined by the reference standard does not match the question?
We judged applicability to be of ’low concern’ for all studies because the method used (phenotypic testing with and without drugs) was
appropriate.
Domain 4: Flow and timing
Risk of bias: could the patient flow have introduced bias?
Signaling question 1: was there an appropriate interval between the index test and reference standard?
We expected the reference standard test to be undertaken at the same time as the index test (i.e. each performed on a paired sample for
most studies). However, we expected some studies to include specimens from patients who had received a reference test on an earlier
sample. The sample applies to some culture isolates, whose drug susceptibility profile might have been confirmed prior to the index
test being available. We answered ’yes’ if the tests were paired or were separated by a few days. We answered ’no’ if reference and index
tests were not done on paired samples and were separated by several months. As patients suspected of second-line drug resistance are
often on some form of anti-TB therapy, it is possible that variation in the microbial population of specimens collected at different time
points may occur. We scored ’unclear’ if it was not stated in the paper or if the authors failed to answer this question.
Signaling question 2: did all patients receive the same reference standard?
Our reference standard for the primary objectives was culture-based DST and we anticipated this reference standard to be used in all
studies. We answered ’yes’ if culture-based DST was applied to all patients or a random sample of patients, ’no’ if the reference standard
was only applied to a selective group of patients, and ’unclear’ if it was not stated in the paper or if the authors failed to answer this
question.
Signaling question 3: were all patients included in the analysis?
We determined the answer to this question by comparing the number of participants enrolled with the number of patients included
in the 2 x 2 tables. We noted if the study authors reported the number of indeterminate assay results. We scored ’yes’ if the number
of participants enrolled was clearly stated and corresponded to the number presented in the analysis or if exclusions were adequately
described. We scored ’no’ if there were participants missing or excluded from the analysis and there was no explanation given. We
scored ’unclear’ if not enough information was given to assess whether participants were excluded from the analysis.
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Appendix 4. Fluoroquinolone resistance, individual drugs, indirect testing
Figure 16 shows forest plots of MTBDRsl sensitivity and specificity for ofloxacin, moxifloxacin, and levofloxacin resistance detection
when performed indirectly and using culture-based DST as a reference standard.
Figure 16. Forest plots of MTBDRsl sensitivity and specificity for ofloxacin, moxifloxacin, and levofloxacin
resistance, the test performed indirectly against culture-based drug susceptibility testing (DST) as a reference
standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between
brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated
sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The individual
studies are ordered by decreasing sensitivity.
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Appendix 5. Drug concentrations used in culture-based drug susceptibility testing
Table 1. Ofloxacin, levofloxacin, and moxifloxacin drug concentrations used in culture-based drug susceptibility
testing in relation to the WHO-recommended critical concentrations
Study Reference standard Concentration used (µg/mL)1 Used WHO-recommended criti-
cal concentration
Ajbani 2012 MGIT 960 Ofloxacin: 2.0 Yes
Moxifloxacin: 0.25 No
Barnard 2012 Middlebrook 7H11 (agar propor-
tion)
Ofloxacin: 2.0 Yes
Brossier 2010a LJ (agar proportion) Ofloxacin: 2.0 Yes
Catanzaro 2015 MGIT 960 Ofloxacin: 2.0 Yes
Moxifloxacin: 0.25 No
Chikamatsu 2012 Ogawa Levofloxacin: 1.0 For Ogawa, there are noWHO-rec-
ommended concentrations
Fan 2011 MGIT 960 Ofloxacin: 2.0 Yes
Moxifloxacin: 0.25 No
Ferro 2013 Middlebrook 7H10 (agar propor-
tion)
Moxifloxacin: 2.0 Yes
Hillemann 2009 MGIT 960 and LJ Ofloxacin: 2.0 for both media Yes for MGIT 960; no for LJ
Huang 2011 MGIT 960 and Middlebrook
7H11
Ofloxacin: 2.0 Yes for both media
Ignatyeva 2012 MGIT 960 Ofloxacin: 2.0 Yes
Jin 2013 LJ and BacT/ALERT 3D Ofloxacin: 5.0 (LJ); 50 (BacT/
ALERT 3D)
No for LJ; for BacT/ALERT 3D,
there are no WHO-recommended
concentrations
Kambli 2015b MGIT 960 Levofloxacin: 1.5 Yes
Kiet 2010 LJ Ofloxacin: 2.0 No
Kontsevaya 2013 MGIT 960 Ofloxacin: 2.0 Yes
Moxifloxacin: 0.25 No
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(Continued)
Lacoma 2012 BACTEC 460TB Moxifloxacin: 0.5 For
BACTEC460, there are no WHO-
recommended concentrations
Lopez-Roa 2012 MGIT 960 Ofloxacin: 2.0 Yes
Miotto 2012 MGIT 960 Ofloxacin: 2.0 Yes
Said 2012 Middlebrook 7H11 Ofloxacin: 2.0 Yes
Simons 2015 MGIT 960 and Middlebrook
7H10 (agar dilution)
Moxifloxacin: 0.5 (MGIT); 1.0
(Middlebrook 7H10)
For moxifloxacin using MGIT 960,
the study used the WHO-recom-
mended low-level concentration
Tagliani 2015 MGIT 960 and LJ (agar propor-
tion)
Ofloxacin: 2.0 (LJ: 4.0) Yes
Moxifloxacin: 0.5 No
Levofloxacin: 1.5 Yes
Tomasicchio 2016 MGIT 960 Ofloxacin: 2.0 Yes
Tukvadze 2014 LJ (proportion method) Ofloxacin: 2.0 No
van Ingen 2010 Middlebrook 7H10 (agar propor-
tion)
Moxifloxacin: 1.0 No
Zivanovic 2012 MGIT 960 and LJ agar proportion Ofloxacin: 2.0 for both media Yes for MGIT 960; no for LJ
Abbreviations: LJ: Lo wenstein-Jensen; MGIT: Mycobacteria Growth Indicator Tube; WHO: World Health Organization.
1We used the high level concentration when available for all drugs. For a discussion of critical concentrations in LJ media, see Rigouts
2016.
Table 2. Amikacin, kanamycin, and capreomycin drug concentrations used in culture-based drug susceptibility
testing in relation to the WHO-recommended critical concentrations
Study Reference standard Concentration used (µg/mL) Used WHO-recommended criti-
cal concentration
Ajbani 2012 MGIT 960 Amikacin: 1.0 Yes
Kanamycin: 2.5 Yes
Capreomycin: 2.5 Yes
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(Continued)
Barnard 2012 Middlebrook 7H11 (agar propor-
tion)
Amikacin: 4.0 There are no WHO-recommended
concentrations for amikacin using
Middlebrook 7H11
Brossier 2010a LJ (agar proportion) Amikacin: 20.0 No
Kanamycin: 20.0 No
Capreomycin: 20.0 No
Catanzaro 2015 MGIT 960 Amikacin: 1.0 Yes
Kanamycin: 2.5 Yes
Capreomycin: 2.5 Yes
Chikamatsu 2012 Ogawa Amikacin: unknown For Ogawa, there are noWHO-rec-
ommended concentrations
Kanamycin: unknown
Capreomycin: unknown
Fan 2011 MGIT 960 Amikacin: 1.0 Yes
Ferro 2013 Middlebrook 7H10 (agar propor-
tion)
Amikacin: 5.0 No
Kanamycin: 5.0 Yes
Hillemann 2009 MGIT 960 and LJ (agar propor-
tion)
Amikacin: 1.0 for MGIT 960 and
40.0 for LJ
Yes for MGIT 960; no for LJ
Capreomycin: 2.5 for MGIT 960
and 40.0 for LJ
Yes for both types of media
Huang 2011 Middlebrook 7H11 and MGIT
960
Amikacin: 1.0 for MGIT 960 and
6.0 for 7H11
Yes for MGIT 960; for 7H11, there
is noWHO-recommended concen-
tration for amikacin
Kanamycin: 2.5 forMGIT 960 and
6.0 for 7H11
Yes for MGIT 960 and 7H11
Capreomycin: 2.5 for MGIT 960
and 10.0 for 7H11
Yes for MGIT 960; for 7H11, there
is noWHO-recommended concen-
tration for capreomycin
Ignatyeva 2012 MGIT 960 Amikacin: 1.0 Yes
Kanamycin: 5.0 No
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(Continued)
Capreomycin: 2.5 Yes
Jin 2013 LJ and BacT/ALERT 3D Kanamycin: 10.0 No
Capreomycin: unknown For BacT/ALERT 3D, there are
no WHO-recommended concen-
trations
Kiet 2010 LJ Kanamycin: 20.0 No
Kontsevaya 2013 MGIT 960 Amikacin: 1.0 Yes
Kanamycin: 5.0 No
Capreomycin: 2.5 Yes
Lacoma 2012 BACTEC 460TB Kanamycin: 5.0 For BACTEC 460, there are
no WHO-recommended concen-
trationsCapreomycin: 1.25
Lopez-Roa 2012 Middlebrook 7H10 and MGIT
960
Amikacin: 4.0 (7H10); 1.0 (MGIT
960)
Yes for both media
Miotto 2012 MGIT 960 Amikacin: 1.0 Yes
Kanamycin: 5.0 No
Capreomycin: 2.5 Yes
Said 2012 Middlebrook 7H11 Kanamycin: 5.0 No
Capreomycin: 10.0 No
Simons 2015 MGIT 960 and Middlebrook
7H10 (agar dilution)
Amikacin: 1.0 for MGIT and 5.0
for Middlebrook 7H10
Yes for MGIT 960; no for 7H10
Capreomycin: 2.5 for MGIT and
10.0 for Middlebrook 7H10
Yes for MGIT 960; no for 7H10
Tagliani 2015 MGIT 960 and LJ (agar propor-
tion)
Amikacin: 1.0 for MGIT 960 and
30.0 for LJ
Yes for both types of media
Kanamycin: 2.5 forMGIT 960 and
30.0 for LJ
Yes for both types of media
Capreomycin: 2.5 for MGIT 960
and 40.0 for LJ
Yes for both types of media
Tomasicchio 2016 MGIT 960 Amikacin: 1.0 Yes
170GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
Tukvadze 2014 LJ Kanamycin: 30.0 Yes
Capreomycin: 40.0 Yes
van Ingen 2010 Middlebrook 7H10 (agar propor-
tion)
Amikacin: 5.0 No
Capreomycin: 10.0 No
Zivanovic 2012 MGIT 960 and LJ agar proportion Amikacin: 1.0 for MGIT 960 and
40.0 for LJ
Yes for MGIT 960; no for LJ
Capreomycin: 2.5 for MGIT 960
and 40.0 for LJ
Yes for both types of media
Abbreviations: LJ: Lo wenstein-Jensen; MGIT: Mycobacteria Growth Indicator Tube; WHO: World Health Organization.
Appendix 6. Fluoroquinolone resistance, different reference standards
Figure 17 shows forest plots of MTBDRsl sensitivity and specificity for fluoroquinolone (FQ) resistance detection when performed
indirectly using different reference standards.
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Figure 17. Forest plots of MTBDRsl sensitivity and specificity for fluoroquinolone (FQ) resistance, the test
performed indirectly against different reference standards. TP = true positive; FP = false positive; FN = false
negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and
specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI
(black horizontal line). The individual studies are ordered by decreasing sensitivity.
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Appendix 7. Fluoroquinolone resistance, individual drugs, direct testing
Figure 18 shows forest plots of MTBDRsl sensitivity and specificity for ofloxacin and moxifloxacin resistance detection when performed
directly and using culture-based drug susceptibility testing (DST) as a reference standard.
Figure 18. Forest plots of MTBDRsl sensitivity and specificity for ofloxacin, moxifloxacin, and levofloxacin
resistance, the test performed directly against culture-based drug susceptibility testing (DST) as a reference
standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between
brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated
sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The individual
studies are ordered by decreasing sensitivity.
Appendix 8. Second-line injectable drug resistance, different reference standards
Figure 19 shows forest plots of MTBDRsl sensitivity and specificity when performed indirectly for second-line injectable drug (SLID)
resistance detection and using different reference standards.
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Figure 19. Forest plots of MTBDRsl sensitivity and specificity for second-line injectable drug (SLID)
resistance, the test performed indirectly against three different reference standards. TP = true positive; FP =
false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence
intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the
study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing
sensitivity.
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WH A T ’ S N E W
Last assessed as up-to-date: 21 September 2015.
Date Event Description
25 July 2016 New search has been performed We updated the search and included six new studies.
We updated tuberculosis (TB) surveillance data in the
Background, and revised the sections of Index tests, Target
conditions, and Statistical analysis and data synthesis.
25 July 2016 New citation required but conclusions have not changed Review updated with six new included studies.
C O N T R I B U T I O N S O F A U T H O R S
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first draft of the review and prepared the ’Summary of findings’ tables. All review authors contributed to the final manuscript.
D E C L A R A T I O N S O F I N T E R E S T
The review authors have no financial involvement with any organization or entity with a financial interest in, or financial conflict with,
the subject matter or materials discussed in the review apart from those disclosed.
S O U R C E S O F S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK.
External sources
• Medical Research Council, South Africa.
Career Development Award held by GT.
• National Research Foundation, South Africa.
Core support to KD.
• ACTG/IMPAACT/HVTN International Tuberculosis Speciality Laboratory, South Africa.
Grant award for support to MB
• Department for International Development (DFID), UK.
Grant: 5242
• United States Agency for International Development (USAID) administered by the World Health Organization (WHO) Global
TB Programme, USA.
• The Bill and Melinda Gates Foundation, USA.
175GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For both the original and updated reviews, we added an additional reference standard defined as two reference tests used together:
phenotypic culture-based drug susceptibility testing (DST) and genetic sequencing of the same samples. We added the question, ”Was
a case-control design avoided?“ to the sensitivity analyses. We stated in the protocol, Theron 2013, that we would perform sensitivity
analyses for each target condition, using the subset of studies that provided one result per patient. However, these studies did not provide
sufficient data for such analyses. We made several revisions in the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2)
tool. After further consultation with technical experts, we changed how we assessed risk of bias with regard to the reference standard
domain of QUADAS-2. We decided to distinguish between studies that used culture-based DST with a WHO-recommended critical
concentration in order to define resistance (answered as ’yes’ if study consistently used recommended critical concentrations), those
studies which did not (answered as ’no’), and those studies which used critical concentrations in some evaluations and not others or the
authors did not specify the critical concentrations used (answered as ’unclear’). For concerns of applicability in the reference standard,
we answered ’unclear’ if sequencing was used as the reference standard and the type of sequencing did not examine the genes known
to be associated with resistance (for example, gyrB for the FQs and eis for the SLIDs). For signalling question 2 in the flow and timing
domain, ”Did all patients receive the same reference standard?“, we answered ’no’ when culture followed by sequencing of discrepant
results was performed. We also clarified concerns about applicability for the index test. We considered studies to be of ’high concern’
when the test was applied differently than recommended by the manufacturer, for example when the test was applied to pooled sputa.
We added an investigation of heterogeneity in relation to microscopy smear grade.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antitubercular Agents [∗therapeutic use]; Cross-Sectional Studies; Extensively Drug-Resistant Tuberculosis [∗diagnosis; drug therapy];
Fluoroquinolones [therapeutic use]; Genotype; Microbial Sensitivity Tests [∗methods; standards]; Mycobacterium tuberculosis [∗drug
effects]; Sensitivity and Specificity
MeSH check words
Adult; Humans
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